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1 | General introduction
Chapter 1
Cancers of the colon and the rectum are the third most common type of cancer in the
world, affecting over a million people annually [1]. In the general population, the lifetime
risk of developing colorectal cancer is 5-6% [2]. An increased risk of colorectal cancer has
been observed for those with a history of colorectal cancer in one (2-fold) or 2 or more (4-
fold) first degree family members [3]. Moreover, the personal risk of colorectal cancer nearly
doubles if a colorectal adenoma, a benign established precursor of colorectal carcinoma [4–7],
is diagnosed in a first-degree relative [3]. A personal history of colorectal adenomas also
increases risk of developing recurrent colorectal carcinomas, particularly for those with a
specific type of adenoma called villous adenoma (standardised incidence ratios (SIR) 2.1-5.0)
[8–10], adenomas 1 cm or larger (SIR 2.1-5.9) [8–10], or multiple adenomas (SIR 1.3-4.8) [10].
Furthermore, inheritance of cancer-associated genes strongly increases personal risk for col-
orectal cancer. Lynch syndrome is a well-known inherited cancer syndrome. Although
Lynch syndrome is “only” responsible for up to 3% of all colorectal cancers [11], penetrance
of colorectal cancer in Lynch syndrome is very high with 70-85% developing colorectal can-
cer [12–17]. Persons with Lynch syndrome inherit a pathogenic germline mutation in one
of the mismatch repair (MMR) genes (MLH1, MSH2, MSH6, and PMS2), which results in mi-
crosatellite instability in tumours [18]. Microsatellites are short and repeated DNA sequences
interspersed throughout the genome [19] that are vulnerable to mutation due to their repet-
itive nature [20]. During DNA replication, repeated sequences may shorten or lengthen,
which causes “instability” and could also lead to protein inactivation [21]. Compared to the
general population, individuals with Lynch syndrome have an increased risk for developing
colorectal cancer to age 70, develop colorectal adenomas at a younger age, and have a higher
lifetime risk for developing other cancers such as those in the endometrium, ovary, stomach,
pancreas, small intestine, biliary system, and brain [13, 22–25]. Figure 1.1 depicts the risk of
developing colorectal cancer across a continuum of these clinical and genetic factors.
In addition to the cancer-related genes and a personal/family history of colorectal adenomas
and carcinomas that predispose to an increased risk of colorectal cancer, dietary and lifestyle
factors are also important in influencing the risk of developing colorectal cancer, possibly in
combination with genetic susceptibility to these exposures due to specific variants in related
metabolising genes [26, 27].
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Figure 1.1 Colorectal cancer risk across a continuum of clinical and genetic factors.
Abbreviations: CRA: colorectal adenoma; CRC: colorectal cancer.
1.1 Diet and colorectal cancer
The 2007 Second Expert Report by the World Cancer Research Fund/American Institute for
Cancer Research (WCRF/AICR) estimates that roughly one-third, and even up to one-half
in some countries, of all colorectal cancers could be prevented by regular physical activity,
an avoidance of body fatness within the normal range of body weight, and proper food and
nutrition [26]. More specifically, as part of the WCRF/AICR Continuous Update Project
(CUP), the Colorectal Cancer 2011 Report judges that with respect to diet, there is con-
vincing evidence that foods containing dietary fibre decrease risk of colorectal cancer, while
red meat, processed meat, and alcoholic drinks (particularly in men) increase risk of devel-
oping colorectal cancer [27]. There is also suggestive evidence that non-starchy vegetables,
fruits, and foods containing vitamin D could lower risk of colorectal cancer [27]. Micronu-
trients such as folate and other B vitamins may also impact risk of developing colorectal
cancer [26, 27].
Folate is a water-soluble B vitamin found naturally in foods that include green leafy veg-
etables, fruits, nuts, dairy products, potatoes and other tubers, and meat products, particu-
larly liver [28, 29]. In contrast to naturally occurring food folate, folic acid is the synthetic,
chemically-stable form of folate and is used for food fortification and in dietary supple-
ments [30]. Other related B vitamins include riboflavin (vitamin B2), pyridoxine (vitamin
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B6), and cobalamin (vitamin B12). In the Netherlands, the best food sources of vitamin B2
are milk and dairy products, while vitamin B6-rich foods include meat, fish, poultry, or-
gan meats, nuts, and lentils; eggs, dairy products, and meat are excellent sources of vitamin
B12 [29]. While not a B vitamin, the essential amino acid methionine is often included along
with B vitamins in explorations between these nutrients and colorectal cancer risk. The
reason behind this stems from the involvement of B vitamins and methionine in many bio-
logical reactions in one-carbon metabolism (OCM) that when disturbed, impact colorectal
carcinogenesis [31, 32]. One-carbon metabolism will be more thoroughly discussed later in
this chapter in paragraph 2 of the section titled “B vitamins, methionine, and DNA methy-
lation”. Good dietary sources of methionine are animal products such as meat, eggs, and
dairy.
As noted above in paragraph 3, variants in metabolising genes such as those involved in
one-carbon metabolism, may modify the relationships between dietary and lifestyle factors
and risk of colorectal cancer. The enzyme methylenetetrahydrofolate reductase (MTHFR)
plays a key role in OCM because its substrate, 5,10-mTHF, mediates one-carbon groups for
pyrimidine synthesis, and its product supplies one-carbon groups for methylation of DNA
and other molecules. The common C to T transition in the MTHFR gene at nucleotide 677
results in an alanine to valine substitution, subsequently producing a thermolabile variant
and reduced enzyme activity [33]. This functional SNP is possibly the most well-studied of
all SNPs in OCM-related genes. Results from several meta-analyses indicate that by itself,
the MTHFR 677TT genotype has not been associated with risk of developing colorectal ade-
nomas [34, 35] but has been associated with a decreased risk of colorectal cancer compared
with the MTHFR 677CC genotype [34–36]. In Lynch syndrome, the CT or TT genotype
was associated with developing colorectal cancer at a later age (average age approximately 43
years) compared to those with the CC genotype (average age approximately 38 years) [37,38].
While the MTHFR 677TT genotype may not be associated with developing colorectal ade-
nomas, it has been known to modify the associations between B vitamins and colorectal
adenoma risk. Specifically, there has been a reduction in risk of colorectal adenomas for
those with high folate intake and the TT genotype [39–41]; low folate intake in persons with
the TT genotype has been associated with an increased risk of colorectal adenomas com-
pared with CC individuals with high folate intake [41]. Likewise, the greatest risk reduction
in colorectal cancer afforded by the MTHFR 677TT genotype is for those with high blood
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folate or folate intake compared to CC or CT individuals with low folate [42–45]. In some in-
stances, low plasma folate in TT individuals increases the risk of developing colorectal cancer
compared to those with high plasma folate and the CC or CT genotype [44].
The relationships between B vitamins and methionine with colorectal cancer are enormously
complex. Not only are they are further complicated by genetic variation in OCM-associated
metabolising genes but also by possible synergistic influences between the B vitamins with
other nutrients in our diet and in combination with different food groups and may impact
colorectal carcinogenesis differently depending on the timing of exposure (i.e. from healthy
tissue to adenoma to carcinoma).
1.1.1 B vitamins, methionine, and colorectal carcinogenesis: evidence
from epidemiological studies
B vitamins, methionine, and colorectal adenoma incidence and recurrence
The WCRF/AICR overview of data describing associations between colorectal adenomas
and food, nutrition, and physical activity was published in 2006 [46]. Using data from two
cohort studies, a meta-analysis of highest versus lowest category of dietary folate intake and
incidence of colorectal adenomas found a non-significant inverse association between dietary
folate intake and colorectal adenoma incidence (overall relative risk (RR) (95%CI) of 0.85
(0.66-1.11)) [46]. Total folate intake (from diet and supplements) was inversely associated
with colorectal adenomas risk (overall RR (95%CI) of 0.75 (0.56-0.99)) [46].
For those who have been diagnosed with at least one colorectal adenoma, a meta-analysis
of prospective cohort studies on dietary folate intake and colorectal adenoma recurrence
showed a non-significant inverse association (overall RR (95%CI) of 0.83 (0.60-1.14)) [46].
Likewise, total folate intake was non-significantly inversely associated with colorectal ade-
noma recurrence (overall RR (95%CI) of 0.78 (0.48-1.29)) [46]. Also increasing plasma fo-
late concentrations decreased risk of adenoma recurrence (OR of 0.66 (95%CI 0.46-0.97); P-
trend=0.04) for high plasma folate vs. low plasma folate) in a prospective cohort study [47].
Five randomised controlled trials have compared the recurrence of adenomas in patients re-
ceiving folic acid supplementation daily to those receiving placebo [48–52]. Two of the trials
observed a benefit of folic acid supplementation [49, 51], while two other trials found no ef-
fect [50,52]. A large trial found a higher risk of having 3 or more adenomas or more advanced
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lesions (≥ 25% villous features, high-grade dysplasia, size ≥ 1 cm, or invasive cancer) with
folic acid supplementation compared with placebo [48].
In individuals with no history of colorectal adenomas, two studies on vitamin B2 intake did
not find an association with colorectal adenoma risk [53,54]. One study did not find an asso-
ciation between plasma vitamin B2 and colorectal adenoma risk [55]. An inverse association
between vitamin B2 intake and colorectal adenoma risk was observed in two studies [56,57],
but only in one of these studies was the association significant [56]. Vitamin B6 intake is
often [47, 53] but also not always [56] inversely associated with developing colorectal ade-
nomas. There are also reports of inverse associations between the main circulating form
of vitamin B6, PLP (pyridoxal 5’-phosphate), and colorectal adenoma risk [55, 58]. In the
majority of studies, vitamin B12 status seems to be unassociated with first colorectal ade-
noma risk [55,56,58]. A meta-analysis of highest versus lowest category of methionine intake
and colorectal adenoma incidence has been conducted using estimates from two cohort stud-
ies [46]. The pooled RR (95%CI) for colorectal adenoma incidence was 0.53 (0.25-1.11) [46].
In a cross-sectional study, plasma methionine was inversely associated with developing distal
colorectal adenomas [55].
For those who have had at least one colorectal adenoma in their lifetime, vitamin B6 intake
was inversely associated with risk of adenoma recurrence (OR of 0.65 (95%CI 0.45-0.94);
P-trend=0.03 for the highest quartile of intake vs. the lowest) [47]. Likewise, vitamin B12
intake was inversely associated with risk of adenoma recurrence in a patients who had pre-
viously participated in an intervention study with wheat bran, but this association did not
reach significance (for the highest quartile of intake vs. lowest quartile OR of 0.74 (95%CI
0.51-1.08); P-trend=0.14) [47]. One cohort study has reported an inverse but not signifi-
cant association between methionine intake and recurrence of colorectal adenomas [47]. We
are unaware of any studies describing vitamin B2 intake and colorectal adenoma recurrence.
Overall, foods containing folate, other B vitamins, and methionine may offer some protec-
tion against developing first or recurrent colorectal adenomas, but studies are not entirely
consistent, particularly for vitamin B2, vitamin B12, and methionine, where the evidence is
also more sparse.
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B vitamins, methionine, and colorectal cancer incidence
The earliest documented epidemiological observation of a link between folate intake and
colorectal cancer was published in 1989 [59]. Decades of epidemiological research on folate,
and more generally diet, and colorectal cancer have since followed. In 2005, Sanjoaquin and
colleagues performed a meta-analysis of 7 cohort studies on folate intake and colorectal can-
cer risk and found an inverse association between dietary folate intake and colorectal cancer
(overall RR for high vs. low intake = 0.75; 95%CI = 0.64-0.89) [60]. These results have
been corroborated by two meta-analyses [26, 61], one of which was from the Second Expert
Report (SER) by the WCRF/AICR that gave a summary effect estimate for the association
between dietary folate intake and colorectal cancer of 0.84 (95%CI 0.76-0.93) per 100 µg
dietary folate/day [26]. Likewise, the most recent WCRF/AICR CUP summary estimates
from meta-analyses for dietary folate intake and risk of colorectal cancer were also in the di-
rection of decreased risk with increasing folate intake but did not reach statistical significance
(summary effect estimate of 0.99 (95%CI 0.93-1.05)) [27].
CUP summary relative risks from meta-analyses for serum/plasma folate (per 2 ng/mL) were
also in the direction of decreased risk for colorectal cancer, colon cancer, and rectal cancer
with increasing serum/plasma folate concentrations but were not significant (summary esti-
mate of 0.97 (95%CI 0.93-1.00) for colorectal cancer, 0.98 (0.85-1.14) for colon cancer, and
0.87 (0.70-1.09) for rectal cancer) [27]. Results from a pooled analysis of 5,720 colon cancer
cases among 725,134 participants from 13 cohort studies showed a borderline significant de-
creased risk for those in the highest quintile of dietary folate intake compared with lowest
group (pooled multivariate RR (95%CI) of 0.92 (0.84-1.00)) [62]. Based on the current evi-
dence, the WCRF/AICR has concluded that the evidence is too limited to draw conclusions
about foods containing folate and risk of colorectal cancer.
Regarding folic acid supplementation trials, a meta-analysis of randomised controlled trials
has found no effect of folic acid supplementation on incidence of colorectal cancer [63]. Based
on these results, folate may contribute a small protective effect against colorectal cancer, but
because there are several inconsistencies, results should be interpreted with prudence.
Concerning the other B vitamins, there have been suggestions that higher vitamin B2 intakes
[64] and higher concentrations of vitamin B2 in plasma/serum [65, 66] are associated with
decreased risk of colorectal cancer, but to the best of our knowledge, no meta-analyses have
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been published thus far. For vitamin B6, the results of a meta-analysis that included nine
prospective studies on vitamin B6 intake and four studies on PLP concentrations showed
inverse associations between colorectal cancer risk and vitamin B6 intake (overall RR of
0.90 (95%CI 0.75-1.07) for the highest vs lowest category) and PLP concentrations (overall
RR of 0.52 (95% CI 0.38-0.71) for the highest vs lowest category) [67]. The relationships
between vitamin B12 intake or plasma/serum vitamin B12 and colorectal cancer are less
clear with most studies observing null associations [66, 68–70]. One study found an inverse
association between methionine intake and colorectal cancer risk [64] while no associations
were observed in two studies [68,70]. Overall, these results taken together emphasise the need
for more unambiguous evidence that describe associations between B vitamins and colorectal
carcinogenesis.
1.2 Colorectal carcinogenesis: a continuum of genetic and epigenetic
changes
Like all cancers, those that develop in the colon and rectum result from unregulated cellular
growth. Over time, a stepwise accumulation of significant alterations, brought on by in-
trinsic or environmental factors – or a combination of both – modify the normal regulatory
functions and dynamics of a cell [26]. As mentioned in paragraph 1 of this introduction, most
precursor lesions of colorectal carcinomas are colorectal adenomas, and evolution from ade-
nomas to carcinomas is termed the adenoma-carcinoma sequence [4–7], during which tissues in
the colon and rectum undergo histopathological changes with tissues becoming increasingly
dysplastic [71]. The transition from normal epithelium to adenoma to carcinoma is accom-
panied by acquired molecular events that include genetic and epigenetic alterations [4,72,73].
1.2.1 Genetic alterations during colorectal carcinogenesis
One of the earliest events of sporadic colorectal cancer progression that is required for col-
orectal adenoma formation is somatic bi-allelic inactivation of the tumour suppressor gene
adenomatous polyposis coli (APC) gene, leading to activation of the Wnt signalling path-
way [74]. As well, Wnt signalling in some cancers may be activated by mutations in β-catenin.
Wnt activation induces genes that include c-myc, cyclin D1, and PPAR-δ [75]. Transforma-
tion from early to late adenomas to carcinomas are likely due to mutations and/or loss of
heterozygosity in the oncogene Kirsten-ras (KRAS) [76]; mutations in the tumour suppressor
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gene p53 are proposed to be later events in the development of colorectal carcinomas [77].
The genetic basis of Lynch syndrome has been discussed in paragraph 2 of this chapter. Ge-
netic changes in a cell during colorectal cancer progression are often accompanied by and
interact with epigenetic modifications.
1.2.2 Epigenetic alterations during colorectal carcinogenesis
Epigenetics was first defined by C.H. Waddington as “the causal interactions between genes
and their products, which bring the phenotype into being” [78]; the definition of epigenet-
ics now encompasses the heritable changes in gene expression that occur independent of
alterations in the DNA sequence [79]. Epigenetic processes include posttranslational modifi-
cations of histone proteins, nucleosome positioning along the DNA, and possibly the best-
known of these processes, DNA methylation [73, 80].
DNA methylation
DNA methylation occurs at the C-5 position of cytosine residues located in the CpG dinu-
cleotide called CpG sites [81]. CpG sites, while under-represented in the genome, are found
clustered together in C- and G-rich regions termed CpG islands, usually in the promoters or
gene-regulating regions of genes. The remaining CpG sites are interspersed throughout the
genome in transposable elements, repetitive sequences or other intronic regions of DNA.
Typically in a healthy cell, most CpG islands are unmethylated and the associated genes
subsequently expressed, while CpG sites are methylated [82, 83]. The methylation of CpG
sites probably works to prevent chromosomal instability, translocations, and gene disruption
caused by reactivation of transposable DNA sequences [84]. There are generally two different
types of DNA methylation that can be described – gene-specific and global.
Gene-specific DNA methylation CpG islands in gene promoters or gene-regulating re-
gions of genes are normally unmethylated in order to allow transcription of their correspond-
ing genes. In cancer, these CpG islands may become more methylated (called gene-specific
or promoter hypermethylation), which results in transcriptional silencing [85]. CpG island
hypermethylation of promoters can affect genes involved in cell cycle, DNA repair, carcino-
gen metabolism, cell-cell interaction, apoptosis, and angiogenesis, all of which are related
9
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to carcinogenesis [82]. In colorectal carcinogenesis, CpG island promoter hypermethyla-
tion has been known to inactivate genes such as MLH1 (mismatch repair), p16INK4a (tumour
suppressor), p14ARF (tumour suppressor), MGMT (DNA repair), and RASSF1A (tumour sup-
pressor) [86, 87] in addition to numerous others.
Global DNA methylation In cancer, CpG sites that are distributed among the genome be-
come less methylated, a process which is called global hypomethylation. Global hypomethy-
lation is an early event in colorectal carcinogenesis [88,89]. More explicitly, Fearon and Vogel-
stein’s Genetic Model for Colorectal Tumorigenesis describes global DNA hypomethylation
as an earlier event along the adenoma-carcinoma sequence with gene-specific DNA methyla-
tion occurring later [4]. Because global DNA methylation is an earlier event in colorectal
carcinogenesis and the aim of this thesis is to investigate relationships between B vitamins
and DNA methylation across a continuum of risk for colorectal cancer that includes low-
risk individuals, this thesis will focus on global DNA methylation.
Measuring global DNA methylation in epidemiological studies A plethora of meth-
ods have been developed to measure global DNA methylation, although the “best” method
will depend on the number of samples, quality and quantity of available DNA, and desired
coverage and resolution [90]. Chromatographic methods for measuring global DNA methy-
lation allow for direct quantification of methylation. Following digestion of DNA into single
strands, chromatographic methods directly measure the total number of 5-methyl cytosines
and cytosines. Chromatography allows for direct quantification of DNA methylation but is
time-consuming, costly and highly specialised equipment as well as large amounts of DNA
are required, which can be cumbersome for large epidemiological studies [91]. As a pos-
sible alternative, in 2004, Yang and colleagues developed a PCR-based method to evaluate
global DNA methylation by semi-quantitatively measuring methylation of long interspersed
nuclear elements (LINEs) using bisulfite pyrosequencing [46]. LINEs are a variety of trans-
posable elements. Transposable elements are mobile sequences of repetitive DNA that can
migrate to different regions of the genome. There are two related LINE families, but the
majority of genomic DNA is comprised of LINE-1 (18%) [47]. Methylation of repetitive
DNA elements such as LINE-1 is frequently used as a surrogate for global DNA methyla-
tion in epidemiological studies, including those where B vitamins are investigated as possible
determinants of global DNA methylation [48–51].
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1.3 B vitamins, methionine, and DNA methylation
As mentioned in paragraph 5, several B vitamins including folate play an essential role in one-
carbon metabolism (OCM), where perturbations of B vitamins and methionine may have an
effect on DNA methylation. One-carbon metabolism is a complex network of intercon-
nected reactions involving a multitude of substrates, enzymes and cofactors [92] (see Figure
1.2). Folate is a carrier of one-carbon units in OCM, where it plays a central role in DNA
methylation, nucleotide synthesis, and maintaining DNA stability and repair [32, 93–96].
In addition to folate, the B vitamins riboflavin (vitamin B2), pyridoxine (vitamin B6), and
cobalamin (vitamin B12), and the essential amino acid methionine are also important in sup-
porting efficient one-carbon metabolism [97]. Riboflavin in its coenzymatic form of flavin
adenine dinucleotide (FAD) is essential for the enzyme methylenetetrahydrofolate reductase
(MTHFR) in the irreversible reduction of 5,10-methylenetetrahydrofolate (5,10-mTHF) to 5-
methyltetrahydrofolate (5-mTHF) [98]. Vitamin B6 as pyridoxal 5’ -phosphate is a coenzyme
for serine hydroxymethyltransferase (SHMT) in the reversible conversion of tetrahydrofolate
(THF) to 5,10-methylene-THF [99] while the remethylation of homocysteine to methionine
by methionine synthase (MTR) and methionine synthase reductase (MTRR) with 5-methyl-
THF as a methyl donor is dependent on cobalamin [100, 101]. Methionine is consequently
metabolised to S-adenosylmethionine (SAM), the universal methyl donor for over one hun-
dred biological reactions including DNA methylation [102]. High concentrations of homo-
cysteine in blood are related to low blood concentrations of folate [103]. Although B vitamins
and methionine are involved in DNA synthesis and DNA stability and repair, which also in-
fluence colorectal cancer, this thesis focuses on the involvement of B vitamins on global DNA
methylation.
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Figure 1.2 Folate-mediated one-carbon metabolism. Abbreviations: DHF: dihydro-
folate; DHFR: dihydrofolate reductase; THF: tetrahydrofolate; SHMT: serine hy-
droxymethyltransferase; 10-formylTHF: 10-formyltetrahydrofolate; 5,10-mTHF: 5,10-
methylenetetrahydrofolate; 5-mTHF: 5-methyltetrahydrofolate; MTHFR: methylenete-
trahydrofolate reductase; MTRR: methionine synthase reductase; MTR: methionine syn-
thase; CBS: cystathionine β-synthase; MT: methyltransferase; SAM: S-adenosylmethionine;
SAH: S-adenosylhomocysteine
1.4 B vitamins and leukocyte DNA methylation: evidence from
epidemiological studies
The role of B vitamins across the continuum of colorectal carcinogenesis is not straightfor-
ward, and may depend on a plethora of factors, such as inefficient OCM, personal history of
colorectal adenomas, a family history of colorectal adenomas and carcinomas, and inherited
mutations in cancer-associated genes. Likewise, the impact of B vitamins on DNA methyla-
tion could be moderated by the presence or absence of these factors.
The relationships between B vitamins and DNA methylation have been studied in normal
colorectal tissues [104, 105], colorectal adenomas [106], and colorectal carcinomas [107, 108].
With this in mind, the intent of this thesis is to better understand the influence of B vitamins
on leukocyte global DNA methylation of populations differing in risk for colorectal cancer.
12
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1.4.1 Low risk population
There have been two relatively short-term (12 weeks) randomised placebo-controlled trials
investigating the effects of folic acid supplementation on leukocyte global DNA methylation
in populations at low-risk for colorectal cancer [109, 110]. At the end of 12 weeks, neither
trial found an effect of 1.2 mg [109] nor 2 mg [110] daily folic acid supplementation on global
DNA methylation. A possible explanation for these null results could be the short dura-
tion of folic acid supplementation and the use of supraphysiological doses of folic acid. Two
cross-sectional studies, one in urban commuters in the United States and the other in older
Brazilians (aged 60-88 years) have reported that neither intake of natural folates nor dietary
folate equivalents was associated with leukocyte LINE-1 methylation [111], nor global DNA
methylation [112]. A third cross-sectional study observed that higher dietary folate intake
was associated with lower global DNA methylation in Japanese women [113]. Geographi-
cal differences, food fortification, different dietary habits, and baseline folate concentrations
are some reasons that could possibly account for these dissimilar results. Similarly, plasma
folate has been unassociated with leukocyte global methylation in a cross-sectional analy-
sis [114] in contrast to two other controlled folate intake studies in women, where leukocyte
global DNA methylation decreased following folate depletion [115, 116]. In one of these
studies, DNA hypomethylation was reversed following folate repletion [115], but not in the
other [116]. This is likely due to the study population, comprised exclusively of elderly
women, where stabilisation of DNA methylation following folate depletion could be de-
layed, resulting also in a slower response to folate repletion.
Three cross-sectional studies have examined relationships between intake of other B vitamins
and leukocyte DNA methylation [111–113]. One study found a weak negative correlation
between vitamin B6 intake and global DNA methylation (Spearman ρ of -0.18, P=0.04) [112].
Vitamin B12 intake was not related to global DNA methylation, and vitamin B2 was not
investigated [112]. On the other hand, intake of vitamins B2, B6, and B12 were not associated
with leukocyte global DNA methylation in an urban American population [111], nor in
Japanese women [113].
1.4.2 High risk population
The association between B vitamins and global DNA methylation has been investigated in
colorectal adenoma patients. These associations have not yet been explored in a Lynch syn-
13
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drome population. In colorectal adenoma patients, the effects of folic acid supplementation
on global DNA methylation were investigated [117]. After 10 weeks of daily supplemen-
tation with 400 µg folic acid, leukocyte global DNA methylation increased 31% (95%CI
16-47%; p=0.05 vs. placebo). Here, the dose and duration of folic acid supplementation
was lower and shorter, respectively than in trials with low-risk participants, but there was
an effect on global DNA methylation, which was measured using the same method as in
the other low-risk trials. Baseline red blood folate also appeared to be similar between the
three populations. Drawing firm conclusions is not possible based on one study, but it is
possible to speculate that folic acid may have a different effect on DNA methylation de-
pending on which phase during carcinogenesis it is given. Additionally, genetic variation in
OCM-related genes, such MTHFR, could modify the relationships between B vitamins and
methionine with DNA methylation.
1.5 B vitamins and DNA methylation: interactions withMTHFRC677T
Main effects of the MTHFR C677T genotype on global DNA methylation have been explored
in several studies. In low risk populations, there has been no difference in leukocyte global
DNA methylation levels between genotypes [112–114]. However, the C677T polymorphism
in this gene may modify associations between plasma folate and global DNA methylation
and LINE-1 DNA methylation.
1.5.1 Low risk population
Two studies have suggested that leukocyte DNA is hypomethylated in persons with low
folate status and homozygous for the TT genotype [33, 118]. In a folate depletion-repletion
study, women with the TT genotype had a greater in increase in leukocyte DNA global DNA
methylation following folate repletion compared with the CC genotype [119]. A similar
folate depletion-repletion study found lower levels of leukocyte DNA methylation in women
with the TT genotype following repletion compared with CC or CT women [120]. The slow
response in DNA methylation levels to folate repletion has been partly attributed to a slow
turnover of whole-body folate pools [121]. On the whole, there seem to be interactions
between folate intake and MTHFR C677T in a low-risk population. The largest variation in
global DNA methylation (i.e. greatest increase and decrease of global DNA methylation) by
folate intake appear to be most clear in those with the MTHFR 677TT genotype.
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1.5.2 High risk population
In very high risk populations, data on B vitamin-colorectal cancer relationships are not yet
available. There was no information about dietary information nor DNA methylation from
the two studies that investigated the main effects of the MTHFR C677T single nucleotide
polymorphism on colorectal cancer risk in persons with Lynch syndrome [37, 38].
1.6 Rationale and Outline of this Thesis
The main purpose of the studies presented in this thesis is to improve our knowledge about
the associations between B vitamin and methionine status and leukocyte global DNA methy-
lation in populations with differential risk for developing colorectal cancer. Figure 1.3 is an
illustration of the clinical, genetic, and nutritional factors that influence differential risk for
colorectal cancer across a continuum as outlined in this thesis according to each chapter.
Given that DNA methylation is one of the major mechanisms linking B vitamins and other
nutritional factors to colorectal cancer, Chapter 2 is a review that summarises the impact
of nutrition on DNA methylation in different cancer sites as explored in epidemiological
studies.
In order to study the relationships between B vitamin status and global DNA methylation in
different risk groups, we use data from four study populations differing in colorectal cancer
risk, as shown in Figure 1.3. Contributions from these studies begin in Chapter 3 where the
relationship between plasma folate and leukocyte LINE-1 methylation in a low risk popula-
tion was explored. A study detailing the effects of folic acid supplementation on leukocyte
global DNA methylation in individuals with moderately elevated homocysteine is presented
in Chapter 4. Moving further along the risk scale for colorectal cancer, Chapter 5 investi-
gates the associations between plasma B vitamins and methionine, and LINE-1 methylation
in colorectal adenoma patients; additional effect modification by number of lifetime colorec-
tal adenomas was also explored. Associations between dietary B vitamin and methionine
intake and risk of colorectal tumours in Lynch Syndrome individuals are studied in Chapter
6. This thesis concludes (Chapter 7) with a discussion of the results from all our studies.
Recommendations for future research and public health implications are additionally consid-
ered.
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Chapter 1
Low
3-5%
General
population
Chapter 3
Medium
4.5-7.5%
Decreased folate
concentrations
Chapter 4
High
20-30%
Personal history
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Family history
of CRC/CRA
Chapter 5
Very high
75-80%
Lynch syndrome
Chapter 6
Colorectal cancer risk
Figure 1.3 Colorectal cancer risk across a continuum of clinical, genetic, and nutritional
factors according to the chapters of this thesis.
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Chapter 2
Cancer is a multistep process caused by changes in normal cellular mechanisms such as DNA
repair, cell cycle, apoptosis, differentiation, proliferation, hormonal regulation, inflammation
and immunity, carcinogen metabolism. Errors in any of these functions may lead to altered
DNA structure and integrity, apoptosis inhibition, and angiogenesis and/or biologically ac-
tive chemical induction. Mutations and/or deletions in DNA and aberrant gene expression
have also been observed. A common observation in human breast cancers and many other
tumour types is epigenetic change consisting of altered methylation of DNA [1–5] and the
histones associated with DNA [6–8]. These changes occur early in the development of cancer
and are observed even in low-grade cancers [9], with the pattern of methylation correlating
with cancer stage [10].
Diet and other environmental exposure such as smoking, physical activity, and overweight
may influence carcinogenesis through one or more of the mechanisms depicted in Figure 2.1,
and there is ample evidence to support this. Butyrate produced by colonic bacteria, diallyl
disulfide in garlic and other Allium vegetables, and sulforaphane found in cruciferous veg-
etables have all been shown to inhibit type I and II HDACs in laboratory studies, thereby
helping to maintain DNA stability [11]. Long-chain n-3 polyunsaturated fatty acids (PUFAs)
found in fish oils, vitamin D, and retinoic acid have been shown to promote cell differentia-
tion, and, in tumour cells, to limit cell proliferation, and increase apoptosis [12–14]. Folate
and other methyl donors such as methionine help regulate DNA synthesis and modulate
epigenetic mechanisms in DNA [14].
The interplay between nutrition and epigenetics in affecting cancer in humans is a relatively
new area of research. DNA methylation is by far the most documented and well-studied
epigenetic event in human cancers. While many different aberrant epigenetic modifications
have been linked to cancer in animal models, laboratory studies, and human observational
studies, so far only DNA methylation has been demonstrated to be influenced by nutrition
in neoplastic transformations. An explosion in interest in the field of epigenetics, coupled
with results from human studies that demonstrate effects of nutrition on DNA methylation
and studies in animal models and human cell lines that highlight the effects of nutrition on
epigenetic processes, continues to fuel this relatively young field of research. This chapter fo-
cuses on the ways in which nutrition can influence epigenetics in carcinogenesis in humans.
Although there are a myriad of nutrition-related lifestyle factors that contribute to cancer
development or prevention by affecting epigenetic processes, this chapter focuses only on
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Figure 2.1 Diet and other lifestyle factors can interfere with the normal functioning of differ-
ent essential cellular processes, which may affect cancer progression or prevention. (Adapted
from the WCRF Second Expert Report [14])
those nutrients that have been shown to influence epigenetic processes in human cancers.
We first summarise the many epigenetic modifications that have been implicated in cancer.
Then we discuss the current evidence on the link between nutrition and cancer development
and progression, with a focus on epigenetics. Finally, we examine the role of nutrition in
epigenetic changes in carcinogenesis considering evidence from observational studies, inter-
vention studies, and randomised, placebo-controlled trials.
2.1 Epigenetics in cancer
Epigenetic modifications continue to garner attention for their role in carcinogenesis. Many
epigenetic modifications are known, and DNA methylation is perhaps the most well studied
of these. Global DNA hypomethylation is thought to promote genomic instability and it is
often found in solid tumours [15] and leukocytes of individuals with cancer [16,17]. In 1983,
Feinberg and Vogelstein pioneered the first study to examine DNA methylation changes in
primary human tumour tissues [15]. Results from studies of adenocarcinoma of the colon
and small cell carcinoma of the lung (as well as a liver metastasis derived from the same cell
type as the primary small cell lung carcinoma) have demonstrated significant hypomethy-
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lation of the growth hormone, γ-globin, and α-globin genes in the tumour compared with
surrounding normal cells from the same patient in four of the five types of cancer. Hy-
pomethylation levels in liver metastasis were even greater than in primary tumour. Global
hypomethylation in concert with hypermethylation of specific promoters have been found
to occur both independently and in conjunction with each other. When occurring together,
global hypomethylation has been proposed as an early step in tumourigenesis, while pro-
moter hypermethylation, which often silences tumour suppressor genes and DNA repair
genes, is a later event [18]. Promoter hypermethylation has also been found in colorectal ade-
nomas that precede colorectal carcinomas [19]. Promoter methylation is found in cytosine-
rich areas, termed CpG islands, in areas associated with promoters of functional genes. These
CpG islands are normally unmethylated and this is thought to allow gene expression. On the
other hand, CpG sites scattered throughout the genome, largely reflecting methylation at re-
peat sequences and in satellite regions of the DNA, are typically highly methylated, which is
important in conferring genomic stability. The number of methylated cytosines is typically
reduced in the genomic DNA of tumours compared with normal tissue [20] and this is asso-
ciated with shorter survival in colon cancer patients [21]. DNA methylation patterns change
with age, with increases in global hypomethylation and gene-specific hypermethylation as
age progresses [22, 23].
Other epigenetic processes such as histone modification have also been implicated in carcino-
genesis. Nucleosomes, composed of a fragment of DNA (146 bp) wrapped around a histone
octomer, are the fundamental repeating units of chromatin. Histones undergo a myriad of
posttranslational alterations including acetylation, which allows the chromatin to unfold and
facilitates gene expression [24]. Aberrant HDAC expression has been found in tumours. In-
creased HDAC expression has been discovered in gastric cancer, esophageal squamous cell
carcinoma, and hormone-refractory prostate cancer [25, 26].
While it is clear that epigenetic alterations influence cancer development, the question of
how and why these alterations occur and whether nutritional factors may influence these
changes still remain unanswered.
2.2 Nutrition and cancer
According to the recent World Cancer Research Fund/American Institute of Cancer Re-
search (WCRF/AICR) Second Expert Report, a healthy diet and weight and physical activity
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can reduce the risk of about a third of all cancers. The WCRF/AICR Report provides evi-
dence from systematic reviews for the protective effects of vegetables and fruits, low body fat-
ness (as measured by body mass index (BMI)), and physical activity on almost all frequently
occurring cancers in high-income countries. The WCRF/AICR Panel recommendations
were to eat foods mostly of plant origin, to be within the range of normal body weight, and
to make physical activity a part of daily life. The Panel also recommended limiting alcohol
intake, as there was suggestive evidence that alcohol may increase risk of some cancers [14].
Here we discuss the evidence in relation to particular nutrients that are thought to influence
epigenetic processes.
2.2.1 Folate and other B vitamins in cancer
Foods such as green leafy vegetables contain natural folate, while folic acid is the synthetic
form of folate and can be found in supplements and fortified foods such as breakfast cere-
als. Folate has been extensively studied in colorectal cancer (CRC), but results have been
inconsistent and inconclusive. Whether folate is protective against or encourages CRC de-
velopment still needs to be determined [27]. Although data from cohort studies do show
an inverse dose–response relationship, this relationship is not always consistent [14]. Impair-
ment of these pathways by folate or because of other B vitamin deficiencies may contribute
to carcinogenesis. There are two possible routes by which folate can influence DNA sta-
bility and subsequently CRC risk. One route by which folate likely affects DNA stability
is through DNA synthesis and repair, while the more well-known route is through DNA
methylation. Folate functions as a donor of one-carbon units for DNA synthesis as well as
DNA methylation. In folate-mediated one-carbon metabolism (Figure 2.2), other nutrients
such as B vitamins also play a crucial role. Vitamin B12 (cobalamin) is a cofactor in both the
conversion of homocysteine to methionine and the conversion of 5-methyltetrahydrofolate
to tetrahydrofolate. Following its biosynthesis from homocysteine, methionine is converted
to S-adenosylmethionine (SAM), which donates methyl groups for DNA methylation.
Many enzymes are involved in folate-mediated one-carbon metabolism, and many of these
enzymes require cofactors, which are often B vitamins. In addition to others, cobalamin
(vitamin B12) is a cofactor for methionine synthase, an enzyme that converts homocysteine
to methionine. Functional polymorphisms in enzyme-encoding genes involved in folate-
mediated one-carbon metabolism play an important role in this cycle. A plethora of poly-
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Figure 2.2 Folate-mediated one-carbon metabolism. Abbreviations: DHF: dihydro-
folate; DHFR: dihydrofolate reductase; THF: tetrahydrofolate; SHMT: serine hy-
droxymethyltransferase; 10-formylTHF: 10-formyltetrahydrofolate; 5,10-mTHF: 5,10-
methylenetetrahydrofolate; 5-mTHF: 5-methyltetrahydrofolate; MTHFR: methylenete-
trahydrofolate reductase; MTRR: methionine synthase reductase; MTR: methionine syn-
thase; CBS: cystathionine β-synthase; MT: methyltransferase; SAM: S-adenosylmethionine;
SAH: S-adenosylhomocysteine
morphisms exist, but the most extensively studied polymorphism is a C-to-T substitution in
methylenetetrahydrofolate reductase (MTHFR) at nucleotide 677, which converts alanine to
valine resulting in decreased in vivo enzyme activity [28]. Genetic polymorphisms and their
interactions with nutrition in cancer are beyond the scope of this chapter, and only MTHFR
C677T will be mentioned in relation to nutrition, cancer, and epigenetics. Many studies on
folate and human cancer risk have been conducted. In the following section, we describe the
most prominent findings from observational studies, intervention studies, and randomised
controlled trials (RCTs).
Observational studies
Colon and rectum The inverse association between high dietary folate intake and risk
of colorectal adenomas was first seen and described both for women in the Nurses’ Health
34
Nutrition, epigenetics, and cancer
Study and for men in the Health Professionals Follow-up Study [29]. Colorectal carcinomas
often follow the adenoma-carcinoma sequence and adenomas are often used as a proxy end-
point for carcinomas [30]. The Nurses’ Health Study is a cohort study that was initiated in
1976 to identify factors that influence women’s health. Almost 122,000 US registered nurses,
30-55 years of age, completed a mailed questionnaire on risk factors for cancer and coronary
heart disease, and 4 years later, they completed a semiquantitative food frequency question-
naire to assess diet from the previous year [31]. Similarly, the Health Professionals Follow-up
Study began in 1986, and followed over 51,500 men, 40-75 years of age, who were dentists,
optometrists, osteopaths, podiatrists, pharmacists, or veterinarians, to prospectively investi-
gate dietary factors influencing cardiovascular disease and cancer risk. The men completed
a semi-quantitative food frequency questionnaire designed to estimate average consumption
during the past year [29,32] found an inverse association between folate intake (from diet and
supplements) and left colon and rectum adenoma risk (highest intake versus lowest intake
multivariate relative risk (RR) = 0.71, 95% confidence interval (CI) = 0.56-0.89). Those in
the highest quintile of folate intake compared to those in the lowest quintile had a reduced
risk of adenoma and this was true for both women (RR = 0.66, 95%CI = 0.46-0.95) and
men (RR = 0.63, 95% CI = 0.41-0.98). There was a weak inverse association between folate
intake from foods alone (supplement use excluded) and adenoma risk in women (RR = 0.91,
95% CI=0.64-1.28) and men (RR = 0.78, 95% CI = 0.52-1.17), again comparing those in
the highest quintile of intake with the lowest. The association between alcohol intake and
adenoma risk was also assessed, as alcohol is a well-known folate antagonist. Compared with
nondrinkers, those who had more than 30 g of alcohol daily had a slightly (not significant)
elevated risk of adenoma (RR = 1.78, 95% CI = 1.28-2.47). Adenoma risk was highest for a
combination high alcohol intake and low folate intake relative to a combination low alcohol
intake and high folate intake (RR = 2.35, 95% CI = 1.56-3.50). The multiple logistic regres-
sions performed were adjusted for age, sex, body blood, occult fecal blood, abdominal pain,
diarrhea (or constipation), and history of endoscopy prior to the study period.
Results from a meta-analysis of seven cohort studies and nine case-control studies investi-
gating the association between folate intake and CRC risk further demonstrated an inverse
association between folate intake and CRC risk [33]. In the cohort studies, a statistically
significant reduced risk for CRC was observed in those with high dietary folate intake com-
pared with those with low dietary folate intake (RR = 0.75, 95% CI = 0.64-0.89), with no
significant heterogeneity between studies. There was a nonsignificant inverse association be-
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tween total folate intake and CRC risk (RR = 0.95, 95% CI = 0.81-1.11), with no significant
heterogeneity between studies. For case-control studies, a statistically significant decreased
risk for CRC was also observed (for high vs. low intake RR = 0.76, 95%CI = 0.60-0.96),
although in this case there was evidence of heterogeneity between studies. There was a non-
significant association between total folate intake and colorectal cancer (RR = 0.81, 95%
CI = 0.62-1.05), with no heterogeneity between studies. The meta-analyses included in the
WCRF/AICR Second Expert Report used four cohort studies to elucidate the association
between dietary folate intake and CRC. They reported a summary estimate of 0.84 (95%
CI = 0.76-0.93) per 100 µg dietary folate per day, with no significant heterogeneity between
studies [14].
Pancreas A meta-analysis of three cohort studies analysing the link between folate intake
and pancreatic cancer reported a protective effect of folate intake (summary cancer risk esti-
mate 0.94, 95% CI = 0.80-1.11) per 100 µg folate per day, with high heterogeneity between
studies [14]. However, a recent cohort study did not find protective effects of folate and pan-
creatic cancer risk when comparing those in the highest folate intake quintile with those in
the lowest folate intake quintile (adjusted hazard ratio (HR) = 1.37, 95% CI = 0.97-1.94) [34].
Esophagus The relationship between dietary folate and esophageal cancer risk has been
explored only in observational case-control studies. Results from these studies indicated a
decreased risk of esophageal cancer for those with the highest intake compared with those
with the lowest intake [14].
Breast A meta-analysis has been carried out on the relationship between folate intake and
risk of breast cancer. For prospective studies, there was no association between breast can-
cer for the highest versus the lowest category of dietary folate intake (summary estimate =
0.96, 95% CI = 0.87-1.05), with some heterogeneity. For case-control studies, there was a sta-
tistically significant inverse association between dietary folate intake and breast cancer risk
(high versus low intake summary estimate = 0.73, 95% CI = 0.64-0.83), with no significant
heterogeneity between studies [35].
Prostate Data on folate intake and prostate cancer risk are limited. A nested case-control
study from Sweden reported a statistically significant positive association between plasma fo-
late and prostate cancer risk (for highest versus lowest quartile, odds ratio (OR) = 1.60, 95%
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CI = 1.03-2.49). The risk for prostate cancer associated with B12 status was even stronger
(highest versus lowest quartile OR = 2.63, 95% CI = 1.61-4.29) [36]. The European Prospec-
tive Investigation into Cancer and Nutrition (EPIC) Study group carried out an investigation
of blood folate and vitamin B12 levels and prostate cancer risk. There was no significant as-
sociation between blood folate and prostate cancer risk (highest intake quintile versus lowest
intake quintile adjusted RR = 1.30, 95% CI = 0.88-1.93). Neither was there any association
between vitamin B12 status and prostate cancer risk (Q5 versus Q1 adjusted RR = 1.19, 95%
CI = 0.87-1.63) [37].
Intervention studies
Potential protective effects of folic acid against several types of cancer have been explored
using RCTs.
Colorectal cancer The Aspirin/Folate Polyp Prevention Trial was a double-blind, pla-
cebo-controlled, randomised trial designed to study the efficacy of aspirin, folic acid, or both
for colorectal adenoma recurrence in those with a history of adenomas. Participants were
recruited at eight clinical centres in the United States and one in Canada over a period of
approximately 4 years. Following a 3 x 2 factorial design, 1021 patients were randomised to
receive either folic acid with or without aspirin or placebo with or without aspirin over a
3-year treatment period. Patients were invited to continue the trial for an additional 3 or 5
years if they had a colonoscopy within the first follow-up interval of 3 years. After the initial
3 years, the risk of developing at least one adenoma was 44.1% for folic acid and 42.4% for
placebo (unadjusted RR = 1.04, 95% CI = 0.90-1.20, P = 0.58). For those 607 who had a
second follow-up, the risk of developing at least one adenoma was 41.9% for folic acid and
37.2% for placebo (unadjusted RR = 1.13, 95% CI = 0.93-1.37, P = 0.23). Additionally, the
risk of developing at least three adenomas after the second follow-up interval was 9.9% for
folic acid and 4.3% for placebo (unadjusted RR = 2.32, 95% CI = 1.23-4.35). Results from
the Aspirin/Folate Polyp Prevention Trial, therefore, do not support the hypothesis that
folic acid supplementation at 1 mg per day reduces colorectal adenoma risk in those with a
history of adenomas [38].
A similar, but smaller, RCT – the United Kingdom Colorectal Adenoma Prevention (UK-
CAP) Trial – was carried out across nine centres in the United Kingdom and one in Denmark
to study whether 300 mg aspirin per day or 0.5 mg folic acid supplementation per day in col-
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orectal adenoma patients could prevent risk of colorectal adenoma recurrence over 3 years.
Following a 2 x 2 factorial design, patients were randomised to receive either 300 mg aspirin
or 0.5 mg folic acid or both or placebo for 3 years. The UKCAP study reported that the risk
of recurrence of at least one adenoma was 26.6% for those taking folic acid and 24.9% for
those taking placebo (RR = 1.07, 95% CI = 0.85-1.34). Furthermore, the risk of developing
at least one advanced adenoma was 12% for those taking folic acid and 12.4% for those tak-
ing placebo (RR = 0.98, 95% CI = 0.68-1.40). There was no evidence that 0.5 mg folic acid
supplementation reduced risk of colorectal adenoma recurrence [39]. Indeed, both studies
report, if anything, an increased risk at these relatively high doses of folic acid though this
effect was not significant in the smaller UKCAP trial and only significant for some measures
in the larger Asprin/Folate Polyp trial.
Animal studies have demonstrated that the protective effects of folate may depend on the
time that it is given and that supplementation with folic acid may accelerate the progression
of existing colorectal neoplasms [40, 41]. Whether or not this is also the case in humans
requires further clarification.
Breast The Women’s Antioxidant and Folic Acid Cardiovascular Study, conducted in the
United States, included 5442 female health professionals with pre-existing cardiovascular dis-
ease. These women, who had no cancer history, were randomised to receive either combined
2.5 mg folic acid per day, 50 mg vitamin B6 per day, and 1 mg vitamin B12 per day or
placebo for 7.3 years in order to study the effect of combined folate, vitamin B6 (pyridoxine
hydrochloride), and vitamin B12 on total invasive cancer or breast cancer prevention. There
was no significant effect of treatment on risk of total invasive cancer (HR = 0.97, 95% CI
= 0.79-1.18; P = 0.75). Individual invasive cancers included were breast, colon and rectum,
lung, uterine, ovary, lymphoma, leukemia, multiple myeloma, pancreas, kidney, urinary
bladder, thyroid, skin melanoma, and others. For breast cancer, the HR was 0.83, 95% CI
= 0.60-1.14, P = 0.24. Combined supplementation with folic acid, vitamin B6, and vitamin
B12 did not offer any significant effect on total invasive cancer or breast cancer risk among
women [42].
Prostate Secondary analyses of the Aspirin/Folate Polyp Prevention Trial (see above) were
performed to better understand the relationship between folic acid supplementation and
prostate cancer risk. Six hundred forty-three men in the Aspirin/Folate Polyp Prevention
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Trial were randomised to receive either folic acid supplementation or placebo. Participants
completed a semi-quantitative food frequency questionnaire, and non-fasting blood samples
to measure the status of folate and other B vitamins were taken at the start of the trial. Base-
line dietary folate intake (modelled as a continuous variable) was non-significantly inversely
associated with prostate cancer risk (multi-variable adjusted HR = 0.65, 95% CI = 0.35-1.20).
Folic acid supplementation, on the other hand, was associated with a significantly increased
risk of prostate cancer (multi-variable adjusted HR = 2.58, 95% CI = 1.14-5.86) [43].
While abundant data on nutrition and cancer risk exist, these data are not always consistent
and in many cases a clear picture in relation to individual nutrients has yet to emerge.
2.3 Nutrition and epigenetics
One way in which nutrition may modulate carcinogenesis is through epigenetic pathways.
In human studies, the best demonstration for this are the ways in which folic acid affects
DNA methylation in CRC.
2.3.1 Diet and DNA methylation patterns in observational studies
Two studies (one cohort study and one case-control study) reported an inverse association
between dietary folate intake and promoter methylation in genes implicated in cancer – APC-
1A, p14ARF, p16INK4A, hMLH1, O6-MGMT, and RASSF1A – and in carcinoma and adenoma
tissue [11, 35]. In both studies, the relationship between folate intake and promoter methy-
lation in genes implicated in CRC were investigated; the case-control study also included a
subanalysis of the effect of MTHFR C677T genotype on this relationship [19]. Those with a
high dietary folate intake (>212 µg per day) were at decreased risk for having at least three
genes methylated (OR for ≥3 methylated versus <3 methylated = 0.66, 95% CI = 0.29–
1.54), although this association was not statistically significant. In the cohort study, CRC
patients were divided into two groups – low folate/high alcohol and high folate/low alcohol.
Those in the low folate/high alcohol intake group were at higher risk of having at least one
gene methylated (84%) compared with those in the high folate/low alcohol group (70%, P =
0.085), though, again, this association was not statistically significant [44]. Subsequent follow-
up of associations between dietary folate, vitamin B2, vitamin B6, methionine, and alcohol
and MLH1 promoter methylation in the same cohort was carried out. Dietary folate intake
did not affect MLH1 hypermethylation in men (tertile 3 versus tertile 1 RR = 0.88, 95% CI
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= 0.36-2.14) or women (tertile 3 versus tertile 1 RR = 0.88, 95% CI = 0.33-2.32). While
there were no associations between folate intake and MLH1 hypermethylation, there was a
significant positive association between vitamin B6 intake and MLH1 hypermethylation in
men (high versus low intake RR = 3.23, 95% CI = 1.15-9.06) [45].
A case-control study investigated the risk of genomic DNA hypomethylation in response
to folate status in colorectal adenoma patients and controls. DNA methylation patterns
were determined in both leukocytes and adenoma tissues. Compared with controls, cancer
patients had 26% lower folate status (95% CI = 6-44%, P = 0.01). Adenoma tissue was 26%
(95% CI = 8-56%, P = 0.009) more hypomethylated than control tissues, while leukocyte
DNA from those with adenomas was 16% more (95% CI = 8-30%) hypomethylated than
from those without adenomas [46].
2.3.2 Diet and DNA methylation in intervention studies
Few studies have evaluated the relationship between controlled folate intake and global DNA
methylation in humans. In the studies, healthy volunteers consumed low-folate diets fol-
lowed by folate repletion and monitoring of global methylation in leukocytes. In one study,
eight women were kept on a low-folate diet (56 µg folate per day to 516 µg folate per day)
for 91 days in a metabolic ward. Blood was drawn on 13 occasions throughout the study
period. Dietary folate was inversely associated with global DNA hypomethylation (analysis
of variance (ANOVA) P < 0.001). Reversal of genome-wide DNA hypomethylation was
observed following folate repletion at 286-516 µg folate per day [47]. A study of genomic
DNA methylation in 33 elderly women showed similar results after folate depletion. These
women were given a folate-deficient diet (118 µg folate per day) for 7 weeks followed by
a folate-repletion diet of 200 or 415 µg folate per day for another 7 weeks. Global DNA
hypomethylation in leukocytes was inversely related to folate intake (P = 0.0025), and this
association was significant, but there were no significant changes to DNA methylation after
folate repletion [48]. Two other folate depletion-repletion studies also looked into the effect
of the MTHFR C677T genotype on global leukocyte DNA methylation [49, 50]. Null as-
sociations were found between global leukocyte DNA methylation and folate depletion or
repletion, and this association was not modified by MTHFR C677T genotype (P > 0.05) for
one study [40], while the second study found a slight increase in global DNA methylation
during folate repletion for those with the MTHFR 677TT genotype [50].
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2.3.3 Folic acid, vitamin B12, and DNA methylation in randomised,
placebo-controlled intervention trials
Randomised, placebo-controlled intervention trials in humans studying the relationship be-
tween nutrients and DNA methylation have, to date, been limited to folate and vitamin B12
supplementation.
Global DNA methylation
To our knowledge, eight randomised, placebo-controlled intervention trials investigating the
effects of supplementation on DNA methylation have been published, nearly all of which
have been carried out in patients with colorectal adenomas. Table 2.1 summarises these
RCTs. Nearly all the studies used supraphysiological doses of folic acid. Two studies used
volunteers without a past or present history of cancer [51, 52]. In a double-blinded, ran-
domised, placebo-controlled, prospective trial conducted in Australia, 63 volunteers were
recruited and given 2 mg folic acid per day and 20 µg vitamin B12 per day or a placebo for 12
weeks. Blood samples from the volunteers were collected at three time points throughout the
intervention trial (baseline, midpoint, end). There were statistically significant increases in
serum vitamin B12 (P=0.004) and red blood cell folate (P < 0.0001) and a decrease in plasma
homocysteine (P < 0.0001) for those in the intervention group at the end compared with
at the start of the trial. When comparing the difference between the placebo group and the
intervention group at midpoint and baseline, there were also statistically significant increases
in serum vitamin B12 (P = 0.01), red blood cell folate (P = 0.0001), and plasma homocys-
teine (P = 0.0001). However, the highly significant changes in B vitamin status were not
reflected in global DNA methylation in the intervention group at the end compared with
the start of the trial, nor when comparing the placebo group with the intervention group
both at midpoint and at the end of the study [52].
In a 2006 study by Basten et al. [51], 61 healthy volunteers with red cell folate concentrations
between 200 and 650 nmol/L were randomised to receive either 1.2 mg folic acid or a placebo
for 12 weeks. Whole blood was obtained from volunteers at the start of the study and
again after the intervention at week 12. The intervention had no significant effect on DNA
methylation.
Five of the other intervention trials, conducted in colorectal adenoma patients, assessed
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global methylation [53–57], while one intervention trial looked into DNA methylation in
promoter regions of specific genes [58] in colorectal tumour tissue. In a study carried out
by Cravo et al. in 1994, nonsignificant changes in DNA methylation levels were observed
after 6 months in those who received placebo, but for those taking very high-dose folic acid
(10 mg per day), there was a significant attenuation of tumour DNA hypomethylation (P <
0.02). DNA hypomethylation was significantly higher in carcinomas than in adenomas (P
< 0.05) [53]. In a long-term crossover intervention trial, 6 months supplementation with
folic acid caused an increase in global DNA methylation in 7 of 20 patients with adenomas
(P = 0.05). Placebo treatment following folic acid supplementation returned global DNA
methylation levels to their original values. This decrease in DNA hypomethylation result-
ing from folic acid intervention was significant only for those presenting a single polyp as
opposed to multiple polyps (P = 0.007) [54]. In another study, folic acid supplementation in
colorectal adenoma patients for 1 year significantly decreased their DNA hypomethylation
levels at both 6 months and 1 year after the start of the intervention (P = 0.001), whereas
for patients in the control group, placebo administration was associated with a significant
increase in genomic DNA methylation only at 1 year (P = 0.04). At 6 months, there was
also significantly higher genomic DNA methylation in the treatment group compared with
placebo group (P = 0.02), but paradoxically this difference disappeared at 1 year. The authors
suggest that the unknown factors that caused an increase in genomic DNA methylation in
the placebo group warranted further investigation [55].
Results from a more recent trial in adenoma patients suggest that folic acid supplementa-
tion significantly attenuated global DNA hypomethylation in leukocytes and colonic mu-
cosa [56]. The latest investigation on the relationship between folate and other B vitamins
and LINE-1 (long interspersed nucleotide element, a retrotransposon that makes up 15% of
the human genome) methylation as a proxy for global DNA methylation was conducted as
part of the Aspirin/Folate Polyp Prevention Study (see above). Three hundred eighty-eight
participants from the Aspirin/Folate Polyp Prevention Study who consented to having nor-
mal bowel mucosa biopsies approximately 3 years after baseline were included in the analyses.
Those randomised to the folic acid supplementation arm had greater LINE-1 methylation
levels (mean = 64.53%, 95% CI = 64.16-64.90) compared with those in the placebo group
(mean = 64.21%, 95% CI = 63.83-64.58, although this difference was not statistically sig-
nificant. Total folate intake, multivitamin use, and dietary intake of vitamins B2 and B6 at
baseline were not associated with LINE-1 methylation at baseline [57].
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The picture emerging from these seven trials remains unclear, with some studies demon-
strating decreases in global DNA hypomethylation [54, 56] and other studies showing no
change [51, 52, 57]. Further research is required to fully delineate the consequences of sup-
plementation as a form of chemoprevention. Epigenetic changes that occur in cancer are
complex, with some genes being hypermethylated and others hypomethylated; therefore
measures of global methylation may be of limited value in elucidating nutrient-mediated
epigenetic effects in cancer.
Gene-promoter methylation
While multiple randomised, placebo-controlled intervention trials on folic acid supplemen-
tation and global DNA methylation have been conducted, to our knowledge, there has only
been one on folic acid supplementation and promoter methylation [58]. Eighty-six patients
with a history of colorectal adenomas were randomly assigned to receive a high dose of 5
mg folic acid per day plus 1.25 mg vitamin B12 per day or placebo for 6 months. Six tu-
mour suppressor and DNA repair genes were assessed for promoter methylation in DNA
from rectal biopsies at baseline and after the intervention. Results suggested that promoter
hypermethylation occurred more often in the folic acid and vitamin B12 supplementation
group compared with the placebo group though the effect was only approaching statistical
significance. If there is folate deficiency, SAM is depleted and any DNA hypomethylation
that might result from this has been hypothesised to cause DNA instability. This study
suggests that extremely high intakes of folic acid (>1 mg per day) and vitamin B12 may
be positively associated with DNA promoter hypermethylation in rectal mucosal DNA, in-
dicating an optimal balance between global DNA hypomethylation and promoter-specific
DNA hypermethylation.
2.4 Conclusion
Body fatness, smoking, and an unhealthy diet are well-established risk factors for cancer.
A healthy diet and other lifestyle habits are recommended to reduce the risk of cancers.
Specific nutrients have been shown to influence carcinogenesis, and one mechanistic route
may operate via an effect on epigenetic processes. This relationship has been most often
studied in relation to folate and DNA methylation in CRC. However, the results from these
studies are not entirely homogeneous, and this may be due in part to differences in study
designs including DNA methylation assays, and duration, dose, and timing of exposure to
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folate/folic acid, which also require further clarification. The links between diet, epigenetics,
and cancer are complicated but the hope is that, ultimately, diet could be used to reverse
epigenetic modifications that predispose to cancer.
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Abstract
Plasma B vitamins and methionine may influence global DNA methylation, an early event
in colorectal carcinogenesis. LINE-1 DNA methylation is often used as an indicator of global
DNA methylation. Data describing the impact of plasma B vitamins on LINE-1 methyla-
tion in colorectal carcinogenesis via one-carbon metabolism in healthy individuals are sparse
but are important given their potential for improving our understanding of cancer processes.
We have used data from 1,142 age- and sex-stratified randomly selected individuals who had
participated in a population-based survey. Those in the extremes (10th (2.69-5.62 nmol/L)
and 90th (37.24-95.94 nmol/L) percentiles) of plasma folate concentrations were selected.
In a total of 275 healthy, cancer-free persons with plasma folate in the 10th (n=138) and
90th (n=137) percentiles, we describe leukocyte LINE-1 DNA methylation in relation to
circulating concentrations of B vitamins (folate, riboflavin, vitamin B6 species (pyridoxal 5’-
phosphate, pyridoxal, and 4-pyridoxic acid), cobalamin, methylmalonic acid (MMA)) and
methionine, and dietary and lifestyle characteristics. Age, sex, and MTHFR C677T genotype
were also examined as possible predictors of LINE-1 methylation in the extremes separately
using multivariable linear regression. Our results suggest no difference in leukocyte LINE-1
DNA methylation between those in the 10th and in the 90th percentile for plasma folate. Age
was inversely related to LINE-1 methylation in both extremes, and LINE-1 DNA methyla-
tion was lower in females compared with males in the 10th percentile of plasma folate, while
there was no association with MTHFR C677T genotype.
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3.1 Introduction
An early event in cancer progression garnering widespread attention is the global loss of
methylated cytosine residues in DNA [1,2], which possibly acts by increasing mutation rates
and affecting chromosomal stability [3, 4]. There is a strong interest in understanding deter-
minants of global DNA methylation in cancer, other diseased states, and during good health.
Folate and other B vitamins are thought to influence DNA methylation because of their
essential role in regulating one-carbon metabolism (OCM), which includes the pathway
directly involved in producing methyl groups for DNA methylation processes. Several
lifestyle and genetic factors may influence OCM: alcohol interferes with folate absorption
and metabolism [5], cigarette smoking reduces systemic circulating concentrations of B vi-
tamins [6], and the T allele of the common 677 C → T polymorphism in the methylenete-
trahydrofolate reductase (MTHFR) gene decreases activity of this enzyme and subsequently
the formation of 5-methyltetrahydrofolate, the most abundant folate species in blood plasma.
Direct quantification of total 5-methylcytosine content is ideal for measuring global DNA
methylation but is often cumbersome in epidemiological studies, as large amounts of DNA
and specialised equipment are needed. As such, PCR-based methods evaluating methylation
at repeat elements, such as long interspersed nuclear element (LINE-1) repeats, have been
developed and are commonly used as a substitute for global DNA methylation. Consensus
about whether LINE-1 methylation is a good surrogate for global DNA methylation for
studies involving folate has not been established, yet it is often used for this very purpose.
Previous studies with healthy persons have observed leukocyte LINE-1 DNA methylation
in association with age [7–9], sex [10, 13], arsenic [11], iron [11], white blood cell count [10],
industrial exposures [14], benzene [15], physical activity [16] and dietary folate intake of for-
tified foods [17]. In healthy subjects, neither intake of natural folates nor dietary folate equiv-
alents have been associated with leukocyte LINE-1 methylation [17], and there are reports
of positive [18] and null associations [19] between plasma folate and LINE-1 methylation.
Measuring B vitamin and methionine concentrations in plasma reflect nutrient absorption,
nutrient-nutrient interactions, tissue turnover, metabolism, and excretion, and the inherent
biases related to dietary assessment tools are avoided [20].
Given the potential importance of folate and other B vitamins as determinants of global
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DNA methylation in health and disease, we aimed to elucidate their cross-sectional associa-
tion to LINE-1 DNA methylation using a population-based survey. Evaluating the relation-
ships between B vitamins and LINE-1 methylation in healthy individuals will further our
understanding of these associations in health and disease. Here, we describe circulating con-
centrations of B vitamins and methionine, dietary and lifestyle characteristics, and leukocyte
LINE-1 DNA methylation in healthy, cancer-free individuals in the 10th and 90th percentiles
of plasma folate concentrations. We also examine age, sex, MTHFR C677T genotype as pos-
sible predictors of LINE-1 methylation in these extremes of folate status, separately. Folate
extremes were selected in order to capture the widest range of plasma folate.
3.2 Materials and methods
3.2.1 Study population
Details about the study design have previously been presented [21]. Briefly, the data were
obtained from the Nijmegen Biomedical Study, a population-based survey conducted by the
Department for Health Evidence and the Department of Clinical Chemistry at Radboud
University Medical Centre. Between November 2001 and February 2002, 21,756 age- and
sex-stratified randomly selected inhabitants of the municipality of Nijmegen in the Nether-
lands received an invitation to complete a postal questionnaire on, e.g., lifestyle and medical
history, and to donate a 10 ml blood sample in a Vacutainer tube. The response to the
questionnaire was 43% (n=9350), and among these, 69% (n=6468) donated a blood sam-
ple. Later, between July 2007 and December 2010, those between the ages of 50 and 70 and
who had previously agreed to be contacted again (n=5363) were invited to complete a food
frequency questionnaire (FFQ), and to give another blood sample, from which plasma B vi-
tamins would be measured [22]. Of the 2506 participants who completed a food frequency
questionnaire, 1149 also gave a blood sample. Plasma concentrations of vitamin metabolites
were measured in these participants. The Institutional Review Board approved the study and
all participants provided written informed consent.
3.2.2 Biochemical analyses
Venous blood samples from non-fasting participants were collected in Vacutainer brand
tubes containing EDTA and were put on ice immediately after collection. Plasma and
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buffy coat were pipetted separately into cryogenic vials and stored at -80oC. Plasma con-
centrations of folate (5-methyltetrahydrofolate) and cobalamin were determined by micro-
biological assays using a colistin-sulfate resistant strain of Lactobacillus leichmannii and a
chloramphenicol-resistant strain of Lactobacillus casei, respectively [23, 24]. Plasma con-
centrations of riboflavin, vitamin 6 species (pyridoxal 5’-phosphate (PLP), pyridoxal (PL),
and 4-pyridoxic acid (PA)), and methionine were measured using liquid chromatography-
tandem mass spectrometry [25, 26], and methylmalonic acid (MMA) was measured by gas
chromatography-tandem mass spectrometry [27]. Samples were analysed in batches of 86
and quality control included 6 calibration samples, 3 control samples, and 1 blank sample
in each batch. Coefficients of variation were 4-5% (folate), 6-13% (riboflavin), 3-11% (vita-
min B6 species), 4-5% (cobalamin), 1-3% (methionine), and 2-3% (MMA). Laboratory staff
were blinded to LINE-1 methylation status of the participants donating a blood sample. All
biomarkers were analysed at BEVITAL AS, Bergen, Norway (www.bevital.no).
3.2.3 DNA extraction, bisulfite conversion, and quantification of LINE-
1 methylation
The Hamilton STAR workstation was used to isolate DNA from buffy coat, as described by
the manufacturer (Hamilton Robotics). First, magnetic beads that bind DNA were added to
the samples. A magnetic box was then used to separate the DNA from other blood com-
ponents. After DNA was eluted in an elution buffer, the amount of DNA in each sam-
ple was determined using a Caliper automation system (Caliper Life Sciences). One hun-
dred nanograms of DNA were bisulfate converted using EZ DNA Methylation GoldTM Kit
(Zymo Research). We have used and adapted the method to quantify global DNA methyla-
tion using bisulfite-PCR and pyrosequencing developed by Yang et al. [28]. Repetitive ele-
ments primers were designed towards a consensus LINE-1 sequence (3 tandem CpG sites at
positions 318, 321, and 327 (GenBank accession number X58075). Analysis of DNA methy-
lation in LINE-1 repetitive elements was performed (Qiagen N.V.). The PCR product was
bound to Sepharose HP (Amersham Biosciences) and the Sepharose beads containing the im-
mobilised PCR product were prepared for pyrosequencing according to the manufacturer’s
instructions (Qiagen N.V.). Pyrosequencing was performed on PCR product with bound
LINE-1 sequencing primer using the Pyromark Q24 System (Qiagen N.V.). The nucleotide
dispensation order was GCT CGT GTA GTC AGT CG. For each CpG site, the degree
of methylation was expressed as the percentage of 5-methylated cytosines (%5mC) over the
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sum of methylated and unmethylated cytosines. Mean LINE-1 methylation was the aver-
age methylation across all three sites. Reproducibility was confirmed by analysing 10% of
the samples in duplicate. The within-sample coefficients of variation in duplicate runs were
3.9-6.8%.
3.2.4 Genotyping assay
Genotyping of the MTHFR C677T polymorphism was determined, in DNA extracted from
buffy coat, using TaqMan R© in accordance with the information provided by Applied Biosys-
tems (http://www.appliedbiosystems.com). Laboratory staff were blinded to B vitamin and
LINE-1 methylation status of the study participants. To assess reproducibility, genotyping
was repeated for 10% of the samples, and complete concordance was found between the two
sets of results. Genotype frequencies were in Hardy-Weinberg equilibrium as tested by a χ2
test (P>0.05).
3.2.5 Statistical analyses
Of the 1149 participants who gave a blood sample, 7 participants were using antibiotics at
the time of blood draw and were subsequently excluded from analyses, as antibiotics interfere
with the microbiological assays used to measure plasma folate and cobalamin, resulting in
artificially low concentrations of these biomarkers. From the remaining 1142 participants,
those in the extremes (the 10th and 90th percentiles) for plasma folate were selected – 151
participants in the 10th percentile of plasma folate (2.69-5.62 nmol/L) and 151 participants
in the 90th percentile of plasma folate (37.24-95.94 nmol/L). Of these 302 participants, there
was no information about MTHFR C677T genotype for 5 persons, and 22 individuals had a
personal history of cancer. Therefore, 275 participants were included in our analyses – 138
with low plasma folate and 137 with high plasma folate.
Descriptive statistics were used to characterise the total population (n=275) stratified by
extremes of plasma folate. Median and corresponding interquartile range (IQR) were cal-
culated for all continuous variables. Categorical variables were expressed in numbers and
corresponding percentages. Comparisons of population characteristics between those in the
10th and 90th percentiles were made using Wilcoxon rank sum test for continuous variables,
and χ2 test or Fisher’s exact test for categorical variables. As an additional examination of the
data, we performed the same analyses stratified by MTHFR C677T genotype (CC vs. TT).
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As well, multivariable linear regression models were used to explore whether age (continu-
ous), sex (male/female), or MTHFR C677T genotype (CC/CT/TT) were related to LINE-1
DNA methylation levels for the 10th and 90th folate percentiles separately. All analyses were
performed using SAS version 9.2 (SAS Institute, Cary, NC).
3.3 Results
Characteristics of the population stratified by plasma folate extremes are presented in Ta-
ble 3.1. Overall, mean LINE-1 DNA methylation expressed as a percentage of methylated
cytosines was not different between the two groups: 73.7 (IQR 72.6-74.6) for the 10th per-
centile and 73.6 (IQR 72.5-74.7) for the 90th percentile. There was also no difference when
we looked at each CpG site separately. Compared with those in the 90th percentile of plasma
folate, those in the 10th percentile were similar in age, were more likely to be male, were less
educated, had higher BMI, consumed less alcohol, had similar family histories of colorec-
tal cancer, and were more likely to have MTHFR 677CT or TT genotype. As expected, all
plasma vitamers were lower in the 10th percentile group except for MMA and methionine,
which were higher. While not statistically significant, there were more ever smokers in the
10th percentile folate group compared with the 90th percentile group.
Table 3.2 depicts the associations between age, sex, and MTHFR C677T genotype with LINE-
1 methylation within plasma folate extremes using multivariable linear models. For those in
the 10th folate percentile, age was inversely related to LINE-1 methylation (β=-0.07, 95%CI
-0.13, -0.01). Compared with males, females had lower LINE-1 methylation levels (β=-0.68,
95%CI -1.37, 0.01). There was no association between MTHFR C677T genotype and LINE-1
methylation (compared with CC genotype, β=0.59, 95%CI -0.15, 1.33 for CT, and β=0.26,
95%CI -0.76, 1.29 for TT). For those in the 90th folate percentile, age was also inversely
related to LINE-1 methylation (β=-0.08, 95%CI -0.14, -0.02). There was no association be-
tween sex (β=-0.41, 95%CI -1.20, 0.38) nor MTHFR C677T genotype and LINE-1 methyla-
tion (compared with CC genotype, β=-0.18, 95%CI -0.99, 0.63 for CT, and β=-0.28, 95%CI
-1.50, 0.95 for TT).
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Table 3.1 Characteristics of the population by extremes of plasma folate concentration.
Plasma folate concentration (nmol/L)
10th percentile 90th percentile
2.69-5.62 nmol/L 37.24-95.94 nmol/L
n=138 n=137
Mean LINE-1 DNA methylation (%), median (IQR) 73.7 (72.6-74.6) 73.6 (72.5-74.7)
Methylation at position 318, median (IQR) 79.2 (77.9-80.0) 78.8 (77.6-79.9)
Methylation at position 321, median (IQR) 70.1 (68.7-71.0) 70.1 (68.8-71.1)
Methylation at position 327, median (IQR) 72.1 (70.7-73.3) 72.3 (70.9-73.5)
Age at blood draw, median (IQR) 62.3 (56.6-66.9) 61.2 (56.0-66.8)
Sex, n (%)a
Female 54 (39.1) 89 (65.0)
Male 84 (60.9) 48 (35.0)
High educationb, n (%)a 39 (29.3) 61 (48.0)
BMI, median (IQR)a 27.5 (25.2-30.1) 25.7 (23.4-28.7)
Plasma concentrations, median (IQR)
Riboflavin (nmol/L)a 11.7 (8.2-17.5) 19.8 (12.6-31.5)
PLP (nmol/L)a 37.4 (28.3-47.1) 96.0 (62.2-140.1)
PL (nmol/L)a 11.9 (9.2-14.6) 21.9 (15.9-33.3)
PA (nmol/L)a 14.0 (10.2-18.3) 28.5 (20.0-44.6)
Sum vitamin B6 (nmol/L)a 63.1 (50.9-79.4) 138.0 (104.7-218.3)
Cobalamin (pmol/L)a 347.0 (272.1-436.8) 435.8 (342.3-548.2)
MMA (µmol/L)a 0.18 (0.14-0.23) 0.16 (0.14-0.20)
Methionine (µmol/L)a 25.5 (22.5-28.4) 23.5 (21.2-26.1)
Alcohol intake (g/day), median (IQR)a 5.4 (0.9-15.0) 9.4 (1.7-22.9)
Smoking status, n (%)
Current smoker 30 (21.7) 17 (12.4)
Former smoker 70 (50.7) 68 (49.6)
Never smoker 38 (27.5) 52 (38.0)
MTHFR C677T genotype, n (%)a
CC 42 (30.4) 75 (54.7)
CT 75 (54.4) 47 (34.3)
TT 21 (15.2) 15 (11.0)
Family history of colorectal cancer, n (%) 11 (8.0) 17 (12.4)
aP value < 0.05; difference tested between 10th and 90th percentiles with χ2 or Fisher’s exact test for categorical
variables and Wilcoxon rank sum test for continuous variables.
bCollege or university.
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Table 3.2 Cross-sectional associations of LINE-1 DNA methylation with age, sex, and
MTHFR C677T genotype according to plasma folate extremes.
Plasma folate concentration (nmol/L)
10th percentile
2.69-5.62 nmol/L
n=138
90th percentile
37.24-95.94 nmol/L
n=137
n %5mC (IQR) β (95%CI) n %5mC (IQR) β (95%CI)
Age at blood draw 138 -0.07 (-0.13, -0.01) 137 -0.08 (-0.14, -0.02)
Sex
Male 84 73.8 (72.5-74.8) Ref.b 48 73.6 (72.4-75.0) Ref.b
Female 54 73.5 (72.6-74.3) -0.68 (-1.37, 0.01) 89 73.6 (72.6-74.5) -0.41 (-1.20, 0.38)
MTHFR C677T genotype
CC 42 73.4 (72.1-74.5) Ref. 75 73.7 (72.6-74.7) Ref.
CT 75 73.9 (72.6-74.7) 0.59 (-0.15, 1.33) 47 73.6 (72.6-74.6) -0.18 (-0.99, 0.63)
TT 21 73.7 (73.2-74.6) 0.26 (-0.76, 1.29) 15 72.9 (72.4-74.5) -0.28 (-1.50, 0.95)
aResults of multivariable linear regression.
bRef. indicates reference category.
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3.4 Discussion
In the present study, we have described leukocyte LINE-1 DNA methylation and circulat-
ing concentrations of B vitamins and methionine, and dietary and lifestyle characteristics in
healthy, cancer-free individuals aged 50-70 in the extreme groups (10th and 90th percentiles)
of plasma folate. We did not observe a difference in leukocyte LINE-1 DNA methylation be-
tween the extremes of plasma folate. In healthy individuals, blood folate concentrations have
previously been positively associated [18] and not associated with global DNA methylation
[19] while dietary folate intake was also not associated with LINE-1 methylation [17]. Unlike
in the current study, Friso et al. [18] and Kok et al. [19] have measured global DNA methyla-
tion using liquid chromatography(LC)-electrospray ionization(ESI)-mass spectrometry(MS)
and stable isotope dilution liquid chromatrography(LC)-electro-spray ionization(ESI)-tandem
mass spectrometry(MS/MS), respectively, as opposed to LINE-1 as we did. However, our re-
sults are consistent with those presented by Kok et al. despite the differences in methods used
to measure global DNA methylation. The previously observed null associations between
LINE-1 methylation and dietary folate from natural foods and dietary folate equivalents [17]
are also in line with our own results.
We have also observed that, as expected, plasma concentrations of circulating B vitamins
were all higher for those in the 90th percentile of plasma folate compared with the 10th
percentile. This may reflect differences in diet or lifestyle between the groups and common
dietary sources of most B vitamins [29]. MMA, as a marker of vitamin B12 status [30] was
higher in participants with low folate, which could be explained by lower vitamin B12 status
in these subjects. Our observation of higher frequency of MTHFR 677CC genotype and
lower frequency of TT genotype in the 90th percentile of plasma folate compared to those
in the 10th percentile is consistent with previous published data [18]. This is explained by
the higher catalytic activity of MTHFR associated with the MTHFR 677CC variant, which
more efficiently converts 5,10-methylenetetrahydrofolate into 5-methyltetrahydrofolate in
the presence of adequate riboflavin [18]. This lends support to the integrity of our data.
Our observation of an inverse association between age and LINE-1 methylation in leukocytes
has been previously reported [7]; the inverse association between age and leukocyte global
DNA methylation has also been documented [8, 9]. Lower LINE-1 methylation [10, 12]
and global DNA methylation [9] in females compared with males have been observed in
the majority of studies. Reasons for sex-specific differences in LINE-1 and global DNA
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methylation have not yet been fully elucidated, but Singer et al. recently confirmed the
presence of LINE-1 hypomethylation on the inactive X chromosome, which could play a
role in maintaining X chromosome inactivation [31]. Natural hormone cycles [32] have
also been proposed as a possible explanation for sex-specific differences in LINE-1 DNA
methylation.
In our dataset, alcohol intake was higher in the 90th percentile than in the 10th percentile,
which may seem paradoxical since alcohol is a folate antagonist, but this could be partly
explained by the adherence to more healthful lifestyle habits by highly educated females and
never smokers in subjects with high folate status [33].
The use of LINE-1 methylation as a surrogate for global DNA methylation is attractive
because it is straightforward and has been reasonably correlated with global DNA methy-
lation [28]. Additionally, age [7, 9], sex [10, 13], arsenic [11], iron [11], white blood cell
count [10], industrial exposures [14], benzene [15], physical activity [16] and dietary folate
intake of fortified foods [17] have been associated with LINE-1 methylation in leukocytes,
and LINE-1 methylation in tumours has been shown to predict cancer survival in colon can-
cer patients [34] and has been associated with microsatellite instability [35]. However, results
from the current study do not support an association between plasma folate and leukocyte
LINE-1 methylation in healthy cancer-free individuals.
Comparisons between different studies are difficult when different methods are used to mea-
sure global DNA methylation (for example, LC-ESI-MS/MS [19] vs. LC-ESI-MS [18]) or
when repeat elements such as LINE-1 are used as a surrogate for global DNA methylation.
Different methods could yield dissimilar results. In the current study, we have quantified
LINE-1 methylation at 3 tandem CpG sites in a LINE-1 promoter. Other studies have mea-
sured LINE-1 at four CpG sites [11], and it may be crucial to consider the variability in
methylation at different loci [31] when interpreting results.
Our study employs a cross-sectional design, which does not allow us to make causal infer-
ences, but nonetheless provide important insight into the relationships between plasma folate
and LINE-1 methylation in healthy individuals. We have measured LINE-1 methylation in
leukocytes, which are comprised of a mixture of granulocytes and agranulocytes. Previous
studies have shown differences in LINE-1 methylation between neutrophils and lympho-
cytes [10]. Blood counts were not measured in the current study, and this should be kept in
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mind when interpreting our results. A strength of our study is that we have measurements
of both plasma folate and LINE-1 methylation in the same blood sample. Moreover, our
study is based on concentrations of B vitamins and biomarkers in plasma, which help avoid
inherent biases associated with dietary assessment using FFQs [20]. The plasma folate con-
centrations in our study were essentially similar to those in other Dutch populations (range
3.1-32.4 nmol/L) [19, 36].
In conclusion, leukocyte LINE-1 DNA methylation levels did not differ between those in the
10th percentile and those in the 90th percentile for plasma folate concentrations in healthy
individuals. For those in the 10th percentile, females had lower LINE-1 methylation com-
pared to males, whereas this difference was not present for individuals in the 90th percentile.
Age was inversely related to LINE-1 methylation independent of plasma folate, and there was
no indication of an association between MTHFR C677T genotype and LINE-1 methylation.
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Abstract
A global loss of cytosine methylation in DNA has been implicated in a wide range of diseases.
There is growing evidence that modifications in DNA methylation can be brought about
by altering the intake of methyl donors such as folate. We examined whether long-term
daily supplementation with 0.8 mg of folic acid would increase global DNA methylation
compared with placebo in individuals with elevated plasma homocysteine. We also inves-
tigated if these effects were modified by MTHFR C677T genotype. Two hundred sixteen
participants out of 818 subjects who had participated in a randomised double-blind placebo-
controlled trial were selected, pre-stratified on MTHFR C677T genotype and matched on age
and smoking status. They were allocated to receive either folic acid (0.8 mg/d; n = 105) or
placebo treatment (n = 111) for three years. Peripheral blood leukocyte DNA methylation
and serum and erythrocyte folate were assessed. Global DNA methylation was measured
using liquid chromatography-tandem mass spectrometry and expressed as a percentage of
5-methylcytosines versus the total number of cytosine. There was no difference in global
DNA methylation between those randomised to folic acid and those in the placebo group
(difference = 0.008, 95%CI = -0.05,0.07, P = 0.79). There was also no difference between
treatment groups when we stratified for MTHFR C677T genotype (CC, n = 76; CT, n =
70; TT, n = 70), baseline erythrocyte folate status or baseline DNA methylation levels. In
moderately hyperhomocysteinemic men and women, long-term folic acid supplementation
does not increase global DNA methylation in peripheral blood leukocytes.
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4.1 Introduction
Disturbances in DNA methylation, one of several epigenetic mechanisms, have been impli-
cated in many diseases ranging from cancers to cardiovascular disease. Two main types of
changes in DNA methylation patterns have been observed – global hypomethylation [1],
and regional hypermethylation, particularly in the promoter regions of certain genes such as
tumour suppressor genes or imprinted genes [2–4]. Global DNA methylation provides ge-
nomic stability and structure [5] while promoter hypermethylation inhibits the transcription
of associated genes, resulting in gene silencing [6].
Folate-mediated one-carbon metabolism is key for DNA methylation as well as for nucleotide
synthesis, and DNA repair and stability. Folate, a water soluble B-vitamin, functions as
a donor and acceptor of one-carbon units in its various forms in cellular metabolism. As
such, manipulation of intake of folate or other factors involved in one-carbon metabolism
can largely influence DNA methylation, and methyl-deficient and repletion diets have been
shown to alter global DNA methylation patterns in animal studies [7] and also in human
studies [8, 9] although the evidence is not unequivocal [10, 11].
Many factors affect the availability of methyl groups in folate-mediated one-carbon metabo-
lism. One of the most extensively studied genetic polymorphisms which can modify fo-
late metabolism is the 677 C→T polymorphism of the gene that codes for the enzyme
methylenetetrahydrofolate reductase (MTHFR). Methylenetetrahydrofolate reductase con-
verts 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, which is required for the
conversion of homocysteine to methionine. Rates of folate metabolism have been shown to
differ between those who have the TT genotype compared to those with the CC genotype;
production of methyl group donors is higher in those with the CC genotype compared to
those with the TT genotype [12].
Indeed, on a functional level, since homocysteine has to be remethylated to form methionine,
individuals with the MTHFR 677TT polymorphism have higher concentrations of plasma
homocysteine when folate status is low compared to those with the other two genotypes
[13, 14]. MTHFR 677TT individuals were also found to have lowered DNA methylation in
their leukocytes when folate status is low compared to those who have the MTHFR 677CC
genotype [15].
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Given the importance of DNA methylation in epigenetic regulation, and the documented
effects of experimental folate deprivation and repletion, it is relevant to know the ways in
which folic acid supplementation impacts DNA methylation. We investigated whether daily
supplementation of 800 mg folic acid for 3 years would increase global DNA methylation
in peripheral blood leukocytes compared with placebo in individuals with elevated homo-
cysteine concentrations. In addition, we addressed effects separately in strata of the MTHFR
C677T genotypes.
4.2 Materials and methods
Ethics statement The study protocol was approved by the Medical Ethics Committee of
Wageningen University. All participants gave written informed consent.
4.2.1 Study participants
Participants were a subset of Dutch men and post-menopausal women aged 50-70 years from
a central-eastern region of the Netherlands and who had participated in the Folic Acid and
Carotid Intima-media Thickness (FACIT) trial [16]. The FACIT trial was designed to in-
vestigate the effect of folic acid supplementation on atherosclerotic progression. Additional
outcomes of the trial were age-related decline in cognitive function and hearing [17–19]. Here
we present data for the effect of folic acid on global DNA methylation for a subset of partic-
ipants.
Detailed participant recruitment for this randomised double blind placebo-controlled trial
has been described previously [17]. Briefly, participants were recruited using municipal and
blood-bank registries and randomised between November 1999 and April 2001. Inclusion
criteria were plasma total homocysteine concentrations between 13 mmol/L and 26 mmol/L,
vitamin B12 less than 200 pmol/L, no intestinal disease, and no current use of B-vitamin
supplements or other medications that could influence folate metabolism or atherosclerotic
progression. Finally, more than 80% self-reported compliance during a 6-week placebo run-in
period was required.
After the initial measurement sessions, participants were randomly allocated to treatment
of 800 mg folic acid per day or placebo with permuted blocks of sizes four and six, which
varied randomly. Specialised staff who were not involved in the study allocated and labelled
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the capsule boxes with participants’ unique sequence number. Those participants in the same
household received the same treatment. The folic acid and placebo capsules were produced by
Swiss-Caps Benelux (Heerhugowaard, Netherlands) and were identical in appearance. Cap-
sules were individually packaged in foil strips containing 28 capsules per strip with the days
of the week printed on the back. Every year, participants received a 13-month supply of
capsules. Compliance was determined by capsule-return counts and a diary that registered
missed capsules. Diaries and capsules were returned by participants every 12 weeks.
For the present study, changes in global DNA methylation were assessed from stored frozen
aliquots from a sub-sample of the FACIT trial participants. Using only the data from the par-
ticipants who had completed the study (n=818), participants in the folic acid arm of the trial
were pre-stratified by MTHFR C677T genotype and matched to participants in the placebo
arm on age and current smoking status. Subjects were matched on these variables because
they are thought to influence global DNA methylation [20–25]. Additionally, sampling was
done such that each group of MTHFR C677T genotype was of the same size. This was done
to increase our power of hypotheses testing related to the genotypes and their effects on
global DNA methylation. Initially, 120 folic acid participants were matched to 120 in the
placebo group, but 24 samples were not measured due to human error in sample retrieval.
4.2.2 Laboratory measurements
Fasting venous blood was processed and samples were stored at -80oC. We measured serum
folate, erythrocyte folate, serum vitamin B12, plasma total homocysteine, plasma vitamin
B6 (pyridoxal 5’-phosphate (PLP)), in addition to serum creatinine and lipids as described
elsewhere [16]. In brief, serum and erythrocyte folate and serum vitamin B12 were mea-
sured using a chemiluminescent immunoassay (Immulite R© 2000, diagnostic Products Corpo-
ration). Erythrocyte folate measurements were done in duplicate. Plasma homocysteine was
determined with high performance liquid chromatography (HPLC) and fluorimetric detec-
tion [26]. Vitamin B6 was measured by HPLC. DNA was extracted from blood leukocytes
and the C677T polymorphism in the methylenetetrahydrofolate reductase (MTHFR) gene
was determined by PCR and restriction digest with HinF1 and attained at the beginning of
the study. Intra- and inter-assay variation coefficients for laboratory analyses were <15%.
A validated food frequency questionnaire was used at baseline and after the intervention to
estimate dietary folate intake during the past 3 months [27].
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Quantification of global DNA methylation was measured by liquid chromatography-tandem
mass spectrometry [28]. Global DNA methylation is expressed as a percentage of 5-methyl-
cytosines versus the total number of cytosines present in the genome.
4.2.3 Statistical methods
Non-parametric tests were used to compare differences within groups and between groups
before and after the intervention. Analysis of covariance (ANCOVA) was used to estimate
differences between groups at baseline and after the intervention and also to compare the ef-
fect of supplementation on global DNA methylation adjusted for baseline DNA methylation
and covariates. Medians, inter-quartile ranges, and 95% confidence intervals are presented.
The variables on which subjects were matched (i.e. age and current smoking status) were
used as covariates in our model. We performed subgroup analyses for those with deficient to
low-normal erythrocyte folate status at baseline and those with low and high baseline DNA
methylation. We also tested if the effect of folic acid on global DNA methylation was mod-
ified by MTHFR C677T genotype, age, current smoking status, alcohol intake, body mass
index (BMI), and sex. Previous literature suggests that BMI may be associated with global
DNA methylation [29, 30] and sex has been shown to influence DNA methylation [31–33].
There was no missing data on any of our outcome variables. Differences were considered
significant at P<0.05. All analyses were computed using SAS version 9.2 (SAS Institute Inc.,
Cary, NC).
4.3 Results
Two hundred sixteen participants (folic acid n= 105 and placebo n= 111) were included in
our analyses. Table 4.1 depicts the baseline characteristics of the population. There were
slightly more men in the placebo group than in the folic acid group (66.7% vs. 62.9%),
and more current smokers in the folic acid group (16.2% vs. 13.5%). Concordant with
the stratification procedure, there were roughly equal numbers of people in each MTHFR
C677T genotype for both treatment groups. Folate intake was similar between the treatment
groups, but alcohol consumption was higher in the folic acid group. Overall, participants
had a low median folate intake (188 mg/day), but there were only 20 serum folate deficient
(≤7 nmol/L) individuals and five individuals, who were deficient based on erythrocyte folate
concentrations (≤305 nmol/L).
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Table 4.2 shows the effects of folic acid supplementation on several metabolites throughout
the study. As expected, there were large increases in serum folate (535% increase), and ery-
throcyte folate (207% increase), and a fall in plasma total homocysteine (21.6% decrease) after
the intervention in the folic acid group compared to placebo (P<0.0001 for all). There were
no changes in dietary folate intake during the course of the intervention.
Median global DNA methylation levels throughout the study can be found in Table 4.3.
There was no significant change in DNA methylation within treatment groups after three
years (folic acid difference = 0.02, 95%CI = -0.05,0.02, P = 0.39; placebo difference = 0.02,
95%CI = -0.06,0.01, P = 0.62). There was also no difference in the effect of supplementa-
tion after three years between the two groups (difference = 0.008, 95%CI = -0.05,0.07, P =
0.79). There was no significant treatment effect of folic acid on global DNA methylation for
those with less than normal baseline red blood cell (RBC) folate (≤500 nmol/L) (Table 4.3)
when compared with the placebo group. Additionally, there was no trend towards higher
methylation following supplementation in those with below median DNA methylation at
baseline (median difference = 0.003, 95%CI = -0.06,0.07, P = 0.92) compared with placebo.
When we stratified according to MTHFR C677T genotype, there was no effect of folic acid
on global DNA methylation in any of the genotype subgroups (from Table 4.3, P = 0.65
for CC, P = 0.32 for CT, P = 0.45 for TT), nor did we observe an effect when we strati-
fied according to alcohol intake (data not shown). Furthermore, for those who were both
MTHFR 677TT and having less than normal baseline RBC folate status, there was also no
significant effect of folic acid on global DNA methylation compared with the placebo group
(data not shown). In other subgroup analyses, there was no difference overall in global DNA
methylation between males and females. Finally, no differences in global DNA methylation
due to folic acid supplementation were observed when we stratified by age, current smoking
status, body mass index (BMI), or sex (data not shown).
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Table 4.1 Baseline characteristics of the population.
Folic acid (n=105) Placebo (n=111)
Demographics
Age (years), mean (SD) 60.9 (5.4) 60.9 (5.5)
Sex, male (%) 66 (62.9%) 74 (66.7%)
Education
High 32 (30.5%) 25 (22.5%)
Middle 41 (39.1%) 43 (38.7%)
Low 32 (30.5%) 43 (38.7%)
Dietary factors
Alcohol intake, g/day, median (IQR) 14.5 (5.5-24.4) 10.3 (3.5-22.0)
Folate intake, µg/day, median (IQR) 185.8 (159.7-220.7) 194.3 (156.0-236.4)
Serum vitamin B12, pmol/L, median (IQR) 295 (259-359) 283 (247-374)
Serum vitamin B6, nmol/L, median (IQR) 31.8 (25.5-41.4) 31.4 (23.7-44.5)
Non-dietary factors
BMI, mean (SD) 26.9 (3.7) 26.4 (4.2)
Current smokers, n (%) 17 (16.2%) 15 (13.5%)
MTHFR C677T genotype, n (%)
CC 36 (34.3%) 40 (36.0)
CT 36 (34.3%) 34 (30.6%)
TT 33 (31.4%) 37 (33.3%)
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Table 4.2 Biochemical measurements throughout the study.
Metabolite Folic acid (n=105) Placebo (n=111) p-value
Serum folate (nmol/L)
Baseline 12.0 (9.9-14.0)a 10.8 (8.5-13.9) 0.01
Year 3 76.3 (53.4-106.0) 12.5 (10.3-16.2) <0.0001
Erythrocyte folate (nmol/L)
Baseline 682.7 (528.8-895.8) 677.5 (548.2-807.6) 0.37
Year 3 2100.7 (1767.2-2611.2) 679.0 (564.6-864.3) <0.0001
Dietary folate intake (µg/day)
Baseline 185.8 (159.7-220.7) 194.3 (156.0-236.4) 0.48
Year 3 173.0 (152.0-197.0) 173.0 (146.0-209.0) 0.48
Plasma total homocysteine (µmol/L)
Baseline 12.5 (11.3-14.5) 13.0 (11.4-15.5) 0.24
Year 3 9.8 (8.8-11.0) 13.4 (11.6-15.1) <0.0001
avalues given are median (inter-quartile range).
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Table 4.3 Folic acid supplementation on global DNA methylation for the whole study pop-
ulation, for those with less than normal RBC folate status at baseline, low and high baseline
methylation, and stratified by MTHFR C677T genotype.
Whole study population
Folic acid (n=105) Placebo (n=111) Difference (95%CI) p-value
Baseline 4.63 (4.53,4.74)a,b 4.60 (4.51,4.72) -0.01 (-0.07,0.05) 0.71
Year 3 4.62 (4.49,4.73) 4.56 (4.56,4.63) 0.004 (-0.06,0.07) 0.90
Difference (95%CI) -0.02 (-0.05,0.02) -0.02 (-0.06,0.01) 0.008 (-0.05,0.07) 0.79
p-value 0.39 0.62
Deficient to low-normal RBC folate status (≤500nmol/L)
Folic acid (n=22) Placebo (n=22) Difference (95%CI) p-value
Baseline 4.62 (4.53,4.64) 4.59 (4.51,4.70) 0.039 (-0.13,0.21) 0.65
Year 3 4.59 (4.52,4.76) 4.69 (4.52,4.73) -0.046 (-0.19,0.10) 0.53
Difference (95%CI) 0.01 (-0.09,0.10) 0.04 (-0.09,0.13) -0.058 (-0.20,0.08) 0.41
p-value 0.81 0.80
Low/high baseline methylation (median split)
Folic acid Placebo Difference (95%CI) p-value
Low <4.615 n=48 n=60
Baseline 4.51 (4.40,4.56) 4.51 (4.42,4.57) -0.002 (-0.05,0.04) 0.92
Year 3 4.53 (4.40,4.66) 4.54 (4.45,4.66) 0.003 (-0.06,0.07) 0.93
Difference (95%CI) 0.04 (-0.01,0.08) 0.02 (-0.02,0.08) 0.003 (-0.06,0.07) 0.92
p-value 0.045 0.045
High ≥ 4.615 n=57 n=51
Baseline 4.72 (4.66,4.82) 4.73 (4.66,4.89) 0.02 (-0.03,0.10) 0.29
Year 3 4.68 (4.59,4.78) 4.66 (4.54,4.78) 0.02 (-0.08,0.14) 0.63
Difference (95%CI) -0.06 (-0.09,-0.03) -0.08 (-0.14,-0.02) 0.008 (-0.10,0.11) 0.87
p-value 0.002 0.006
avalues are given as median (inter-quartile range).
bglobal DNA methylation is expressed as a percentage of 5-methylcytosines versus the total number of cytosines
present in the genome.
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Table 4.3 Folic acid supplementation on global DNA methylation for the whole study pop-
ulation, for those with less than normal RBC folate status at baseline, low and high baseline
methylation, and stratified by MTHFR C677T genotype. (continued)
MTHFR C677T genotype
Folic acid Placebo Difference (95%CI) p-value
CC n=36 n=40
Baseline 4.63 (4.60,4.64) 4.60 (4.57,4.65) -0.035 (-0.12,0.05) 0.41
Year 3 4.58 (4.49,4.69) 4.58 (4.51,4.63) -0.035 (-0.12,0.05) 0.42
Difference (95%CI) -0.07 (-0.13,-0.01) -0.06 (-0.10,-0.01) -0.017 (-0.09,0.06) 0.65
p-value 0.02 0.03
CT n=36 n=34
Baseline 4.63 (4.56,4.69) 4.54 (4.47,4.64) -0.06 (-0.16,0.04) 0.27
Year 3 4.63 (4.57,4.69) 4.66 (4.55,4.70) 0.06 (-0.07,0.19) 0.37
Difference (95%CI) -0.01 (-0.06,0.04) 0.05 (0.00,0.13) 0.07 (-0.06,0.20) 0.32
p-value 0.78 0.10
TT n=33 n=37
Baseline 4.64 (4.54,4.71) 4.63 (4.58,4.70) 0.06 (-0.05,0.18) 0.29
Year 3 4.62 (4.56,4.72) 4.59 (4.54,4.64) -0.01 (-0.14,0.12) 0.86
Difference (95%CI) 0.02 (-0.03,0.10) -0.04 (-0.09,0.04) -0.04 (-0.16,0.07) 0.45
p-value 0.32 0.61
avalues are given as median (inter-quartile range).
bglobal DNA methylation is expressed as a percentage of 5-methylcytosines versus the total number of cytosines
present in the genome.
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4.4 Discussion
In this double-blind randomised controlled trial of daily folic acid supplementation in a
Dutch population with moderately elevated homocysteine, we did not find any evidence
of changes in global DNA methylation after three years of supplementation. Those whose
genotype has previously been associated with lower leukocyte DNA methylation were no
exception.
To our knowledge, seven randomised controlled trials have previously examined the effect of
folic acid on global DNA methylation (Table 4.4). Two of these trials were also performed
in cancer-free populations, but were short-term (12 weeks duration), used supraphysiological
doses of folic acid (2 mg folic acid and 20 mg vitamin B12 and 1.2 mg folic acid, respectively),
and used small sample sizes (included 63 and 61 volunteers, respectively [34, 35]. No effect
of folic acid on global DNA methylation in leukocytes was observed in both these stud-
ies, which used [3H] methylation incorporation to assess DNA methylation. Additionally,
five randomised controlled trials in cancer-related studies were performed, as a global loss of
methylated cytosines is frequently observed in cancers [36] and continues to be an active area
of research. Two of these studies reported null results [37, 38] and three studies, all of which
were carried out in populations with colorectal carcinomas or adenomas, noted an increase
in global DNA methylation following daily administration with 10 mg, 5 mg, and 400 mg
folic acid, respectively [39–41]. In these studies, global DNA methylation was assessed only
in colorectal tissues with the exception of one study that also measured global DNA methy-
lation in leukocytes in addition to colonic mucosa [41]. In the latter study, there was a slight
increase in global DNA methylation in peripheral blood leukocytes of individuals taking
folic acid compared to those in the placebo group (P= 0.05), but not in colonic mucosa of
colorectal adenoma patients following 400 mg daily folic acid supplementation for 10 weeks.
Their study was conducted in colorectal adenoma patients, in whom folic acid metabolism
may already be altered, subsequently affecting DNA methylation, which may explain for
our differences in results. Our findings are aligned with those in other trials with cancer-free
volunteers.
On the other hand, our findings are unexpected, as dietary folate depletion/repletion studies
in women have previously reported global DNA hypomethylation reversal following folate
repletion [8–10]. In the United States, Shelnutt et al. conducted a separate folate feeding trial
of young women aged 20 to 30, who were either MTHFR 677CC or MTHFR 677TT, partici-
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pants were put on a folate depletion diet of 115 mg dietary folate equivalents (DFE)/day for
7 weeks followed by a 7-week folate repletion diet of 400 mg DFE/day. Overall, global DNA
methylation (measured using the liquid chromatography tandem mass spectrometry assay
identical to the one we used in our study) decreased after folate depletion diet, but following
folate repletion with folic acid supplementation, global DNA methylation significantly in-
creased only in those with the TT genotype [42, 43]. In contrast with these findings, we did
not find an effect of folic acid treatment according to genotype. As expected, baseline global
DNA methylation in this American population was higher than baseline levels in our study,
which was conducted in the Netherlands, where unlike the United States, folic acid fortifi-
cation is not mandatory. Furthermore, baseline global DNA methylation in the Shelnutt et
al. study was still higher than global DNA methylation in our population even after 3 years
folic acid supplementation. This may be explained in part by the fact that our study pop-
ulation is substantially older than theirs and that their study only included women. Given
that DNA hypomethylation seems to increase with age, reversion of DNA hypomethylation
may be more difficult and may take longer in older individuals. Furthermore, there may be
differences between the effects of folic acid supplementation (the synthetic form of folate)
and natural dietary folate supplementation on DNA methylation, as folic acid and natural
dietary folates enter the folate-mediated one-carbon metabolism cycle as different folate vita-
mers and may impact DNA methylation by uniquely altering metabolic flux of reactions in
folate-mediated one-carbon metabolism.
In a study by Ingrosso et al. [43] that was partly designed to investigate the effects of folic
acid administration on DNA methylation in men with hyperhomocysteinemia and uremia,
DNA hypomethylation was higher in those with hyperhomocysteinemia compared to con-
trols. Following supplementation with 15 mg of 5-methyltetrahydrofolate daily for 8 weeks,
this DNA hypomethylation was reversed, which does not corroborate with our own find-
ings. Although not a randomised controlled trial, the study conducted by Ingrosso et al.
is insightful in presenting evidence of a lowering effect of the metabolically active form of
folate on DNA methylation in men with hyperhomocysteinemia.
Our study is not without limitations. Firstly, we restricted the study population to those
likely to benefit from folic acid supplementation; only those with elevated homocysteine
were selected to participate in the FACIT trial since high homocysteine is a very sensitive in-
dicator of low folate status. Intuitively, effects of folic acid supplementation are expected to be
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most pronounced in these individuals. We were not able to test whether effects are different
in those with lower homocysteine concentrations. Genetic variability and other environ-
mental factors and interactions between any of these also play a large role in folate-mediated
one-carbon metabolism [44] and may subsequently influence DNA methylation [45]. Fur-
thermore, while our results suggest that folic acid supplementation does not increase global
DNA methylation, this does not preclude the possibility that folic acid supplementation has
an effect on the methylation of specific individual genes, possibly in certain tissues. Folic
acid supplementation may also have an effect on DNA methylation in subgroups of the pop-
ulation, such as those where polymorphisms from other folate-metabolising genes have been
observed to influence folate [46] and homocysteine [46, 47] concentrations.
Despite these limitations, our study has some noteworthy strengths. We were able to in-
clude two hundred sixteen participants in our analyses, making this the largest study to date
investigating the effects of folic acid supplementation on global DNA methylation in healthy
volunteers. Furthermore, we were able to carry out our study prospectively over three years,
and this relatively long duration of folic acid supplementation can give us a better idea of the
longer-term effects of folic acid.
In conclusion, our study shows that daily supplementation with 800 mg folic acid, while
increasing folate status in blood, did not simultaneously alter long-term global DNA methy-
lation in leukocytes of individuals with elevated homocysteine. The role of natural and
synthetic folates in DNA methylation remains an area for further research. The relationship
between leukocyte DNA methylation and DNA methylation in specific tissues should also
be explored as well as genetic variability of folate-mediated one-carbon metabolism genes and
other environmental factors that may have an impact on DNA methylation.
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Abstract
Scope: Low concentrations of folate, other B vitamins and methionine are associated with
colorectal cancer (CRC) risk, possibly by changing DNA methylation patterns. Here, we
examine whether plasma concentrations of B vitamins and methionine are associated with
methylation of long interspersed nuclear element-1 (LINE-1) among those at high risk of
colorectal cancer, i.e. patients with at least one histologically confirmed colorectal adenoma
(CRA) in their life.
Methods and results: We used LINE-1 bisulfite pyrosequencing to measure global DNA
methylation levels in leukocytes of 281 CRA patients. Multivariable linear regression was
used to assess associations between plasma B vitamin concentrations and LINE-1 methylation
levels. Plasma folate was inversely associated with LINE-1 methylation in CRA patients,
while plasma methionine was positively associated with LINE-1 methylation.
Conclusion: This study does not provide evidence that in CRA patients, plasma folate con-
centrations are positively related to LINE-1 methylation in leukocytes but does suggest a
direct association between plasma methionine and LINE-1 methylation in leukocytes.
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5.1 Introduction
Changes in DNA methylation appear to be crucial in colorectal carcinogenesis. Both an in-
crease of DNA methylation at CpG islands in or near the promoters of specific genes [1, 2]
and a global loss of methylated cytosines [3] have been implicated in colorectal cancer de-
velopment. DNA hypermethylation contributes to the silencing of certain genes such as
tumour suppressor genes [4], while global DNA hypomethylation is thought to contribute
to carcinogenesis by affecting chromosomal stability, telomeric regulation, transposable el-
ement reactivation, and gene expression regulation [5]. Methylation of long interspersed
nuclear element (LINE-1) repeats is often used as a surrogate for genome-wide DNA methy-
lation. LINE-1 repeats comprise approximately 18% of the human genome and are heavily
methylated in normal somatic cells [6].
Owing to the current challenges of obtaining target tissues in humans such as that in the
large bowel, DNA methylation in blood is gaining widespread use as a proxy for DNA
methylation in specific tissues, including colorectal tissue, in epidemiological studies [7–10].
A decrease in LINE-1 methylation in leukocytes has been associated with an increased risk for
CRC [11]; likewise, a decrease in global DNA methylation in leukocytes has been associated
with risk for CRA [7, 8], which are established precursors for colorectal cancer [12–14].
Folate, vitamins B2 (riboflavin), B6 (pyridoxal 5’-phosphate is the active form), B12 (cobal-
amin), and methionine are essential in one-carbon metabolism [15]; B vitamins are needed
for DNA synthesis, and are vital to the production of S-adenosylmethionine (SAM), the uni-
versal methyl donor required for DNA methylation. Alcohol may limit methyl group avail-
ability by interfering with folate absorption and folate-metabolising enzymes [16]; cigarette
smoking reduces systemic circulating levels of B vitamins, possibly by increasing the activity
of antioxidant defence enzymes in tissues, which require folate, B6 species and riboflavin [17].
Furthermore, the common 677 C→ T polymorphism in the methylenetetrahydrofolate re-
ductase (MTHFR) gene has been shown to increase the risk of colorectal cancer [18] and
colorectal adenomas [19] when folate status is low, although this association has not been
consistently observed [20–22]. Riboflavin in its coenzymatic form of flavin adenine dinu-
cleotide (FAD) is an essential cofactor for MTHFR. For those who have the MTHFR 677TT
genotype, MTHFR enzyme activity decreases as a result of its inability to retain the FAD
cofactor. Folate may protect against activity loss by increasing the affinity of MTHFR for
FAD in the presence of folate [23, 24]. Folate intake in combination with a low or medium
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intake of vitamin B2 was shown to be a risk factor for colorectal adenomas in a previous
study in the same population [25].
The relationships between B vitamin concentrations and global DNA methylation in leuko-
cytes are unclear. Results from several feeding trials in healthy subjects have been incon-
clusive [26–29]. Additionally, to our knowledge, data describing the relationships between
circulating levels of B vitamins and global DNA methylation in leukocytes of subjects at
relatively high risk for colorectal cancer, i.e. those with previous adenomas [30, 31] and/or
those with a family history of colorectal cancer in a first degree relative [32], do not yet exist.
Similarly, randomised controlled trials studying folic acid supplementation on global DNA
methylation in leukocytes and colon tissue both with healthy subjects and with adenoma
patients yielded equivocal findings [33–40]. There is emerging evidence about the dual role
of folate, where high levels of folate may protect against development of colorectal neoplasia,
but could promote established colorectal adenomas [41, 42]. Additionally, results from a
recent meta-analysis showed that the number of adenomas is strongly associated with risk of
developing advanced and nonadvanced metachronous neoplasms [31].
We investigated the associations between circulating levels of (combined) B vitamins, methio-
nine and LINE-1 methylation in leukocytes of colorectal adenoma patients. We also examine
whether these relationships were influenced by number of lifetime adenomas, history of col-
orectal cancer among first degree relatives, MTHFR C677T genotype, smoking status, and
alcohol intake.
5.2 Materials and methods
5.2.1 Study design and population
The POLIEP follow-up study is a cohort study of the cases (n=767), who had formerly
participated in the POLIEP study [43], a Dutch case-control study comprising ten different
hospitals in the Netherlands and conducted between 1997 and 2002. The study was designed
to investigate gene-environment interactions and risk of colorectal adenomas. All partici-
pants in the study had at least one histologically-confirmed colorectal adenoma ever in their
life. Additional inclusion criteria are that participants were Dutch speaking, of European
origin, between the ages of 18-75 years at the time of an endoscopy for eligibility into the
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case-control study, had no hereditary colorectal cancer syndromes, no chronic inflammatory
bowel disease, no history of colorectal cancer, and no (partial) bowel resection. All cases who
agreed to be involved in the follow-up study and those for whom we had a recent address
were invited (n=519) to complete a validated semi-quantitative food frequency questionnaire
(FFQ) [44], a lifestyle questionnaire, and to give a blood sample. The FFQ was used to ascer-
tain dietary intake and supplement use. Supplement use included any multivitamins, folic
acid supplements, and B vitamin complex supplements. All participants who gave a blood
sample, in which LINE-1 methylation levels could be assessed, were included in our analyses
(n=281). Self-reported family history of colorectal cancer is defined as having at least one
first degree family member diagnosed with this cancer. Participants had a full colonoscopy
or a sigmoidoscopy at entry into the case-control study and medical and pathology infor-
mation from past and subsequent colonoscopies from the earliest colonoscopy up to and
including the most recent colonoscopy were collected. Adenoma occurrence was ascertained
by colonoscopy and pathology reports. Written informed consent was obtained from each
participant. This study was approved by the Radboud University Medical Centre Ethics
Committee (CMO-nr: 2005/283) and by the review board of every participating outpatient
clinic.
5.2.2 Biochemical analyses
Blood samples were collected from non-fasting participants in EDTA tubes and put directly
on ice and protected from sunlight. Within 30 minutes of collection, the samples were cen-
trifuged at 1000 rpm for 3 minutes followed by 2000 rpm for 5 minutes at 4oC. Plasma and
buffy coat were pipetted separately into cryogenic vials and stored at -80oC. Plasma concen-
trations of folate and cobalamin were determined by microbiological assays using a colistin-
sulfate resistant strain of Lactobacillus leichmannii and a chloramphenicol-resistant strain of
Lactobacillus casei, respectively [45,46]. Plasma concentrations of methionine, riboflavin, and
vitamin B6 species (pyridoxal 5’-phosphate (PLP), pyridoxal (PL), and 4-pyridoxic acid (PA))
were measured using liquid chromatography-tandem mass spectrometry [47, 48]. Samples
were analysed in batches of 86 and quality control included 6 calibration samples, 3 control
samples, and 1 blank sample in each batch. Coefficients of variation were 4 - 5% (folate), 0.7
- 2.9% (methionine), 5.5 - 13.2% (riboflavin), 2.6 - 11.1% (vitamin B6 species), 4 - 5% (cobal-
amin), and 1.1 - 8.1% (methylmalonic acid (MMA)). Samples were analysed in random order.
The laboratory staff was blinded to the clinical outcome status of the patients donating the
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blood samples. All biomarkers were analysed at BEVITAL AS, Norway (www.bevital.no).
5.2.3 Genotyping assay
DNA was isolated from whole blood, and the MTHFR C677T polymorphism was genotyped
using a PCR-RFLP method [49]. PCR was performed with internal negative controls. Re-
producibility was confirmed by analysing 20% of the samples in duplicate. There was also an
external quality control program, and results showed a 100% match with expected genotype.
5.2.4 LINE-1 analysis
DNA extraction and bisulfite conversion of DNA
DNA was isolated from buffy coat using the Hamilton STAR workstation, as described by
the manufacturer (Hamilton Robotics, Bonaduz, Switzerland). Magnetic beads that bind
DNA were added to the samples. A magnetic box was then used to separate the DNA
from other components of blood. DNA was eluted in an elution buffer. The amount of
DNA in each sample was determined using a Caliper automation system (Caliper Life Sci-
ences, Hopkinton, MA, USA). One hundred nanograms of DNA (concentration 25 ng/µl)
were bisulfite converted using EZ DNA Methylation GoldTM Kit (Zymo Research, Orange,
CA, USA) according to the manufacturer’s protocol. Bisulfite-converted DNA was used for
LINE-1 PCR immediately following conversion.
LINE-1 PCR and pyrosequencing
The use of pyrosequencing to measure LINE-1 methylation is a validated method and pre-
vious studies have demonstrated that LINE-1 methylation is a good indicator of cellular 5-
methylcytosine levels [6]. We used and adapted the method developed by Yang et al. Global
DNA methylation was quantified using bisulfite-PCR and pyrosequencing [6]. Repetitive
elements primers were designed towards a consensus LINE-1 sequence (positions 331 to 318
for LINE-1 (GenBank accession number X58075). Analysis of DNA methylation in LINE-1
repetitive elements was performed (Qiagen N.V., Germany). PCR conditions consisted of
an initialisation step of 95oC for 15 minutes followed by touchdown PCR with denaturation
at 95oC for 30 seconds, annealing at 53oC for 30 seconds (-1oC each cycle), and extension at
72oC for 40 seconds for a total of 5 cycles then 35 cycles of 95oC for 30 seconds, 50oC for
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30 seconds, 72oC for 40 seconds, followed by a final extension at 72oC for 10 minutes. The
PCR product was bound to Sepharose HP (Amersham Biosciences, Uppsala, Sweden) and the
Sepharose beads containing the immobilised PCR product were prepared for pyrosequencing
according to the manufacturer’s instructions (Qiagen N.V., Germany). Pyrosequencing was
performed on PCR product with bound LINE-1 sequencing primer and using the Pyromark
Q24 System (Qiagen N.V., Germany). The nucleotide dispensation order was GCT CGT
GTA GTC AGT CG. Methylation quantification was performed using the provided soft-
ware, Pyromark. The degree of methylation was expressed as the percentage of 5-methylated
cytosines (%5mC) over the sum of methylated and unmethylated cytosines. Reproducibility
was confirmed by analysing 10% of the samples in duplicate. The within-sample coefficients
of variation in duplicate runs were 4.3 - 7.3%.
5.2.5 Statistical analyses
Statistical analyses were performed using SAS version 9.2. Natural logarithmic transforma-
tions were applied to normalise distributions of all plasma metabolites, alcohol intake, and
BMI because the original distributions were skewed towards higher values. Median and cor-
responding interquartile ranges (IQR) were calculated for all continuous variables with the
exception of age and number of endoscopies, which were presented as a mean with the cor-
responding standard deviation. Categorical variables were expressed in numbers and corre-
sponding percentages. Results are presented separately for number of lifetime adenomas (one
adenoma versus at least two adenomas). We also tested for significant differences in dietary
and lifestyle characteristics between cases with one adenoma and cases with at least two ade-
nomas. For categorical variables, we used the χ2 test, and for none of the variables were
there cells with less than 5 observations. For non-parametric variables, the Wilcoxon-Mann-
Whitney test was applied, and a Student’s unpaired t test was used for parametric data.
To evaluate the associations between log-transformed B vitamins and LINE-1 methylation,
we used unadjusted and multivariable least squares linear regression analyses. We estimated
individual associations of plasma folate, methionine, riboflavin, PLP, PL, PA, and cobalamin
with LINE-1 methylation in separate models. We also constructed separate models for those
with 1 adenoma and for those with ≥2 adenomas. We calculated beta estimates (β) and cor-
responding 95% confidence intervals (95%CIs) to determine the associations between the B
vitamins and LINE-1 methylation levels. To test for confounding in the association between
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plasma B vitamins and LINE-1 methylation, we added potential confounders to the models
and checked whether crude estimates changed by more than 10% when added to the linear
regression models. Potential confounders that were selected a priori were smoking status,
family history of CRC, BMI, alcohol intake, age, sex, and number of endoscopies. Corre-
lation between the analytes was checked using Spearman correlation coefficients. The final
linear regression models included the covariates age, sex, BMI, alcohol intake, smoking status,
family history of colorectal cancer, and other analytes (mutual B-vitamins and methionine).
The assumption of linearity between LINE-1 methylation in leukocytes and independent
variables was confirmed using graphic methods.
In order to examine if a family history of colorectal cancer in a first-degree relative would
change associations between B vitamins and LINE-1 methylation, we performed a stratified
analysis. We also examined whether the associations between each B vitamin and LINE-1
methylation were modified by MTHFR C677T genotype, smoking status, alcohol intake, and
sex. Interaction between plasma folate and plasma vitamin B2 was studied by stratification
by tertiles of plasma vitamin B2. Given that folate intake in combination with a low or
medium intake of vitamin B2 was a risk factor for CRA in earlier analyses within the same
population [25], it would be worthwhile to explore this interaction in relation to LINE-1
methylation by stratifying by vitamin B2; in addition to stratification by vitamin B2, we
also stratified by methionine, the sum of vitamin B6, cobalamin, and MMA. Because the
independent variables were log-transformed, the resulting regression coefficient, β, should
be interpreted as a 1% change in the independent variable corresponds to a β/100 change in
the LINE-1 methylation. Statistical significance was tested at the 0.05 level.
5.3 Results
5.3.1 Characteristics of the study population
Dietary and lifestyle characteristics of the population can be found in Table 5.1. Two hun-
dred eighty-one patients were included in our analyses. Patients with at least two lifetime
adenomas were older (mean age=67.4 years, SD=7.7) than those with one adenoma (mean
age=64.4 years, SD=9.4). The proportion of females was similar between the two groups
(about 41%). Use of supplements containing B vitamins was higher in those with only one
adenoma (26.2%) compared to those with at least 2 adenomas (21.2%). With the exception
of PA and cobalamin, B vitamin plasma concentrations were all lower in the ≥ 2 adenoma
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group compared to the one adenoma group (Table 5.1). LINE-1 methylation in leukocytes
was also slightly lower in those with recurrent adenomas (72.7%, IQR 68.9-75.0) compared
to those with one adenoma (73.3%, IQR 70.9-74.8).
Plasma analytes were not correlated (Spearman rank correlation coefficients between analytes
-0.25 < ρ< 0.56) with the exception of the plasma B6 vitamers PLP, PL, and PA, which were
highly correlated (PLP and PL ρ=0.86, PLP and PA ρ=0.68, PL and PA ρ=0.82). Therefore,
we excluded the B6 vitamers as covariates, using instead the sum of these vitamers in the
multivariable regression model.
5.3.2 B vitamins and LINE-1 methylation levels according to number
of lifetime adenomas
The overall multivariable-adjusted β-estimate (95%CI) between plasma folate and LINE-1
methylation for the entire population was -1.46 (-2.65, -0.27). The results from multivariable
linear regression analyses according to number of lifetimes adenomas are shown in Table
5.2. Plasma folate was inversely associated with LINE-1 methylation for those with one
lifetime adenoma (multivariable adjusted β-estimate (95%CI) of -2.01 (-3.85, -0.19) as well
as for patients with at least two lifetime adenomas (multivariable adjusted β of -1.70 (-3.35,
-0.06). The significant inverse relationship between plasma folate and LINE-1 methylation
means that for patients with ≥ 2 adenomas, a 1% increase in plasma folate is associated
with a decrease of -1.70/100=-0.017 (β/100) units in LINE-1 methylation (%5-methylated
cytosines/total amount of cytosines). There were null associations between other B vitamins
and LINE-1 methylation according to number of lifetime adenomas.
5.3.3 B vitamins and LINE-1 methylation levels according to family
history of colorectal cancer
The associations between B vitamins and LINE-1 methylation stratified by family history of
colorectal cancer can be found in Table 5.3. In patients with a family history of CRC, we
found a borderline significant inverse association between plasma folate and LINE-1 methy-
lation (β of -2.77 (-5.57, 0.02)), adjusted for age, sex, BMI, alcohol intake, smoking status,
and other analytes. There was a positive association between plasma methionine and LINE-1
methylation (multivariable-adjusted β-estimate of 3.91 (0.39, 7.42)), but only in patients with
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no family history. No other statistically significant associations were observed.
5.3.4 B vitamin and LINE-1 methylation levels according to MTHFR
C677T genotype
The associations between plasma B vitamins and LINE-1 methylation levels according to
MTHFR C677T genotype are shown in Table 5.4. We found an inverse association between
plasma folate and LINE-1 methylation for those with the MTHFR 677CC genotype (β of
-2.01 (-3.77, -0.25)). For those with the MTHFR 677TT genotype, there was an inverse as-
sociation between plasma riboflavin and LINE-1 methylation (multivariable adjusted β of
-9.08 (-15.47, -2.69) and a positive association between the sum of B6 vitamers and LINE-1
methylation (multivariable adjusted β of 12.00 (0.85, 23.15). No interaction terms reached
statistical significance (data not shown).
5.3.5 Plasma folate and LINE-1 methylation levels according to plasma
riboflavin, smoking status, and alcohol intake
The associations between plasma folate and LINE-1 methylation levels stratified by plasma
riboflavin, smoking status, and alcohol intake are shown in Table 5.5. Plasma riboflavin
and alcohol intake were each divided into tertiles while smoking status was categorised as
current, former, or never. We found inverse associations of LINE-1 methylation levels with
plasma folate in the lowest tertile of plasma riboflavin (β of-3.84 (-6.27, -1.40)) and in never
smokers (β of -3.19 (-6.23, -0.15)), and only in the second tertile of alcohol consumption (β
of -3.56 (-5.88, -1.04)). There were inverse associations between plasma folate and LINE-1
methylation for all levels of plasma methionine, cobalamin, sum of vitamin B6, and MMA
but none were significant (data not shown).
5.4 Discussion
In the present cohort study with patients, who have had a history of at least one colorec-
tal adenoma ever in their life, we observed inverse associations between plasma folate and
LINE-1 methylation from peripheral blood leukocytes. An increase in plasma folate concen-
trations was related to a decrease in LINE-1 methylation in those with one adenoma and in
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those with at least two lifetime adenomas. Our results are somewhat unexpected, as we hy-
pothesised that higher plasma folate concentrations would be associated with higher LINE-1
methylation, as folate is important for the availability of S-adenosylmethionine, the universal
methyl donor required for DNA methylation. On the other hand, there is growing evidence
that high levels of folate may be protective in early carcinogenesis but may accelerate the
growth of established colorectal neoplasia, as mentioned earlier. The complex dual role of
folate in colorectal carcinogenesis depends on the timing of exposure in addition to dose and
duration [41, 42, 50, 51]. In our population of exclusively adenoma patients, it may not be
too surprising that plasma folate was inversely related to LINE-1 methylation in leukocytes,
as increasing levels of plasma folate could promote adenoma growth, where increased levels
of global DNA hypomethylation exist.
Results from a cross-sectional study with healthy Dutch participants showed no association
between plasma folate and global DNA methylation, as measured by liquid chromatography-
tandem mass spectrometry [29], and plasma folate concentrations in this study were similar
to those measured by us. In controlled folate feeding trials with healthy, postmenopausal
women, folate status was positively associated with global DNA methylation levels in leuko-
cytes [26, 27]. In these feeding trials, female volunteers consumed low-folate diets for 7
weeks [26] or 91 days [27] showing a concomitant gradual loss of global DNA methylation.
Furthermore, five randomised controlled trials have explored the effects of folic acid, the
synthetic form of folate, on global DNA methylation in colorectal tissues [33–36, 52] and
leukocytes [52] of colorectal adenoma patients. While the aim of these studies was not to
examine the relationship between plasma folate and global DNA methylation, they are rele-
vant, as they demonstrate the influence of folic acid on changes in global DNA methylation
levels. Following folic acid supplementation, three of these studies observed an increase in
global DNA methylation [33, 36, 52], while results were null in others [34, 35].
Possible reasons for inconsistent results include differences in study design. Selection biases
may occur in case-control studies but are unlikely in cohort studies, where loss to follow-up
is not related to exposure. There are also differences in methods of measuring DNA methy-
lation, type of tissue studied (colon vs. leukocytes), study participants (healthy vs. cancer pa-
tients), and adjustments for confounding factors. Furthermore, many of the aforementioned
studies were conducted in the United States where folic acid fortification is mandatory, and
subsequently plasma concentrations of study participants were relatively high.
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Table 5.1 Dietary and lifestyle characteristics by number of lifetime adenomas.
One adenoma ≥ 2 adenomas
Demographics
Number of patients (%) 149 (53.0) 132 (47.0)
Age at blood draw (years), meana (SD) 64.4 (9.4) 67.4 (7.7)
Sex, female (%) 59 (40.7) 53 (41.7)
Education, n (%)
High 39 (26.2) 30 (22.7)
Medium 64 (43.0) 61 (46.2)
Low 37 (24.8) 36 (27.3)
Dietary intake, median (IQR)
Folate (µg/day) 192.9 (154.5-240.7) 185.5 (152.4-230.0)
Vitamin B2 (riboflavin) (mg/day) 1.6 (1.2-1.9) 1.5 (1.2-2.0)
Vitamin B6 (mg/day) 1.7 (1.4-2.0) 1.7 (1.5-2.1)
Vitamin B12 (cobalamin)a (µg/day) 3.9 (3.1-5.1) 4.3 (3.3-5.6)
Alcohol intake (g/day) 10.0 (2.8-25.0) 9.8 (1.7-22.1)
Plasma concentrations, median (IQR)
Folate (nmol/L) 8.1 (5.49-13.47) 7.6 (5.2-11.5)
Methionine (µmol/L) 28.5 (24.6-34.1) 28.3 (24.6-32.9)
Riboflavin (nmol/L) 17.7 (11.4-30.6) 16.02 (10.2-30.2)
Vitamin B6 sum (nmol/L) 120.6 (90.1-186.3) 116.8 (85.5-177.2)
PLP (nmol/L) 78.1 (50.6-113.8) 72.5 (53.8-111.5)
PL (nmol/L) 16.6 (12.2-25.4) 16.4 (11.6-25.7)
aP-value < 0.05 for difference between one adenoma and ≥ 2 adenomas.
bIncludes multivitamins, folic acid supplements, and B vitamin complex supplements.
cAdvanced adenomas are defined as villous or tubulovillous adenomas and/or size ≥ 10mm and/or high-grade
dysplasia and/or 3 or more adenomas detected during a colonic examination.
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Table 5.1 Dietary and lifestyle characteristics by number of lifetime adenomas.
(continued)
One adenoma ≥ 2 adenomas
PA (nmol/L) 25.7 (19.0-45.5) 26.6 (19.9-39.7)
Cobalamin (pmol/L) 337.9 (278.8-411.2) 356.0 (284.0-431.4)
MMA (µmol/L) 0.2 (0.2-0.3) 0.2 (0.2-0.3)
Lifestyle characteristics
BMI (kg/m2), median (IQR) 25.7 (23.5-27.7) 25.8 (24.2-28.3)
Supplement use, yes (%)b 39 (26.2) 28 (21.2)
Smoking habits, n (%)
Current 21 (14.5%) 14 (11.0%)
Ever 80 (55.2%) 80 (63.0%)
Never 44 (30.3%) 31 (24.4%)
Other characteristics
MTHFR C677T genotype, n (%)
CC 72 (49.7%) 53 (40.5%)
CT 62 (42.8%) 64 (48.9%)
TT 11 (7.6%) 14 (10.7%)
First degree family history of CRC, n (%) 42 (28.2%) 39 (29.6%)
Number of endoscopies, mean (SD)a 2.9 (1.5) 4.7 (2.2)
Advanced adenomas, n (%)a,c 69 (46.3%) 94 (71.2%)
LINE-1 methylation (%), median (IQR) 73.3 (70.9-74.8) 72.7 (68.9-75.0)
aP-value < 0.05 for difference between one adenoma and ≥ 2 adenomas.
bIncludes multivitamins, folic acid supplements, and B vitamin complex supplements.
cAdvanced adenomas are defined as villous or tubulovillous adenomas and/or size ≥ 10mm and/or high-grade
dysplasia and/or 3 or more adenomas detected during a colonic examination.
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Table 5.3 Associations between plasma B vitamins and LINE-1 methylation according to
family history using multivariable linear regression.
Family history of CRC (n=81) No family history of CRC (n=200)
Multivariable adjusteda βc
(95% confidence interval)
Multivariable adjusteda βc
(95% confidence interval)
Folateb -2.77 (-5.57, 0.02) -1.02 (-2.32, 0.29)
Methionineb -2.37 (-8.03, 3.30) 3.91 (0.39, 7.42)
Riboflavinb -1.30 (-3.66, 1.06) -0.17 (-1.36, 1.02)
Vitamin B6 sumb 1.88 (-1.42, 5.17) -0.27 (-1.93, 1.39)
PLPb 1.84 (-1.79, 5.47) 0.20 (-1.52, 1.91)
PLb 0.53 (-1.95, 3.01) -0.83 (-2.27, 0.61)
PAb 1.15 (-1.15, 3.44) -0.69 (-1.99, 0.61)
Cobalaminb 4.90 (-1.03, 10.82) 0.35 (-2.22, 2.92)
MMAb 2.26 (-1.90, 6.43) -0.93 (-3.31, 1.45)
aAdjusted for age, sex, BMI, alcohol intake, smoking status, and other analytes.
bThese variables were log-transformed.
cThe independent variables were log-transformed before inclusion into the models. A 1% change in the independent
variable corresponds to a β/100 change in the dependent variable (LINE-1 methylation).
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Table 5.4 Associations between plasma B vitamins and LINE-1 methylation according to
MTHFR C677T genotype.
MTHFR C677T genotype
CC (n=125) CT (n=126) TT (n=25)
Multivariable adjusteda βc
(95% confidence interval)
Multivariable adjusteda βc
(95% confidence interval)
Multivariable adjusteda βc
(95% confidence interval)
Folateb -2.01 (-3.77, -0.25) -1.56 (-3.57, 0.46) 5.48 (-0.60, 11.56)
Methionineb 2.13 (-2.93, 7.18) 0.49 (-4.20, 5.18) 1.29 (-11.46, 14.05)
Riboflavinb -0.75 (-2.52, 1.01) -0.12 (-1.72, 1.48) -9.08 (-15.47, -2.69)
Vitamin B6 sumb 0.97 (-1.29, 3.23) -0.09 (-2.66, 2.47) 12.00 (0.85, 23.15)
PLPb 1.32 (-1.09, 3.72) 0.29 (-2.49, 3.08) 9.63 (-2.76, 22.01)
PLb 0.13 (-1.77, 2.03) -0.73 (-2.79, 1.34) 7.25 (-2.50, 16.99)
PAb 0.33 (-1.29, 1.95) -0.56 (-2.45, 1.33) 4.54 (-6.14, 15.22)
Cobalaminb 0.01 (-4.00, 4.03) 2.46 (-0.90, 5.82) -5.68 (-20.67, 9.31)
MMAb 0.08 (-3.09, 3.24) -0.28 (-3.32, 2.77) -9.22 (-19.51, 1.07)
aAdjusted for age, sex, BMI, alcohol intake, smoking status, family history of colorectal cancer, and other analytes.
bThese variables were log-transformed.
cThe independent variables were log-transformed before inclusion into the models. A 1% change in the independent
variable corresponds to a β/100 change in the dependent variable (LINE-1 methylation).
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Table 5.5 Associations between plasma folate and LINE-1 methylation stratified by plasma
riboflavin, smoking status, and alcohol intake using a multivariable regression model.
Association between plasma folatea and
LINE-1 methylation
Multivariable adjustedb βc
(95%confidence interval)
Plasma riboflavin
1 (2.48-12.34 nmol/L) (n=87) -3.84 (-6.27, -1.40)
2 (12.35-24.19 nmol/L) (n=88) -1.16 (-3.16, 0.85)
3 (24.20-329.76 nmol/L) (n=87) -0.24 (-2.10, 2.57)
Smoking status
Never (n=75) -3.19 (-6.23, -0.15)
Former (n=160) -1.38 (-2.91, 0.16)
Current (n=35) -0.14 (-2.82, 2.53)
Alcohol intake
1 (0.00-4.38 g/day) (n=90) -0.41 (-2.73, 1.90)
2 (4.39-17.90 g/day) (n=90) -3.56 (-5.88, -1.04)
3 (17.91-143.50 g/day) (n=90) -1.32 (-3.37, 0.73)
aThis variable was log-transformed.
bAdjusted for age, sex, BMI, alcohol intake, smoking status, family history of colorectal cancer, and other analytes.
cThe independent variables were log-transformed before inclusion into the models. A 1% change in the independent
variable corresopnds to a β/100 change in the dependent variable (LINE-1 methylation).
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The small RCT performed by Pufulete et al. in the United Kingdom, where folic acid forti-
fication is not compulsory, is interesting because global DNA methylation was measured in
both leukocytes as well as colon tissue in adenoma patients [52]. Subjects were randomised
to receive 400 µg/day folic acid for a short period of time (10 weeks), and there was a border-
line significant increase in global DNA methylation in leukocytes (P=0.05), measured using
[3H] methyl incorporation assay, in the intervention group compared to those in the placebo
group following supplementation. There was also a borderline significant increase in global
DNA methylation in colon tissue following folic acid intervention (P=0.09), and the weaker
increase in colon tissue may be a consequence of blood being “closer” than colon tissue to en-
vironmental exposures [53]. Additionally, the absorption and metabolism of natural folates
and synthetic folates, i.e. folic acid, are different, and may therefore have dissimilar effects on
one carbon metabolism [54, 55].
Methionine is an essential amino acid, and like folate, it is required for the synthesis of
S-adenosylmethionine, and as such, we would expect a positive relationship between me-
thionine and LINE-1 methylation. Indeed, we found a positive association between plasma
methionine and LINE-1 methylation in patients without a family history of CRC. For those
with a family history of CRC, there was no significant association between plasma methio-
nine and LINE-1 methylation perhaps indicating that family history of CRC may modulate
the associations between plasma methionine and LINE-1 methylation, although it may be
premature to draw definitive conclusions based on a small subgroup analysis.
The significant inverse relationship in the current study between plasma folate and LINE-
1 methylation in patients with the MTHFR 677CC genotype is in contrast to those with
the MTHFR 677CT or MTHFR 677TT genotype, where there was no association. Based
on the premise that the C to T base transition resulting in an alanine to valine substitu-
tion impairs enzyme activity, and decreases plasma folate concentrations [23, 56] and that
folate is required for the production of SAM for DNA methylation, we had expected direct
associations between plasma folate and LINE-1 methylation in persons with the TT geno-
type. Our results are inconsistent with the results from an observational Italian study using
cross-sectional data, which revealed lower global DNA methylation in subjects with the TT
genotype compared to those with the CC genotype when plasma folate concentrations were
low [57]. However, results from controlled folate feeding trials have also been unexpected.
No changes in global leukocyte DNA methylation following short-term folate restriction
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in healthy women with the MTHFR 677CC genotype have been reported [28], while other
studies in women have demonstrated changes in global DNA methylation in those with the
TT genotype following folate repletion [58, 59]. Results from the feeding trials and our own
results in the current study should be interpreted with prudence, as there were relatively few
patients with the MTHFR 677TT genotype.
Results from additional exploratory analyses indicated significant inverse associations be-
tween plasma folate and LINE-1 methylation for those in the lowest category of plasma
riboflavin, those who had never smoked and those in the middle category for alcohol intake.
We had expected that smoking and alcohol would decrease concentrations of B vitamins and
subsequently decrease LINE-1 methylation.
Our study possesses several strengths. It is, to our knowledge, the first to provide a snapshot
of the relationship between plasma B vitamins and global DNA methylation in patients
with a history of adenomas. Our study population is fairly large and exclusively includes
subjects with a history of colorectal adenomas, and is therefore at higher risk for developing
colorectal cancer. We were able to measure plasma B vitamins rather than assessing exposure
using recall methods such as an FFQ.
This study also has some limitations. Cross-sectional data does not allow us to make causal
inferences from associations between plasma analytes and LINE-1 methylation. It may
be of interest for future studies to include measurements of S-adenosylmethionine and S-
adenosylhomocysteine, and to take repeated blood measurements at different time points.
Red blood cell folate concentrations may represent a better long-term measure of folate sta-
tus, but a single measurement of plasma folate per subject seems to be sufficient in large
epidemiological studies [60]. Although we have measured LINE-1 methylation, we do not
have information about specific promoter methylation, and we cannot eliminate the possi-
bility that the correlations between plasma B vitamins and promoter methylation may differ
in those with different number of adenomas, family history of colorectal cancer, MTHFR
C677T genotype, smoking, and alcohol intake. CpG island promoter methylation could, in
fact, be more frequent among individuals with lower LINE-1 methylation, a proxy for global
DNA methylation [61]. Furthermore, to date, while we are unaware of studies having defini-
tively proven the relationship between leukocyte methylation and methylation in colon tis-
sue, the results from Pufulete et al. [52] do suggest similarities in DNA methylation between
the two tissues in response to folic acid. Additionally, because obtaining target tissues in
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humans is so often problematic and complicated, global DNA methylation in leukocytes are
commonly used as a substitute for target tissues in epidemiological studies [7–10].
For our analyses, we used the follow-up FFQ and blood sample, so indeed, some CRA pa-
tients could have been diagnosed over a decade prior to measurement of B-vitamin status and
LINE-1 methylation. However, in the original case-control study, few cases could confirm
that they changed their diets when asked about dietary changes after diagnosis of CRA [62],
and certainly while LINE-1 methylation levels in leukocytes have changed since diagnosis of
CRA, we were interested in capturing the relationships between plasma B vitamins and me-
thionine and LINE-1 methylation in adenoma patients during follow-up. We would expect
then that the fact that measurements of B-vitamins and LINE-1 methylation were done after
diagnosis of CRA would have little implication for the interpretation of our findings.
It is unclear why there is an inverse association between plasma folate and LINE-1 methyla-
tion. Patients with colorectal adenomas may experience changes in their one-carbon metabo-
lism and may be more sensitive to these nutrients. Nevertheless, in light of the current unex-
pected results, more research is warranted to further elucidate the true relationships between
B vitamins and global DNA methylation in healthy individuals as well as in individuals at
high risk for developing colorectal cancer.
In conclusion, our study suggests that plasma folate is inversely associated with LINE-1
methylation in leukocytes of colorectal adenoma patients. Plasma methionine was positively
associated with LINE-1 methylation. We also observed indications that these relationships
may be potentially modified by family history of colorectal cancer, and MTHFR 677 C →
T genotype although drawing definitive conclusions may be difficult due to relatively small
sample sizes in our subgroup analyses.
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Chapter 6
Abstract
Purpose: Dietary intake of B vitamins and methionine, essential components of DNA syn-
thesis and methylation pathways, may influence colorectal tumour (CRT) development. The
impact of B vitamins on colorectal carcinogenesis in individuals with Lynch Syndrome (LS)
is unknown but is of great importance given their high lifetime risk of developing neoplasms.
The role of MTHFR C677T genotype in modifying these relationships in LS individuals is
also unclear. We investigated associations between dietary intakes of folate, vitamins B2, B6,
B12, and methionine and CRT development in a prospective cohort study of 470 mismatch
repair gene mutation carriers.
Methods: Dietary intakes were assessed by food frequency questionnaire. Cox regression
models with robust sandwich covariance estimation, adjusted for age, sex, physical activity,
number of colonoscopies during person-time, NSAID use, and mutual vitamins were used
to calculate hazard ratios (HR) and 95% confidence intervals (95% CI). Analyses were also
stratified by MTHFR C677T genotype.
Results: Compared to the lowest tertile of intake, adjusted HRs (95%CI)s for CRT develop-
ment in the highest tertile were 1.06 (0.59-1.91) for folate, 0.77 (0.39-1.51) for vitamin B2, 0.98
(0.59-1.62) for vitamin B6, 1.24 (0.77-2.00) for vitamin B12, and 1.36 (0.83-2.20) for methion-
ine. Low vitamin B2 and low methionine intake was statistically significantly associated with
an increased risk of CRT in MTHFR 677TT individuals compared to a combined reference
of persons with low intake and CC genotype.
Conclusions: There was no suggestion that intake of any dietary B vitamin or methionine
was associated with CRT development among those with Lynch Syndrome.
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6.1 Introduction
Lynch Syndrome (LS), the most common form of hereditary colorectal cancer, is an auto-
somal dominant disorder. Individuals with LS carry inactivating germline mutations in one
of the DNA mismatch repair (MMR) genes MLH1, MSH2, MSH6, and PMS2 [1–4]. Com-
pared to the general population, LS individuals are at considerably higher risk for devel-
oping colorectal cancer (CRC) to age 70, develop colorectal adenomas (CRA) at a younger
age, and have a higher lifetime risk for other types of cancers such as, but not exclusive to,
those in the endometrium, ovary, and stomach [5–7]. Colorectal adenomas, precursors of
CRC [8, 9] progress through the adenoma-carcinoma sequence, which seems to be accelerated
in LS [10, 11].
Overweight [12], smoking [13], and a dietary pattern containing high amounts of fried and
fast food snacks [14] have previously been reported to increase the risk of CRA in LS, whereas
daily aspirin use decreased CRC risk [15]. This indicates that modifiable lifestyle factors in
addition to genetic factors are important among this high risk population.
B vitamins and methionine are essential for nucleotide synthesis, and DNA methylation
and repair reactions. Folate plays a central role in mediating one-carbon units for both
DNA synthesis and DNA methylation, the two main pathways in folate-mediated one-
carbon metabolism. The other B vitamins act as cofactors in folate metabolism reactions,
and methionine is converted to S-adenosylmethionine (SAM), the universal methyl donor
for cellular methylation reactions. Decades of research into the role of B vitamins and me-
thionine in colorectal tumour (CRT) development in the general population have resulted
in the majority of studies pointing towards an inverse association between folate intake and
risk of sporadic CRA [16–18], but inconsistencies [19–22] have prompted hesitation by the
World Cancer Research Fund Continuous Update Project in drawing firm conclusions [23].
Similarly, the relationships between other B vitamins and methionine and CRT development
remain unresolved.
Dietary folate intake in combination with the common 677 C → T single nucleotide poly-
morphism (SNP) in the methylenetetrahydrofolate reductase (MTHFR) gene, vital for folate-
mediated one-carbon metabolism, is usually inversely associated with CRT risk [24, 25], al-
though this interaction is not consistently observed [21, 26, 27]. While extensive strides in
research have been made to elucidate the associations between B vitamin and methionine
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intake and risk of sporadic CRT, there still remains a paucity of data describing these rela-
tionships in a LS population, where given their high lifetime risk of developing neoplasms
and the current contentious nature of B vitamins in CRT development, uncovering whether
B vitamin and methionine intake can modify this risk would be certainly pertinent.
To the best of our knowledge, no studies have previously examined dietary B vitamin in-
take in relation to colorectal adenomas or carcinomas in a LS population. We, therefore,
conducted a prospective cohort study to evaluate the associations between dietary folate,
vitamin B2, vitamin B6, vitamin B12, and methionine intake and colorectal tumour (colorec-
tal adenoma or carcinoma) development in individuals with LS. We also assessed whether
MTHFR C677T genotype modified these relationships.
6.2 Material and methods
6.2.1 Study subjects
The GEOLynch prospective cohort study has been previously described [12]. Briefly, all
eligible MMR gene mutation carriers were identified at the Netherlands Foundation for the
Detection of Hereditary Tumours (NFDHT) in Leiden, Radboud University Medical Center
(RUMC) in Nijmegen, and University Medical Centre Groningen (UMCG) in Groningen
(all in the Netherlands). Information about MMR gene mutation carrier status was collected
at the NFDHT. Eligible patients were Dutch-speaking, Caucasian, mentally competent to
participate men and women between 18 and 80 years of age who were screened regularly by
colonoscopy. Terminally ill patients, and those with familial adenomatous polyposis (FAP),
inflammatory bowel diseases, a history of a complete proctocolectomy or colostomy were
excluded.
Between July 2006 and July 2008, a total of 713 MMR gene mutation carriers appeared to be
eligible to participate in the study after approval by their medical specialist. Nine participants
were ineligible. A total of 499 individuals (71% of 704) were willing to participate in the
study. We were unable to retrieve medical and personal information from 29 participants.
In total, 470 persons from at least 161 families were included in this study. Approval for this
study was given by the RUMC medical ethical committee. All participants provided written
informed consent.
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6.2.2 Exposure assessment
Usual dietary intake was assessed by a validated 183-item semi-quantitative self-administered
food frequency questionnaire (FFQ) [28, 29]. Using this FFQ, subjects reported types and
portions of food they consumed within the last month. Response choices for frequency
were never, 1 day/month, 2-3 days/month, 1 day/week, 2-3 days/week, 4-5 days/week, 6-
7 days/week. Response choices for portion size relative to a standard portion were half
portion, 1 portion, 1.5 portions, 2 or more portions. Dietary intake of folate (µg dietary
folate equivalents/day), vitamin B2 (mg/day), vitamin B6 (mg/day), vitamin B12 (µg/day),
methionine (mg/day), alcohol (g/day), and total energy (kJ/day) were calculated using the
Dutch food composition table from 2006 [30]. Information about age, sex, medical history,
and lifestyle factors, such as smoking status, physical activity [31], BMI, NSAID use, and
education level was obtained from a standardised self-administered questionnaire.
6.2.3 MTHFR genotyping
Participants were provided an Oragene DNA self-collection kit for saliva collection. Geno-
typing of the MTHFR C677T polymorphism was determined using TaqMan R© in accordance
with the information provided from the Applied Biosystems website (http://www.applied-
biosystems.com) in DNA extracted from saliva (DNA Genoteck Inc.). Laboratory staff was
blinded to the clinical outcome status of the patients donating a saliva sample. To assess re-
producibility, genotyping was repeated for 10% of the samples, and complete concordance
was found between the two sets of results. Genotype frequencies were in Hardy-Weinberg
equilibrium as tested by a χ2 test (P>0.05).
6.2.4 Outcome data
Information about colorectal tumours from colonoscopies was determined at the NFDHT
[32] and from medical records at RUMC and UMCG. Information about colonic surgeries,
CRCs, and CRAs from prior colonoscopies was also collected before recruitment and during
follow-up until December 2010. Location, size, and histology for all documented tumours
were obtained from pathology reports.
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6.2.5 Statistical analyses
Total energy-adjusted nutrient intake was computed using the linear residuals method [33].
Descriptive statistics were used to describe the baseline characteristics for the total population
of MMR carriers (n=470) stratified by tertiles of folate intake.
Cox proportional hazards regression was used to calculate hazard ratios (HRs) and 95% con-
fidence intervals (CIs) to estimate risk of developing colorectal tumours from dietary B vita-
min and methionine intake. Robust sandwich covariance estimation was used to account for
dependency of observations within families. The lowest tertile of B vitamin and methionine
intake was set as the reference category. The crude model included age and sex as covariates.
The following were evaluated as possible confounders: age (continuous), sex, BMI (continu-
ous), history of colorectal tumours (yes/no), number of colonoscopies during person time
(continuous), NSAID use (< one per week/≥ one per week), education (high vs. lower edu-
cated), physical activity (high vs. lower physical activity), smoking (current/former/never),
alcohol (continuous), energy intake (continuous), dietary fiber (continuous), supplement use
(yes/no). A covariate was considered to be a confounder if it was associated with vitamin
intake and was also a risk factor for CRT; additionally, the covariate must have changed one
of the HRs by at least 10% using manual backward selection. For all vitamins, the fully
adjusted model included age, sex, physical activity (high vs. lower), number of colonoscopies
during person-time (continuous), and NSAID use (< one per week/≥ one per week). A
fully adjusted model including mutual B vitamins (continuous) and methionine (continuous)
was also constructed.
Person-time started at the time of questionnaire completion and ended at the date of colono-
scopy at which the first colorectal adenoma was diagnosed during follow-up. For colorectal
carcinomas during follow-up, the end date was the date of carcinoma diagnosis. For those
without a detectable CRT during follow-up, censoring was at the date of their last known
colonoscopy.
Effect measure modification by MTHFR C677T genotype was investigated by stratification.
We performed a median split for each vitamin intake and we chose low folate, low vita-
min B2, low vitamin B6, low vitamin B12, and low methionine intakes in those with the
CC genotype as the reference category. To test for multiplicative nutrient-gene interaction,
we created a product term between B vitamin intake (low/high) and MTHFR C677T geno-
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type and included this term into our final model. We also examined possible interactions
between dietary intakes of folate, vitamin B2, vitamin B6, vitamin B12, methionine and al-
cohol (low/high) and smoking status (never, former, current), where a combination of low
intakes with either low alcohol intake or never smokers was chosen as the reference category.
For stratification by MMR gene mutation, we set low intake as the reference for each of the
genes MLH1, MSH2, and MSH6. There was not enough statistical power to stratify by PMS2.
The lifetest procedure was used to evaluate if the proportional hazards models met the as-
sumption of proportionality; no violation of the proportional hazards assumption was ob-
served by visual inspection. Sensitivity analyses were performed by 1) excluding those with
a history of colorectal tumours before the start of the study period (n=232) and 2) excluding
those who developed CRCs during follow-up (n=7). All analyses were performed using SAS
version 9.2 (SAS Institute, Cary, NC).
6.3 Results
In this prospective cohort study of MMR gene mutation carriers, 131 of 470 persons de-
veloped a CRT during a median person-time of 28.0 months. Table 6.1 shows the baseline
characteristics of the total cohort stratified by tertiles of folate intake. There was a greater
proportion of females in the medium folate intake group compared to the low and high in-
take groups. Compared to individuals in the lowest tertile of folate, persons in the highest
tertile of folate, were older, had a higher education, reported higher intakes of vitamin B2,
B6, B12, methionine and a higher consumption of vegetables, fruit, and dietary fiber. In ad-
dition, those in the highest tertile of folate, were less likely to be current smokers and more
likely to be highly physically active compared with the lowest folate tertile. While those in
the highest tertile of folate intake were less likely to have a history of colorectal tumours,
they were more likely to have a history of other cancers, compared to those in the lowest
tertile.
As can be seen in Table 6.2, there was no clear association between dietary intake of any B vi-
tamin or methionine and colorectal tumour risk after adjusting for age, sex, physical activity,
number of colonoscopies during person time, and NSAID use, nor when mutual vitamins
and methionine were included as covariates. Compared to the lowest tertile of intake, ad-
justed HRs (including mutual B vitamins and methionine) for CRT risk and corresponding
95%CIs for the highest tertile were 1.06 (0.59-1.91) for folate, 0.77 (0.39-1.51) for vitamin
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B2, 0.98 (0.59-1.62) for vitamin B6, 1.24 (0.77-2.00) for vitamin B12, and 1.36 (0.83-2.20) for
methionine.
We did not observe an association between MTHFR C677T genotype and risk of CRT (data
not shown). Table 6.3 shows that there was no effect measure modification by MTHFR
C677T genotype in the associations between dietary vitamin B and methionine intake and
CRT risk (p for interaction > 0.05 for all). However, it is worthy to note that there was
a significant increased risk for developing CRT in LS patients homozygous for the variant
MTHFR C677T allele who consumed low amounts of vitamin B2 compared to those in the
reference category (HR=2.44, 95%CI=1.20-4.93), while a non-significant reduction in CRT
risk was seen for high vitamin B2 intake in combination with the MTHFR 677TT genotype.
We observed a similar relationship between methionine intake and CRT risk – a signifi-
cant increased risk for individuals with the MTHFR 677TT genotype in combination with
low methionine intake compared to low methionine intake in MTHFR 677CC individuals
(HR=2.64, 95%CI=1.06-6.58), whereas no association with CRT risk was seen for high me-
thionine intake in combination with the TT genotype.
Investigations for possible interactions between dietary vitamins and smoking and alcohol
in the development of CRT showed a significant interaction between dietary folate and alco-
hol intake (p for interaction=0.02). Compared to low folate/low alcohol, adjusted HRs and
corresponding 95%CIs were 0.56 (0.29-1.09) for high folate/low alcohol, 0.84 (0.46-1.54) for
low folate/high alcohol, 1.23 (0.66-2.32) for high folate/high alcohol. There was no interac-
tion between any vitamin and smoking, nor were there any interactions between the other
vitamins (all p-interaction > 0.05). Stratification by MMR gene mutation showed no strik-
ing differences for the different mutations. Compared to low folate intake, adjusted HRs
and 95%CIs for high folate intake were 1.11 (0.49-2.51) for MSH1 mutation carriers, 1.64
(0.82-3.29) for MSH2 mutation carriers, and 0.42 (0.12-1.48) for MSH6 mutation carriers.
In sensitivity analyses, B vitamin and methionine intake were not associated with CRT risk
when those with prevalent tumours during person-time were excluded. Compared to the
lowest tertile of intake, adjusted HRs including mutual vitamins and corresponding 95%CIs
for the highest tertile of intake was 0.59 (0.19-1.85) for folate, 0.82 (0.25-2.69) for vitamin
B2, 1.98 (0.77-5.06) for vitamin B6, 1.56 (0.69-3.51) for vitamin B12, and 1.65 (0.74-3.68)
for methionine. Restricting analyses to those who developed a CRA during person-time,
adjusted HRs including mutual vitamins for developing CRA and corresponding 95%CIs for
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the highest tertile was 1.02 (0.56-1.86) for folate, 0.82 (0.42-1.60) for vitamin B2, 0.95 (0.57-
1.58) for vitamin B6, 1.18 (0.73-1.93) for vitamin B12, and 1.60 (0.97-2.60) for methionine
compared to the lowest tertile of intake.
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Table 6.1 Baseline characteristics of the population by total energy-adjusted folate intake.
Low folate intake
≤183.71 µg/day
(n=155)
Medium folate intake
183.72-224.29 µg/day
(n=156)
High folate intake
>224.29 µg/day
(n=155)
Person-months, median (IQR) 27.2 (17.3-38.9) 28.9 (17.3-39.0) 29.7 (16.5-40.0)
Patient characteristics
Age (years), median (IQR) 46.8 (39.1-56.7) 48.3 (39.4-57.7) 53.1 (45.1-60.7)
Sex (female), n (%) 91 (58.7) 96 (61.5) 92 (59.4)
BMI (kg/m2), median (IQR) 24.4 (21.8-27.4) 24.8 (22.8-26.9) 24.2 (22.7-26.3)
Higher education, n (%)a 41 (26.6) 56 (36.1) 61 (40.1)
Dietary vitamin intakes, median (IQR)
Vitamin B2 (mg/day) 1.5 (1.2-1.7) 1.6 (1.4-1.9) 1.9 (1.7-2.2)
Vitamin B6 (mg/day) 1.7 (1.5-1.9) 1.9 (1.7-2.1) 2.0 (1.8-2.2)
Vitamin B12 (µg/day) 3.4 (2.6-4.3) 3.8 (3.1-4.7) 4.2 (3.4-5.8)
Methionine (mg/day) 1 233.9 (1 106.1-1 413.9) 1 359.9 (1 175.1-1 503.3) 1 388.7 (1 269.0-1 569.2)
Other dietary and lifestyle factors
Energy (kJ/day), median (IQR) 8 750.3 8 181.1 8 876.9
(7 095.4-10 735.9) (6 800.8-10 269.4) (7 337.2-10 969.7)
Vegetable (g/day), median (IQR) 72.8 (50.5-110.8) 125.2 (88.3-161.9) 177.2 (136.0-224.3)
Fruit (g/day), median (IQR) 80.8 (42.4-166.2) 154.9 (79.8-232.2) 226.6 (149.6-333.6)
Dietary fiber (g/day), median
(IQR)
20.2 (15.7-25.2) 24.0 (19.7-29.3) 28.8 (24.3-34.1)
Red meat intake (g/day), median
(IQR)
48.7 (40.5-72.0) 47.3 (30.7-63.8) 42.7 (24.4-54.1)
Supplement useb, n (%) 39 (25.2) 43 (27.6) 46 (29.7)
Alcohol (g/day), median (IQR) 7.2 (1.6-17.3) 7.3 (0.9-16.0) 6.8 (1.8-16.5)
aCollege or university degree.
bRegular use of any folic acid- or B vitamin-containing supplement in the last month.
cHighest tertile of physical activity score.
128
Dietary B vitamins and CRT risk in Lynch Syndrome
Table 6.1 Baseline characteristics of the population by total energy-adjusted folate intake.
(continued)
Low folate intake
≤183.71 µg/day
(n=155)
Medium folate intake
183.72-224.29 µg/day
(n=156)
High folate intake
>224.29 µg/day
(n=155)
Smoking status, n (%)
Current 38 (24.5) 30 (19.2) 16 (10.3)
Former 61 (39.4) 61 (39.1) 80 (51.6)
Never 56 (36.1) 65 (41.7) 58 (37.4)
NSAID use (<1/week), n (%) 134 (86.5) 140 (89.7) 140 (90.3)
High physical activity, n (%)c 46 (30.1) 43 (28.1) 62 (41.1)
Clinical characteristics, n (%)
History of colorectal tumours 79 (51.0) 76 (48.7) 76 (49.0)
History of other cancers 18 (11.6) 25 (16.0) 39 (25.2)
Colonoscopies during
person-time
1 64 (41.3) 49 (31.4) 61 (39.4)
2 65 (41.9) 71 (45.5) 59 (38.1)
≥3 26 (16.8) 35 (22.4) 34 (21.9)
MMR gene mutation
MLH1 59 (38.1) 66 (42.3) 52 (33.6)
MSH2 65 (41.9) 64 (41.0) 62 (40.0)
MSH6 30 (19.4) 23 (14.7) 40 (25.8)
PMS2 0 (0.0) 2 (1.3) 1 (0.7)
MTHFRC677T genotype, n (%)
CC 60 (42.0) 60 (40.5) 62 (41.6)
CT 64 (44.8) 73 (49.3) 78 (52.4)
TT 19 (13.3) 15 (10.1) 9 (6.0)
aCollege or university degree.
bRegular use of any folic acid- or B vitamin-containing supplement in the last month.
cHighest tertile of physical activity score.
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6.4 Discussion
In this prospective cohort study of MMR gene mutation carriers, our results do not suggest
an association between dietary folate, vitamin B2, vitamin B6, vitamin B12, and methionine
intake and risk of CRT development. There was also no effect measure modification by
MTHFR C677T genotype in the relationship between any B vitamin or methionine and
CRT risk. There was, however, suggestion that low vitamin B2 intake in MTHFR 677TT
individuals was related to increased risk of CRT compared to low intake in 677CC. Likewise,
the same pattern was observed for methionine intake – low intake of methionine in MTHFR
677TT was associated with an increased risk of CRT compared to low intake in MTHFR
677CC persons.
The role of B vitamin and methionine intake in the development of CRT is an area of consid-
erable and ongoing interest; although the evidence is not entirely consistent, there is general
consensus that dietary intake of folate is inversely associated with risk of sporadic CRT in the
general population. Indeed, for dietary folate intake, inverse [16, 17, 34], null [19, 22, 35, 36],
and direct [21] associations with risk of CRT have been reported in both cohort [17,22,34,35]
and case-control studies [16, 19, 21, 36] investigating these relationships. Vitamin B2 intake
has been directly associated with CRA risk in a Dutch case-control study [21], but unas-
sociated with CRT in other studies [19, 20, 22, 35]. A meta-analysis of prospective studies
revealed an inverse association between vitamin B6 intake and CRC risk [37], while other
studies did not [19, 20, 22, 38]. There are also accounts of no association between vitamin
B12 and CRT risk [19, 20]. Likewise, methionine intake has been both unassociated with
CRT risk [20,35], and inversely associated [22]. Given the these inconsistencies, the relation-
ship between folate [39], other B vitamins and methionine and sporadic CRT development
remains unresolved.
Our results are in agreement with previous reports of null associations between dietary folate
intake in sporadic CRT [19, 20, 22], as well as with those from randomised controlled trials
of folic acid and combined folic acid, vitamin B6, and vitamin B12 supplementation and
sporadic CRA development [40–42]. Various explanations could possibly account for the
mixed findings between observational studies. We considered that range of dietary folate
intake could influence the direction of the associations, but examination of the data does
not show this to be a factor, as narrow ranges of dietary folate intake have been reported to
be inversely associated [43], directly associated [21], and unassociated [22] with risk of CRT
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(<150 µg/day vs. > 212 µg/day, <191 µg/day vs. > 220 µg/day, <168 µg/day vs. > 297
µg/day, respectively). Additionally, dietary folate intake could be higher in the United States
and Canada compared to countries in Europe such as the Netherlands, where mandatory
food fortification does not exist, and this could also alter development of CRT. This does
not seem to be the case, however, as studies supporting associations between folate and CRT
came from both American [17] and non-American populations [16, 34].
The absence of a clear association between dietary B vitamins and methionine and CRT
risk in our study could be in part due to the disparity in timing of the adenoma-carcinoma
sequence in the general population compared to that in LS, where the progression from
adenoma to carcinoma is less than 4 years [10, 44] compared to roughly ten years in the
general population [45]. Given the rapid process of initiation to malignant transformation of
CRT in LS, exposure to B vitamins and methionine in this brief window could theoretically
be too short to be meaningful for CRT risk.
Another explanation of our results could be that the pathways in CRT development in the
general population are different from that in LS. Fearon and Vogelstein have proposed a ge-
netic model of colorectal tumourigenesis that describes the transition from healthy colonic
tissue to neoplasia through a series of steps involving the accumulation of genetic and epi-
genetic changes [8]. In sporadic CRC, a mutation in the adenomatous polyposis coli (APC)
gene, is frequently one of the earliest events in initiating colorectal carcinogenesis [46] but is
uncommon in hereditary nonpolyposis colorectal cancer (HNPCC) tumours [47]. We could
infer that this and other differences in microsatellite instability and MLH1 promoter hyper-
methylation could hypothetically alter the still-unclear fundamental mechanisms connecting
folate-mediated one-carbon metabolism to CRT development.
In stratified analyses, we observed an increased risk of CRT with low vitamin B2 intake in
those with the MTHFR 677TT genotype compared with MTHFR 677CC, whereas this was
not observed for high intakes in TT carriers. Our findings in this subgroup analysis were
based on small numbers, so prudence should be taken when interpreting the results. The
presence of the T allele results in a thermolabile protein and reduces MTHFR activity in vitro
by approximately two-thirds in TT-homozygotes [48], and this coupled with low levels of its
cofactor – riboflavin in its coenzymatic form (flavin adenine dinucleotide) – was associated
with a significant increased risk of colorectal carcinogenesis in our population of MMR gene
mutation carriers. van den Donk et al. have also reported inverse associations between
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vitamin B2 intake and risk of sporadic CRA for all MTHFR C677T genotypes but with more
pronounced associations among those with the TT genotype [21]. Low vitamin B intake was
non-significantly linked to an increased risk of CRA in those with the TT genotype [21]. The
significant association between low methionine intake and increased CRT risk for MTHFR
677TT individuals compared to low methionine intake in MTHFR 677CC that we observed
has also been seen in a general Portuguese population [49]. Nevertheless, based on the small
number of subjects in our stratified analysis, our results should be interpreted with discretion
and certainly necessitate confirmation by other studies.
We found an interaction between dietary folate intake and alcohol intake (p-interaction =
0.02). Although not statistically significant, the reduction in CRT risk by high folate intake
was mitigated by high alcohol intake (HR=1.23, 95%CI=0.66-2.32 for high folate/high al-
cohol vs. low folate/low alcohol). Alcohol is a folate antagonist, and as such interferes with
folate bioavailability, transport, and metabolism [50].
The major strengths of this study are its relatively large size, and prospective cohort design
with a reasonably long follow-up period. Furthermore, all participants in our study were
exclusively confirmed MMR gene mutation carriers. A high response rate of 71%, which
reduces the possibility of selection bias and recall, would allow our results to be generalised
to other LS patients. There was also extensive information about many possible confounding
factors, making possible their inclusion as covariates in our analyses.
Our study also has some limitations. As is the case with all observational studies, the po-
tential for residual confounding, resulting from unmeasured or inadequately measured con-
founders, cannot be negated. Furthermore, while this study is a large prospective cohort
study of MMR gene mutation carriers, it can be considered a small prospective study when
compared to cohort studies in the general population, and we had limited power in our sub-
group analyses. Misclassification of exposure data is possible since dietary intake was assessed
using a self-administered FFQ, and although this FFQ has been sufficiently validated [28,29],
it may be worthwhile for future studies to consider determining vitamin status from blood
samples. Measuring vitamin status in blood also has the added advantages of accounting for
uptake, distribution, and metabolism of vitamins in the body.
In conclusion, in this Lynch Syndrome population, intake of dietary folate, other B vitamins,
and methionine were unassociated with CRT development. These associations, however,
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may depend on MTHFR genotype. Larger studies with longer follow-up times are needed to
further clarify the relationships between dietary B vitamin and methionine intake and risk
of CRT in LS patients.
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Chapter 7
The aim of this thesis was to investigate the role of plasma B vitamins as determinants of
global DNA methylation, an intermediate biomarker in colorectal carcinogenesis, in low
(Nijmegen Biomedical Study (NBS)), medium (Folic Acid and Carotid Intima-media Thick-
ness (FACIT)), and high risk (POLIEP-follow-up) populations for colorectal cancer. B vita-
min intake and risk of developing colorectal tumours was also investigated in a population
with an inherited mutation conferring very high risk for developing colorectal cancer (GE-
OLynch). The purpose of this chapter is to summarise the main findings of the studies in this
research project as well as compare and contrast these results to those known in literature.
Strengths and limitations of our studies will also be discussed. The chapter concludes with fi-
nal remarks and based on our results, we offer implications for public health and suggestions
for future research that will further our understanding of one-carbon metabolism and DNA
methylation in colorectal carcinogenesis.
7.1 Main findings for folate/folic acid
Table 7.1 summarises the main findings of folate/folic acid by study population. In a low risk
population (NBS), healthy persons between 50-70 years of age without a personal history of
cancer participating in a population-based survey were ranked based on their plasma folate
status and those in the 10th percentile (n=138) and the 90th (n=137) percentile were selected.
We did not observe a difference in leukocyte LINE-1 DNA methylation levels between the
two groups. We did observe, however, that age was inversely associated with LINE-1 methy-
lation independent of plasma folate concentrations. LINE-1 DNA methylation was also
lower in females compared with males, and MTHFR C677T genotype not associated with
LINE-1 methylation.
In a medium risk population, participants in the randomised-controlled trial (n=218) were
cancer-free men and post-menopausal women between 50-70 years of age with moderately
elevated homocysteine concentrations. There was no difference in global DNA methylation,
measured by liquid chromatography-tandem mass spectrometry, at baseline and following
800 µg daily supplementation with folic acid for 3 years between the treatment and placebo
groups. There was no difference in global DNA methylation between those in the folate
group and those in the placebo group after stratification by MTHFR C677T genotype, base-
line erythrocyte folate concentrations, baseline DNA methylation levels, age, current smok-
ing status, alcohol intake, body mass index, or sex.
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In a high risk population consisting of sporadic colorectal adenoma patients (n=281), plasma
folate was inversely related to LINE-1 DNA methylation. After stratification by number of
lifetime adenomas (1 vs. ≥2), a persistent inverse association between plasma folate and
LINE-1 methylation was observed in both strata. Plasma folate was inversely related to
LINE-1 methylation in MTHFR 677CC individuals, but not in CT nor TT persons. Plasma
folate was borderline inversely associated with LINE-1 methylation for those with a family
history of colorectal cancer, but not in those without a family history.
In a prospective cohort study of a very high risk population for developing colorectal cancer
– germline MMR gene mutation carriers – 131 out of 470 persons developed a CRT during a
median person-time of 28.0 months. There was no association between dietary folate intake
and colorectal tumour risk. The MMR gene mutation carriers in our study are scattered
throughout the Netherlands making blood collection additionally challenging, but we were
able to collect blood samples from a subset of participants, namely those in the Nijmegen co-
hort (n=88). Therefore, we were able to investigate preliminary cross-sectional relationships
between plasma B vitamins and global DNA methylation in these individuals. Following ex-
clusion of those for which we had no information on plasma folate or DNA methylation, 78
persons were included in the analyses. DNA methylation levels, measured using the lumino-
metric methylation assay (LUMA), were between 26.6-75.8%. Multivariable linear regression
was used to evaluate associations between plasma folate and global DNA methylation adjust-
ing for age, sex, and mutual analytes. There was no association between plasma folate and
global DNA methylation (β-estimate 0.01, 95%CI -0.08, 0.07). The results stemming from
these preliminary analyses will not be discussed further in this thesis.
In conclusion, there was no association between plasma folate and leukocyte LINE-1 methy-
lation in a low risk population, between folic acid supplementation and leukocyte global
DNA methylation in a medium risk population, between plasma folate and leukocyte DNA
methylation in a very high risk population (preliminary findings), nor between dietary folate
intake and CRT development in a very high risk population. Only in a high risk population
– persons with a history of sporadic CRA – was plasma folate inversely related to leukocyte
LINE-1 methylation.
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7.2 Main findings for other B vitamins and methionine
Table 7.2 summarises findings for other B vitamins and methionine by study population.
Based on the study design for our low and medium risk populations, other B vitamins and
methionine could not be analysed as a main exposure.
In patients with a history of colorectal adenomas, there was a positive association between
plasma methionine and LINE-1 methylation in those without a family history of colorectal
cancer, but not in those with a family history of colorectal cancer. We additionally observed
an inverse association between plasma riboflavin and LINE-1 methylation in MTHFR 677TT
individuals but not in CC nor CT persons.
In the prospective cohort study of germline MMR gene mutation carriers, no association
between dietary intake of any B vitamin nor methionine and CRT risk was observed, and
stratified analyses with MTHFR C677T genotype did not reveal significant nutrient-gene in-
teractions for any of the B vitamins or methionine.
7.3 Main findings – a comparison and contrast with others
Our results seem to be fairly unexpected when compared to the bulk of current literature.
In order to improve our understanding of our results as a contribution to the literature,
here we describe and give possible explanations for the differences between our results and
earlier reports from others. The research described in this thesis focuses predominantly on
the relationships between plasma B vitamins and leukocyte LINE-1 DNA methylation across
various populations at differential risk for colorectal cancer. In this section, we compare (the
similarities) and contrast (the differences) the results of our studies with those in the literature
in order to give a better overview of how our studies complement those of others and how
together these studies contribute to our overall understanding so far of the relationships
between plasma B vitamins and LINE-1 methylation in different populations.
We first examine all randomised-controlled trials of folic acid supplementation on leukocyte
global DNA methylation in low and medium risk individuals (Table 7.3). Then we recapitu-
late investigations of controlled intake of dietary folate and folic acid from enriched foods on
leukocyte global DNA methylation in low risk populations (Table 7.4) followed by reports
that have investigated associations between folate status (intake and plasma concentrations)
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and leukocyte global DNA methylation also in low risk populations (Table 7.5). This section
concludes with studies that have looked at folate status and leukocyte global DNA methyla-
tion in high risk populations (i.e. persons with a history of colorectal adenoma or colorectal
carcinoma) (Table 7.6).
7.3.1 Low and medium risk populations
At the time of submission of this thesis, to the best of our knowledge, there were two other
randomised placebo-controlled trials that investigated the effects of folic acid supplementa-
tion on leukocyte global DNA methylation in low and medium risk individuals (Table 7.3).
There was no effect of folic acid supplementation on leukocyte global DNA methylation in
all three trials. The methyl acceptance assay was used in two of the trials (not in our own
study); this semi-quantitative method reflects the capacity of DNA to accept [3H]-labelled
methyl groups in the presence of SssI prokaryotic methylase enzyme. [3H]methyl group in-
corporation into DNA is inversely related to DNA methylation, so high [3H]-methyl group
incorporation suggests low global DNA methylation and vice versa [1].
As far as we know, there are currently four studies that have investigated controlled intake of
dietary folate and folic acid from enriched foods on global DNA methylation in leukocytes
of low risk persons (Table 7.4). All of these studies were carried out in the United States,
where mandatory enrichment of flour, rice, pasta, and other grain products with 140 µg
of folic acid per 100 g began in 1998 [2]. There were no differences in DNA methylation
between the groups at baseline in all studies. In two studies, folate depletion was followed
by an increase in [3H]methyl incorporation implying a decrease in global DNA methylation
[3, 4]. Following folate repletion, a decrease in [3H]methyl incorporation (increased DNA
methylation) was reported [3]; using liquid chromatography tandem mass spectrometry to
measure DNA methylation, however, seemed to result in an increase in the mCyt/tCyt ratio
(increased DNA methylation) only in persons with the MTHFR 677TT genotype [5]. There
was no change in DNA methylation after folate depletion nor repletion when the methyl
acceptance assay was used to measure DNA methylation in the same study [5].
A total of seven studies, including one of our own, have explored the association between
folate status (biomarker or intake) and global DNA methylation in leukocytes of low risk
individuals (Table 7.5). Plasma folate was explored in three studies [6–8], dietary folate intake
in three others [9–11], and red blood cell folate in one study [12]. There was no association in
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the majority of studies. In the three studies with plasma folate, there was no association with
global DNA methylation in two studies [7, 8]. There was a positive association between red
blood cell folate [12] in one study and plasma folate [6] in another study with global DNA
methylation, but only in those with the MTHFR 677TT genotype and not in persons with
the CC genotype.
7.3.2 High risk population
As can be seen in Table 7.6, there have been two studies that have investigated either the effect
of folic acid supplementation on leukocyte DNA methylation [13] or associations between
plasma folate and leukocyte DNA methylation in persons at high risk for colorectal cancer
(i.e. colorectal adenoma patients) [14]. The effect of folic acid supplementation on leukocyte
DNA methylation has been explored in a British population of CRA patients. Results from
this RCT conducted by Pufulete et al. show that DNA methylation in leukocytes of CRA
patients increased after 10 weeks 400 µg folic acid supplementation daily compared with the
placebo group [13]. Conversely, our own study has indicated an inverse association between
plasma folate and LINE-1 methylation [14]. Global DNA methylation was measured differ-
ently between the two studies (global DNA methylation [13] vs LINE-1 methylation [14]),
and the methods used to quantify DNA methylation also differed (methyl acceptance as-
say [13] vs pyrosequencing [14]), which could partially contribute to the discrepancies in
methylation seen between the studies.
7.3.3 Very high risk population
To the very best of our knowledge, associations between B vitamins and DNA methylation
in very high risk populations, such as a Lynch syndrome, are still unknown. Neither dietary
information nor DNA methylation measurements were assessed in reports describing a later
age of onset of colorectal cancer for Lynch syndrome individuals with the MTHFR 677CT or
TT genotype compared to those with the CC genotype [15, 16]. In chapter 6 of this thesis,
our results seem to indicate null associations between B vitamin and methionine intake and
colorectal tumour risk. Additional preliminary cross-sectional analyses in a small population
also did not suggest significant relationships between plasma B vitamins and methionine with
leukocyte global DNA methylation, but stratified analyses and replication in larger studies
are needed to better understand these relationships.
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7.4 Challenges in estimating B vitamin status
7.4.1 Using food frequency questionnaires
In our very high risk population, the GEOLynch study, we have used the same self-adminis-
tered food frequency questionnaire (FFQ) as we used in our other studies to assess habitual
dietary intake. This questionnaire has been previously validated for folate and vitamin B12
[17] in addition to fats and cholesterol [18]. Because blood samples were only provided by
88 persons in the Nijmegen cohort of the GEOLynch study, we elected to use dietary intake
information, which was available from all 470 participants.
Dietary folate intake was expressed as micrograms (µg) per day of dietary folate equivalents
(DFEs), a unit which accounts for the differences in absorption of naturally-occurring food
folates and the more bioavailable synthetic folic acid form of folate. The number of DFEs
in natural foods is equivalent to the micrograms of folate in that food, and the number
of DFEs in fortified foods is the micrograms of food folate in that food plus 1.7 times the
micrograms of added folic acid [19]. Folic acid from supplements is not commonly used in the
Netherlands [20] and our FFQ was also not validated for folic acid from supplements – only
folate from foods was assessed [17]. Often validations of FFQs can show better correlations if
supplement use was included in the analyses [21–23]. Including supplement use in our linear
regression models and Cox regression models did not change our results appreciably.
FFQs in assessing habitual dietary intake are regularly used in epidemiological studies be-
cause they are relatively inexpensive, measure long-term dietary intake, and straightforward
for participants to complete [24] although there is more measurement error involved com-
pared with recalls and dietary records and may not be entirely accurate [25, 26]. Difficulties
in collecting information about all possible foods, frequency of foods eaten and serving size
add to the measurement error involved with FFQs [27]. Recall bias is less likely to happen in
cohort studies than in case-control studies because diets are reported before the occurrence
of disease; however, other measurement errors may exist. The ranking of subjects can be
influenced when persons with high intake under-report their intake and when persons with
low intake over-report their intake [28]. The associated random variation would furthermore
attenuate risk estimates [29].
As mentioned, the FFQ used in all our studies including the GEOLynch study has previously
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been validated for folate and vitamin B12 [17]. For 81 Lynch Syndrome participants of the
Nijmegen cohort in our study, Spearman correlation coefficients between B vitamin intake
and related biomarkers were 0.11 for folate, 0.13 for vitamin B2, 0.13 for vitamin B6, -0.05
for vitamin B12, and 0.24 for methionine, demonstrating poor correlation between dietary
intake and plasma vitamers. This is not surprising, as dietary folate intake and plasma folate
are usually poorly correlated [22, 30, 31]. More specifically, for the population in which our
FFQ was validated, the correlation coefficient between serum folate and the FFQ was 0.20,
similar to blood folate-FFQ folate correlations from other studies [22, 30, 31]. The minor
differences between this correlation coefficient and the one from our Lynch population could
be due to differences in blood collection protocols, methods to measure plasma/serum folate,
time between blood collection and analysis, seasonal variation, and sample size.
7.4.2 Using biomarkers
In the NBS and POLIEP-follow up studies, vitamers in plasma were measured using micro-
biological assays and liquid chromatography-tandem mass spectrometry, and the biomarkers
have shown good intraindividual reproducibility and are regarded as reliable measures in epi-
demiological studies [32]. For plasma folate, we have measured the vitaminer 5-methyltetra-
hydrofolate using a well-known microbiological assay [33]. There are many forms of folate in
plasma with 5-methyltetrahydrofolate being the predominant form as well as the form that
donates methyl groups for DNA methylation [34].
There is disagreement whether B vitamin concentrations in blood reflect those in colorec-
tal mucosa. Three studies have reported direct correlations between serum and red blood
cell folate with colonic mucosal folate [35–37] while other studies did not observe significant
correlations [34, 38, 39]. Tissue folate extraction, tissue folate determination (i.e. two differ-
ent microbiological assays [36, 39] vs liquid chromatography [34]), and source of folate (i.e.
colonocytes [38, 39] vs. colonic mucosa [34–36]) could partially account for the disparate
results between studies. Furthermore, tissue storage time could also contribute to these dif-
ferences (i.e. 6 years 34 vs 2 months [36]), as folate loss in blood stored at -20oC can already
be detected after a few years [40, 41] and in certain cases even as early as 6 days after blood
draw [42]. As well, these studies all tended to be small, which could also contribute to the
observed differences in results.
Results from a 1-year randomised controlled trial with 5 mg folic acid daily in 17 persons
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with a history of colorectal adenomas showed serum and red blood cell folate concentrations
directly correlating with colonic mucosal folate concentrations at baseline, 6 months, and
at 1 year [35]. Further inspection of the data revealed that at the 6 month and 1 year time
points, serum and red blood cell folate were directly related to colonic folate in persons in
the placebo group (at 6 months, ρ of 0.79 for serum folate and ρ of 0.67 for red blood cell
folate; at 1 year, ρ of 0.79 for serum folate and ρ of 0.68 for red blood cell folate) but not
in persons in the folic acid group (at 6 months, ρ of 0.25 for serum folate and ρ of 0.03 for
red blood cell folate; at 1 year, ρ of 0.49 for serum folate and ρ of 0.12 for red blood cell fo-
late), demonstrating that perhaps serum and red blood cell folate are correlated with colonic
mucosal folate under conventional physiological ranges of folic acid concentrations but not
following supraphysiological doses [35]. There is no national food fortification programme
in the Netherlands, where dietary supplement use, while increasing, is not yet common-
place (18-41% of the adult Dutch population between spring and autumn and 29-54% in
the winter [20]), so it is unlikely that persons in our study populations (including those in
our randomised controlled trial where participants were allocated to either placebo or 0.8
mg/day folic acid) were exposed to supraphysiological doses of folic acid, which may settle
possible reservations concerning correlations between concentrations of folate in plasma and
colonic mucosal in our studies.
Measurement of biomarkers and other exposures in our studies is similar to those performed
in other studies. And like other studies, measurement error is unavoidable. Random mea-
surement error in plasma metabolites (exposure) will bias regression coefficients towards the
null [43, 44].
7.5 Assessing global DNA methylation
We have used several methods to assess global DNA methylation. As mentioned, we used
liquid chromatography-tandem mass spectrometry 8 to assess global DNA methylation in
the randomised controlled trial. We have used bisulfite PCR and pyrosequencing of LINE-
1 to estimate global DNA methylation in the NBS and POLIEP-follow-up studies. In the
GEOLynch study, we used the LUMA method to measure global DNA methylation. We
selected to use LUMA and LINE-1 pyrosequencing because of their frequent use in numer-
ous epidemiological studies [45, 46]. Prior to using these analytical techniques, DNA must
be isolated from blood. We have collected blood in EDTA Vacutainers, which were then
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spun, and plasma and buffy coat were removed and stored at -80oC in separate vials. DNA
was extracted and isolated from buffy coat using two different methods – for the NBS and
POLIEP-follow-up studies, a Hamilton STAR robot was used, and for the GEOLynch study,
DNA was isolated manually using a kit (Qiagen Puregene Kit B). There are reports that dif-
ferent DNA isolation techniques could yield variable global DNA methylation levels using
LUMA, and this should be taken into account when interpreting results from the LUMA
method [47].
The LUMA method was developed by Karimi and colleagues 48 and employs the restriction
endonucleases HpaII and MspI, respectively. HpaII is sensitive to 5-methyldeoxycytosine (5-
mdC) methylation at all CCGG sequences in the genome while MspI is insensitive. A third
enzyme called EcoRI digests the DNA and creates an overhang with a sequence devoid of any
cytosine and guanine nucleotides and serves as a control of DNA in the assay. The percentage
of DNA methylation is expressed as
[1− (HpaII/EcoRI
∑
G/
∑
T)/(MspI/EcoRI
∑
G/
∑
T)] ∗ 100
In addition to the LUMA, a number of other methods have been developed to measure global
DNA methylation (reviewed in [49]). Because repetitive elements represent between 30 to
50% of the human genome 50 and contain CpG methylation in healthy cells [51], measuring
DNA methylation in repetitive elements such as LINE-1 and Alu sequences, centromere-
adjacent satellite 2 (Sat2), and centromeric satellite alpha (Satα) DNA sequences has been used
as a substitute for global DNA methylation [52]. The “best” method to use in a particular
study will depend on the number of samples, quality and quantity of available DNA, desired
coverage, and required resolution [49].
As noted above, we have used LINE-1 DNA methylation as a surrogate for global DNA
methylation in the NBS and POLIEP-follow up studies. Despite the prolific use of DNA
methylation in repeat elements as a proxy for global DNA methylation, several recent reports
have suggested that neither leukocyte methylation in LINE-1 nor Alu are good surrogates
for global DNA methylation, as methylation levels in LINE-1 and Alu do not accurately
represent global methylation levels [34, 53]. Global DNA methylation is the total genomic
5-mdC level and reflects DNA methylation not only in LINE-1 or other repeat elements
but also in CpG islands and CpG sites located outside repeat elements. This could partially
account for the differences in methylation between the two methods.
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In our study of persons at very high risk for developing colorectal cancer (GEOLynch cohort
study), we have also collected sputum samples. There are various methods available to isolate
and extract high quality DNA from sputum, but there is not yet evidence that global DNA
methylation in sputum assessed using any method is related to colorectal carcinogenesis,
whereas several studies have observed an association between global DNA methylation in
leukocytes and colorectal development [54]. Furthermore, DNA methylation is likely to be
tissue-specific [34, 55], and because we had measured leukocyte global DNA methylation in
our three other populations, measuring DNA methylation in leukocytes in the GEOLynch
study would allow for better comparisons between our studies.
We have measured DNA methylation using methods also widely employed in other studies,
but as in all observational studies, measurement error is unavoidable. Random measure-
ment error in LINE-1 methylation (outcome) will increase standard error of the estimates
and consequently widen the corresponding confidence intervals making us less sure of our
estimate [43, 44].
7.6 Global vs. gene-specific DNA methylation
As mentioned in Chapter 1, in addition to global DNA methylation in colorectal carcinogen-
esis, specific genes such as tumour-suppressor genes, can be silenced through DNA methyla-
tion at promoter regions of those genes [56, 57]. Hypermethylation of CpG islands in gene
promoters results in inactivation of transcriptional activity of the gene [58]. Approximately
5% of all genes are hypermethylated in colorectal cancer [59]. Using LINE-1 pyrosequenc-
ing or the LUMA method to measure global DNA methylation does not provide us with
information about gene-specific DNA methylation. Based on our results, then, we cannot
discount the influence of plasma folate, other B vitamins or methionine on gene-specific
methylation as B vitamins have previously been associated with gene-specific methylation in
colorectal adenomas [60] and carcinomas [61].
With this in mind, we have collected colorectal adenoma and carcinoma tissues of partic-
ipants in our POLIEP-follow up study, which is comprised of persons with a history of
colorectal adenomas and are therefore considered at high risk for colorectal cancer. The
national network and registry of histopathology and cytopathology reports (Pathologisch
Anatomisch Landelijk Geautomatiseerd Archief (PALGA)) [62] was used to identify and lo-
cate tumour tissues from the patients in our study. DNA was extracted from formalin-fixed,
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paraffin-embedded colorectal adenoma and carcinoma tissue using the PuregeneTM DNA
isolation kit, and microdissection was performed, and only areas containing > 70% tumour
cells were used. We have data on gene-specific methylation of CACNA1G, IGF2, NEUROG1,
RUNX3, and SOCS1 quantified using MethyLight [63], and statistical analyses will be per-
formed shortly.
7.7 Study populations: from low-risk to very high-risk
In this PhD project, we have utilised four different study populations in order to collectively
investigate the role of plasma B vitamins as determinants of global DNA methylation across
a continuum of colorectal cancer risk. Each of these four studies is unique in represent-
ing a specific risk population for colorectal cancer. The NBS included low-risk individuals
in a population-based survey, the FACIT trial was comprised of medium-risk persons in a
randomised-controlled trial, the POLIEP-follow-up of high-risk patients in a cohort study,
and the GEOLynch cohort study consisted of those at very high risk for developing col-
orectal cancer. Methodological issues present in observational epidemiological studies merit
further discussion.
7.8 Study design
We have used a cross-sectional analysis in two of our studies (chapters 3 and 5), a randomised-
controlled trial in another (chapter 4), and our fourth study employed a cohort design (chap-
ter 6). A well-known evidence-based pyramid describing the best research evidence places
randomised-controlled trials above cohort studies and cohort studies above cross-sectional
studies. Participants in our cohort study of MMR mutation carriers were identified through
a national hereditary cancer registry, which registers families based on their family history
of cancer in order to facilitate screening in these high risk families. However, not all patients
and their families may be registered, particularly smaller families, and therefore would not
represent all MMR mutation carriers in the Netherlands. It is unlikely, though, that iden-
tification and selection of registered MMR mutation carriers is related to B vitamin status,
and would affect our results. While informative, the nature of cross-sectional studies cannot
reveal whether LINE-1 methylation is a result of plasma folate concentrations, as the timing
of events or causality cannot be inferred from this type of study.
In all types of observational studies and small randomised trials, confounding may influence
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the observed associations. Confounding refers to the mixing of effects. When the effect of
the exposure is mixed with the effect of another variable, this causes confounding. In order
to be a confounder, the variable must be a risk factor for the outcome (in this thesis: global
DNA methylation or risk of CRT) and also be associated with the exposure (in this thesis:
usually plasma folate concentrations). Possible confounders can be identified a priori based
on literature and knowledge of mechanisms. Possible confounders can then be confirmed
during statistical analyses by noting a change in risk estimate or regression coefficients after
inclusion of the potential confounder into the model. In all our studies, we have included
potential confounders if they changed the hazards ratio or regression coefficients by at least
10% using manual backwards selection. Still, the presence of residual confounding due to
improperly measured (measurement errors) or unmeasured variables cannot be excluded.
7.9 Effect modification
We have also explored possible effect modification by the MTHFR C677T genotype, family
history of colorectal cancer, alcohol intake, and smoking status in the associations between
plasma B vitamins and methionine with global DNA methylation and between B vitamin
and methionine intake and risk of colorectal tumours.
7.9.1 MTHFR C677T genotype (rs1801133)
The common C to T transition in the MTHFR gene at nucleotide 677 results in an alanine
to valine substitution, subsequently producing a thermolabile variant and reduced enzyme
activity [6]. This functional single nucleotide polymorphism (SNP) is possibly the most
well-studied of all SNPs in one-carbon metabolism (OCM)-related genes. The TT genotype
has been implicated with modifying associations between plasma folate or folate intake and
global DNA methylation [5, 6, 12, 64, 65].
In our studies, the MTHFR C677T genotype was not an effect modifier in the associations
between folic acid supplementation and global DNA methylation in the medium risk group.
In the high risk group, plasma folate was inversely associated with LINE-1 methylation in
persons with the CC genotype while plasma riboflavin was inversely associated with LINE-1
methylation in persons with the TT genotype. In high risk groups, the effect of MTHFR
C667T genotype was unexpected. There was an inverse association between plasma folate
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and LINE-1 methylation for those with the CC genotype, and for those with the TT geno-
type, there was an inverse association between plasma riboflavin and LINE-1 methylation,
although no interaction terms reached statistical significance.
7.9.2 Family history of colorectal cancer
The associations between B vitamin status and global DNA methylation could also be differ-
ent for those with a family history of colorectal cancer compared to those without a family
history. A history of colorectal cancer in a first degree relative has been associated with
increased personal risk for sporadic colorectal cancer [66, 67]. The mechanisms involved in
bringing about this increased risk are unknown, but a recent study did reveal that those with
a positive colorectal cancer family history were more likely to develop LINE-1 methylation-
low colorectal tumours compared to those without a family history of colorectal cancer [68].
Furthermore, in the pre-folic acid fortification era in the United States, Fuchs et al. have
observed a stronger inverse association between folate intake and colorectal cancer risk in
women with a family history of colorectal cancer compared with those without a family his-
tory [69]. Known syndromes of familial clustering of colorectal cancer such as Lynch Syn-
drome, caused by a germline mutation in one of the DNA mismatch repair genes (MLH1,
MSH2, MSH6, PMS2) [70], constitute less than 5% of all colorectal cancer [71]. The mecha-
nisms associated with familial clustering of colorectal cancer in nonfamilial colorectal cancer
(i.e. not the known familial colorectal cancer syndromes) are unknown, but genetic factors
in combination with environmental factors likely play a role [72].
We have investigated family history of colorectal cancer as a possible effect modifier in the
association between plasma B vitamins and leukocyte LINE-1 methylation in those previ-
ously diagnosed with colorectal adenomas. Family history of colorectal cancer in biological
first-degree family members (i.e. parents, siblings, children) was assessed using a general ques-
tionnaire. Participants were asked for the number of siblings, and children they have and the
age at which their biological parents, siblings, and children were first diagnosed with cancer
and the type of cancer. For each participant, it was possible to include information about
family history for up to and including 4 children and 4 siblings.
Family history of cancers was self-reported using a questionnaire, a method often used in
epidemiological studies [73, 74], but whose precision and accuracy has been widely debated
against medical records and cancer registries [75–77]. Patient-reported family cancer histo-
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ries for first-degree relatives, however, seem to be precise and accurate for colorectal cancer
according to results of an evidence-based analysis [78]. Our high risk cohort consisted exclu-
sively of persons with a history of colorectal adenomas, and reporting of family history of
colorectal cancer was similar between those with one adenoma and those with at least two
adenomas. We have observed a positive association between plasma methionine and LINE-1
methylation but only in those with no family history of colorectal cancer. This relationship
was not observed in those with a family history of colorectal cancer.
7.9.3 Alcohol and smoking
Alcohol interferes with folate absorption and folate-metabolising enzymes [79], which could
disturb one-carbon metabolism and limit methyl group availability for DNA methylation.
Cigarette smoking has been shown to reduce systemic circulating concentrations of B vi-
tamins by possibly increasing the activity of antioxidant defense enzymes in tissues, which
require folate, B6 species, and riboflavin [80], but smoking was not an effect modifier in the
association between folate intake and global DNA methylation in a study of low risk for
colorectal cancer older adults [9].
Smoking [81], similar to other unfavourable lifestyle habits, as well as alcohol intake [82] are
likely to be underreported. This underreporting of smoking could result in overreporting
of former or never smokers in our studies. We have studied smoking using the categories
never smoker, former smoker, and current smoker, and did not find smoking to be an effect
modifier in the associations between plasma B vitamin concentrations and LINE-1 DNA
methylation. In the randomised-controlled trial, participants were matched on smoking sta-
tus.
Underreporting of alcohol intake can also affect the ranking of participants [82], but in
our studies, the food frequency questionnaire used to estimate alcohol intake was validated
against a 24-hour recall and showed high correlation for alcohol intake [83] as well for rank-
ing subjects on alcoholic drinks [84]. We have stratified using tertiles of alcohol intake, but
no effect modification by alcohol intake in the associations between plasma B vitamins and
LINE-1 methylation and folic acid supplementation and global DNA methylation were ob-
served.
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7.9.4 Other potential effect modifiers
Although other genetic variants in OCM genes do exist (such as MTR A2756G, MTRR A66G,
and another functional SNP MTHFR A1298C in addition to others), few studies have investi-
gated the relationships between these variants with B vitamin intake or biomarkers in healthy
individuals and also in colorectal neoplasia (reviewed in [85]). This review concludes that the
evidence on polymorphisms other than MTHFR C677T in combination with folate and/or
related nutrients and their relationship to colorectal cancer are tentative at best [85]. There-
fore, while genetic variation in additional OCM-associated SNPs could theoretically in part
affect our results, based on the current evidence, it does not seem likely that these SNPs
would change our conclusions.
7.10 Public health implications
The overall findings of this thesis suggest that status of folate and other B vitamins may not
be associated with global DNA methylation nor LINE-1 DNA methylation in leukocytes
except possibly in persons with a history of colorectal adenomas.
The current recommendations for cancer prevention outlined by the World Cancer Research
Fund/American Institute for Cancer Research in their 2007 Second Expert Report is based
on systematic literature reviews of literature on food, nutrition, and physical activity [86].
The eight recommendations are to be as lean as possible, be physically active, limit consump-
tion of energy-dense foods, eat plant-based foods, limit intake of red meat and avoid processed
meat, limit alcohol intake, limit salt consumption and avoid mouldy grains and legumes, and
aim to meet nutritional needs through diet alone (i.e. without the use of dietary supple-
ments). Although research on food, nutrition, physical activity, and cancer survival is still in
its infancy, these recommendations are suggested for cancer survivors as well [86], and could
help cancer survivors improve their quality of life [87].
The results from our studies support the current evidence-based recommendations set out by
the WCRF/AICR, as they pertain to the status of folate and other B vitamins and colorectal
cancer prevention. Because neither our results nor those of others provide evidence to suggest
that a low or high folate status could influence leukocyte DNA methylation in individuals
at differential risk for colorectal cancer, these results taken together would not support revi-
sions to the current recommendations. It may be important to reiterate that based on our
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findings and in line with the WCRF/AICR recommendations, individuals should seek to
meet nutritional needs through diet and not through dietary supplementation, for example,
through the use of folic acid supplements. Given the age range of the populations we have
studied, our studies do not provide data on the effect of folate status early or very late in
life, and because epigenetic patterns are established in utero, and maternal folate status and
early life exposures could affect DNA methylation levels in offspring, as some studies have
demonstrated [88, 89], B vitamins could similarly impact DNA methylation in early or later
life differently.
7.11 Future research
The influence of one-carbon metabolism in connection with DNA methylation in the aetiol-
ogy of colorectal cancer is complicated and intricate due to the complexity of these processes.
Consequently, the task of unravelling this puzzle is daunting. There are, however, further
steps that we can take to help improve our understanding of folate and DNA methylation in
colorectal carcinogenesis.
One-carbon metabolism is very complex involving interactions between a multitude of ge-
netic and nutritional/environmental factors, so the use of pathway-based approaches that can
simultaneously model many variables [90–92] would be beneficial. DNA methylation pat-
terns in specific loci as well as in the whole genome in response to B vitamin intake and over
time as well in different risk populations should be explored as well. An epigenome-wide
association study (EWAS) could help us identify colorectal cancer related epigenome pro-
files. However, because DNA methylation patterns are not static but change over time and
in response to environmental factors, it would be informative to perform an EWAS every
10 years starting in early life and follow these persons over a lifetime. Furthermore, in light
of the continuous lively discussions about folic acid fortification in the Netherlands and the
rest of Europe [93], a long-term randomised controlled trial in healthy younger individuals
could be conducted to investigate effects of folic acid fortification on DNA methylation and
also DNA synthesis, as mathematical modelling and in vivo studies show DNA methylation
competing with DNA synthesis pathways for folate species [94, 95]. Future research into
this field is necessary to increase our understanding into the roles of B vitamins and DNA
methylation in colorectal carcinogenesis and will be the foundation in developing additional
effective colorectal cancer prevention strategies.
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Cancers of the colon and the rectum are the third most common type of cancer in the world,
affecting over one million people annually. Many clinical, genetic, and nutritional risk fac-
tors that modify risk of colorectal cancer have been identified. A history of colorectal cancer
in one and two or more first-degree family members increases personal risk of developing
colorectal cancer two- and four-fold, respectively. A personal history of colorectal adeno-
mas, benign established precursors of colorectal carcinomas, also increases risk of developing
colorectal carcinomas, particularly if the adenomas are of the villous variety, at least 1 cm, or
develop in multiples. Inheritance of cancer-associated genes also strongly increases personal
risk for developing colorectal cancer. Lynch syndrome is a well-known inherited cancer syn-
drome, in which individuals with Lynch syndrome inherit a pathogenic germline mutation
in one of the mismatch repair (MMR) genes, which results in microsatellite instability in tu-
mours. Compared to the general population, where the lifetime risk of developing colorectal
cancer is 5-6%, Lynch syndrome individuals have a 70-85% risk of developing colorectal can-
cer to age 70. Dietary and lifestyle factors also influence the risk of developing colorectal
cancer, by possibly interacting with genetic susceptibility to these exposures due to specific
variants in related metabolising genes. The World Cancer Research Fund/American Insti-
tute for Cancer Research estimates that roughly one-third, and even up to one-half in some
countries, of all colorectal cancers could be prevented by regular physical activity, an avoid-
ance of body fatness within the normal range of body weight, and proper food and nutrition.
Micronutrients such as folate and other B vitamins have also been found to decrease risk of
developing colorectal cancer.
Aberrant DNA methylation occurs during colorectal carcinogenesis. Global hypomethy-
lation as well as gene-specific hypermethylation of promoter regions have been observed in
colorectal tumours. Both these processes depend on the efficiency of one-carbon metabolism,
where folate and other B vitamins play a key role. Folate is a mediator of one-carbon groups
in one-carbon metabolism, while vitamins B2, B6, and B12 are cofactors for biological re-
actions. Methionine is an essential amino acid that is converted to S-adenosylmethionine,
the universal donor of methyl groups for a multitude of reactions including DNA methyla-
tion. The studies described in this thesis aim to improve our knowledge about the impact
of B vitamin status on global DNA methylation in persons at differential risk for colorectal
cancer.
Chapter 1 is a general introduction to B vitamins, DNA methylation, and colorectal car-
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cinogenesis. A description of the studies conducted as part of this thesis is also included.
Chapter 2 is a literature review that summarises the impact of nutrition on global and gene-
specific DNA methylation in different cancer sites as explored in epidemiological studies.
Chapter 3 is based on data collected from persons at low risk for developing colorectal can-
cer. Here, a cross-sectional study was conducted to describe the impact of plasma B vitamins
on long interspersed nuclear element-1 (LINE-1) methylation in low risk persons in order
to improve our understanding of cancer processes. We used data from 1,142 age-and sex-
stratified randomly selected individuals who had participated in a population-based survey.
Those in the extremes (10th (2.69-5.62 nmol/L) and 90th (37.24-95.94 nmol/L) percentiles)
of plasma folate concentrations were selected. In a total of 275 healthy, cancer-free persons
with plasma folate in the 10th (n=138) and 90th (n=137) percentiles, we describe leukocyte
LINE-1 DNA methylation in relation to circulating concentrations of B vitamins (folate, ri-
boflavin, vitamin B6 species (pyridoxal 5’-phosphate, pyridoxal, and 4-pyridoxic acid), cobal-
amin, methylmalonic acid (MMA)) and methionine, and dietary and lifestyle characteristics.
Age, sex, and MTHFR C677T genotype were also examined as possible predictors of LINE-
1 methylation in the extremes separately using multivariable linear regression adjusted for
each other. Our results suggest no difference in leukocyte LINE-1 DNA methylation be-
tween those in the 10th and in the 90th percentile for plasma folate. Mean percentage of
LINE-1 DNA methylation (IQR) for those in the 10th percentile was 73.7 (72.6-74.6) and
73.6 (72.5-74.7) for those in the 90th percentile. Age at blood draw was inversely related to
LINE-1 methylation in both extremes (β estimate (95%CI) of 0.07 (-0.13, -0.01) for the 10th
percentile and -0.08 (-0.14, -0.02) for the 90th percentile), and LINE-1 DNA methylation
was lower in females compared with males in the 10th percentile of plasma folate (β estimate
(95%CI) of -0.68 (-1.37, 0.01)), while there was no association with MTHFR C677T genotype.
In a population at medium risk for colorectal cancer, the effect of folic acid supplemen-
tation on global DNA methylation was investigated (Chapter 4). We examined whether
long-term daily supplementation with 0.8 mg of folic acid increases global DNA methyla-
tion compared with placebo in individuals with elevated plasma homocysteine. We also
investigated if these effects are modified by MTHFR C677T genotype. Two hundred sixteen
participants out of 818 subjects who had participated in a randomised double-blind placebo-
controlled trial were selected, pre-stratified on MTHFR C677T genotype and matched on age
and smoking status. They were allocated to receive either folic acid (0.8 mg/d; n = 105) or
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placebo treatment (n = 111) for three years. Peripheral blood leukocyte DNA methylation
and serum and erythrocyte folate were assessed. Global DNA methylation was measured
using liquid chromatography-tandem mass spectrometry and expressed as a percentage of 5-
methylcytosines versus the total number of cytosine. Analysis of covariance (ANCOVA) was
used to estimate differences between groups at baseline and after the intervention and also
to compare the effect of supplementation on global DNA methylation, adjusted for baseline
DNA methylation and the variables on which subjects were matched (i.e. age and current
smoking status). Following three years of folic acid supplementation, there was no difference
in global DNA methylation between those randomised to folic acid and those in the placebo
group (difference = 0.008, 95%CI =20.05,0.07, P = 0.79). There was also no difference be-
tween treatment groups when stratified for MTHFR C677T genotype (CC, n = 76; CT, n
= 70; TT, n = 70), baseline erythrocyte folate status or baseline DNA methylation levels.
Our results indicate that in moderately hyperhomocysteinemic men and women, long-term
folic acid supplementation does not increase global DNA methylation in peripheral blood
leukocytes.
Moving further along the continuum for colorectal cancer risk, Chapter 5 illustrates the
association between plasma B vitamins and LINE-1 DNA methylation in leukocytes of per-
sons at high risk for developing colorectal cancer (i.e. patients with at least one histologically
confirmed colorectal adenoma ever in their life). We used LINE-1 bisulfite pyrosequencing
to measure global DNA methylation levels in leukocytes of 281 colorectal adenoma patients.
Multivariable least squares linear regression was used to assess associations between plasma
B vitamin concentrations and LINE-1 methylation levels. The final linear regression mod-
els included the covariates age, sex, BMI, alcohol intake, smoking status, family history of
colorectal cancer, and other measured analytes (i.e. mutual B vitamins and methionine).
Analyses were also stratified by number of lifetime adenomas (one vs at least two), family
history of colorectal cancer in a first-degree relative, and MTHFR C677T genotype. Plasma
folate was inversely associated with LINE-1 methylation in the entire population of colorec-
tal adenoma patients (adjusted β estimate (95%CI) of -1.46 (-2.65, -0.27)). For those with
one adenoma, plasma methionine was positively associated with LINE-1 methylation (ad-
justed β estimate of 3.47 (-0.40, 7.33)). Based on our results, there is no evidence to suggest
that in colorectal adenoma patients (persons at high risk for colorectal cancer), plasma folate
concentrations are positively related to LINE-1 methylation in leukocytes.
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Chapter 6 presents a prospective cohort study that was conducted to explore the impact of
folate, vitamin B2, vitamin B6, vitamin B12, and methionine intake on colorectal carcinogen-
esis in 470 mismatch repair gene mutation carriers (i.e. persons with Lynch Syndrome), who
have a very high lifetime risk for developing colorectal cancer. Dietary intakes were assessed
by food frequency questionnaire. Cox regression models with robust sandwich covariance
estimation, adjusted for age, sex, physical activity, number of colonoscopies during person-
time, NSAID use, and mutual vitamins were used to calculate hazard ratios (HR) and 95%
confidence intervals (95% CI). Analyses were also stratified by MTHFR C677T genotype.
Compared to the lowest tertile of intake, adjusted HRs (95%CI)s for CRT development in
the highest tertile are 1.06 (0.59-1.91) for folate, 0.77 (0.39-1.51) for vitamin B2, 0.98 (0.59-
1.62) for vitamin B6, 1.24 (0.77-2.00) for vitamin B12, and 1.36 (0.83-2.20) for methionine.
Low vitamin B2 and low methionine intake were statistically significantly associated with
an increased risk of CRT in MTHFR 677TT individuals compared to a combined reference
of persons with low intake and CC genotype, but there was no significant interaction. In
conclusion, there is no suggestion that intake of any dietary B vitamin or methionine is
associated with CRT development among those with Lynch Syndrome.
The final chapter (Chapter 7) contains the general discussion, where we consider the results
from all our studies as presented in the previous chapters as a whole. Our results in compari-
son to studies by others are also considered to help us make a more thoughtful and thorough
insight into the scientific consequences of our work. The overall findings of this thesis suggest
that status of folate and other B vitamins may not be associated with global DNA methyla-
tion nor LINE-1 DNA methylation in leukocytes except possibly in persons with a history
of colorectal adenomas. Because neither our results nor those of others provide evidence
to suggest that a low or high folate status could influence leukocyte DNA methylation in
individuals at differential risk for colorectal cancer, these results taken together would not
endorse revisions to the current recommendations. Because DNA methylation patterns are
not static, but change over the course of a lifetime and in response to different environmental
factors, it would be informative to perform an epigenome-wide association study every 10
years starting in early life and follow these persons over a lifetime. Furthermore, mathemat-
ical modelling and in vivo studies have shown that DNA methylation competes with DNA
synthesis pathways for folate species, so a long-term randomised controlled trial of folic acid
supplementation in healthy younger persons would help improve our knowledge about the
impact of folic acid on DNA synthesis and methylation from a younger age onwards.
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Samenvatting
Per jaar krijgen meer dan één miljoen mensen dikke darmkanker. Daarmee is dikke darm-
kanker de derde meest voorkomende vorm van kanker in de wereld. Diverse klinische,
genetische, en voedingsfactoren kunnen het risico op dikke darmkanker beïnvloeden.
Dikke darmkanker bij één of meer eerstegraads familie leden verdubbelt het persoonlijk
risico op dikke darmkanker. Mensen met eerdere dikke darmpoliepen (adenoom), een niet-
kwaadaardig voorstadium van dikke darmkanker, hebben eveneens een verhoogt risico op
het ontwikkelen van dikke darmkanker. Dit is vooral het geval als het adenoom een villi
vorm heeft, groter is dan 1 cm, of meervoudig aanwezig is.
Ook kan dikke darmkanker erfelijk zijn. Lynch syndroom is een bekende erfelijke vorm
van kanker. Mensen met het syndroom van Lynch erven een pathogene germline mutatie
in één van de mismatch repair (MMR) genen. Deze mutatie in een MMR gen zorgt voor
microsatelliet instabiliteit bij tumoren. Het risico op het ontwikkelen van dikke darmkanker
is in de algemene bevolking 5-6%. Mensen met het Lynch syndroom hebben een risico van
70-85% op het ontwikkelen van dikke darmkanker voor hun zeventigste jaar.
Naast klinische en genetische factoren beïnvloeden voeding en andere levensstijlfactoren eve-
neens het risico op dikke darmkanker. Dit gebeurt mogelijk in samenspel met een verhoogde
genetische gevoeligheid voor deze factoren als gevolg van specifiek varianten in genen be-
trokken bij het metabolisme, zoals het gen dat codeert voor het enzym MTHFR. Het World
Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) schatten dat
ruwweg één derde, en in sommige landen zelfs tot één half, van alle dikke darmkanker kan
worden voorkomen door regelmatige lichaamsbeweging, beperken van lichaamsvet binnen
de standaard normen van lichaamsgewicht, en gezonde voeding. Micronutriënten, zoals
foliumzuur en andere B vitamines, dragen ook bij aan het verlagen van het risico op het
ontwikkelen van dikke darm kanker.
Tijdens de ontwikkeling van dikke darmkanker ontstaat een afwijkende DNA methylering
in de tumor. In dikke darm tumoren is zowel globale hypomethylering als gen specifieke
hypermethylering van promotor regios gevonden. Deze beide processen zijn afhankelijk van
de efficiëntie van het zogenaamde één-koolstof (1-C) metabolisme. In dit metabolisme spelen
foliumzuur en andere B-vitamines een sleutelrol waarin foliumzuur één-koolstof (methyl)
groepen aanlevert en de vitamines B2, B6 en B12 cofactoren zijn voor biologische reac-
ties. Methionine is een essentieel aminozuur dat wordt omgezet naar S-adenosylmethionine,
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de universele donor van methyl groepen voor een verscheidenheid aan reacties, waaronder
DNA. De studies die in dit proefschrift zijn beschreven zijn bedoeld om onze kennis te ver-
beteren over het effect van B-vitamine status op globale DNA methylering in personen met
een laag tot hoog risico op dikke darmkanker, nl. 1) mensen waarbij nog geen darmpoliepen
of darmkanker is gediagnosticeerd, 2) mensen met eerdere darmpoliepen en 3) mensen met
Lynch Syndroom.
Hoofdstuk 1 is een algemene inleiding over B vitaminen, DNA methylering en dikke darm-
kanker. De inleiding bevat tevens een beschrijving van de uitgevoerde studies die onderdeel
zijn van dit proefschrift.
Hoofdstuk 2 is een literatuur overzicht over de impact van voeding op globale en genspeci-
fieke DNA methylering bij verschillende vormen van kanker zoals onderzocht in epidemiol-
ogische studies.
Hoofdstuk 3 is gebaseerd op data verzameld van personen met een laag risico voor het
ontwikkelen van dikke darmkanker. Een cross-sectionele studie is uitgevoerd om de rol
van B vitamines in plasma op methylering van LINE-1 elementen te bestuderen. Hiervoor
zijn gegevens gebruikt van 1,142 willekeurig geselecteerde individuen binnen de Nijmegen
Biomedische Studie. Individuen met uiterste plasma waarden van folaat (10de and 90ste per-
centielen) werden geselecteerd. Onze resultaten wijzen niet op een verschil in LINE-1 DNA
methylering tussen personen in de 10de en 90ste percentielen van folaat in plasma. Leeftijd
op het moment van bloed afname was omgekeerd evenredig gerelateerd aan LINE-1 methy-
lering in beide extremen. De LINE-1 DNA methylering was lager in vrouwen dan mannen
terwijl er met het MTHFR C677T genotype geen associatie gevonden werd.
Het effect van lange termijn foliumzuur suppletie op globale DNA methylering is vervolgens
onderzocht in een populatie met een gemiddeld risico voor dikke darm kanker, in individuen
met een verhoogd plasma homocysteine (Hoofdstuk 4). Ook is onderzocht of het MTHFR
C677T genotype de associatie beïnvloedde. Van 818 deelnemers van een gerandomiseerd
dubbelblinde placebo gecontroleerde trial werden 216 deelnemers geselecteerd, gestratificeerd
op MTHFR C677T genotype, leeftijd en rookgewoonten. De deelnemers slikten drie jaar lang
foliumzuur (0.8 mg/dag; n = 105) of placebo pillen (n = 111). DNA methylering in witte
bloedcellen en de folaat concentraties in rode bloedcellen en serum werden bepaald voor en
na suppletie. Onze resultaten wijzen erop dat bij mannen en vrouwen met gematigd hyper-
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homocysteinemie, de globale DNA methylering niveaus in witte bloedcellen niet verhoogd
worden door lange termijn foliumzuur suppletie.
Hoofdstuk 5 beschrijft de associatie tussen plasma B vitamines en LINE-1 DNA methy-
lering in witte bloedcellen van personen met een verhoogd risico op het ontwikkelen van
dikke darmkanker, (i.e. individuen met tenminste één histologisch bevestigde colorectale
adenoom). Plasma folaat bleek omgekeerd evenredig geassocieerd met LINE-1 methylering
in de gehele populatie van dikke darm adenoom patiënten. Plasma methionine bleek positief
geassocieerd met LINE-1 methylering in personen met één adenoom. Geen belangrijke ver-
schillen werden gevonden wanneer de analyses werden gestratificeerd voor het aantal adeno-
mas (één vs tenminste twee), familiale achtergrond van dikke darm kanker in een eerstegraads
familielid, en MTHFR C677T genotype.
Hoofdstuk 6 presenteert de resultaten van een prospectieve cohort studie (GeoLynch studie)
bij 470 mensen met het Lynch syndroom, mensen met een heel hoog risico op het krijgen
van dikke darmkanker. Hierin werd gekeken naar de associatie tussen het ontstaan van col-
orectale adenomen en de inname van folaat, vitamine B2, vitamine B6, vitamine B12 en
methionine. Inname van de nutrienten werd bepaald door middel van een voedselfrequen-
tievragenlijst. Cox regressie modellen met robuuste sandwich covariatie schatting, gecor-
rigeerd voor leeftijd, geslacht, lichamelijke activiteit, aantal colonoscopieen tijdens de studie
en het gebruik van NSAIDs werden gebruikt om de hazard ratio (HR) en de bijbehorende
95% btbhi te berekenen. De inname van B vitaminen en methionine uit de voeding leek niet
geassocieerd te zijn met adenoom ontwikkeling in mensen met het Lynch Syndroom, ook
niet wanneer werd gecorrigeerd voor leeftijd, geslacht, lichamelijke activiteit, aantal colono-
scopieen tijdens de studie en het gebruik van NSAIDs.
Het laatste hoofdstuk (Hoofdstuk 7) bevat de algemene discussie, waarin de resultaten,
zoals gepresenteerd in de voorgaande hoofdstukken, als geheel worden besproken en be-
discussieerd. De algehele bevindingen van dit proefschrift duiden erop dat de status van
folaat en andere B vitaminen mogelijk niet geassocieerd zijn met globale DNA methyler-
ing, noch met LINE-1 DNA methylering in witte bloedcellen, behalve mogelijk in perso-
nen met een voorgeschiedenis van dikke darm adenomen. Omdat zowel onze resultaten als
die van anderen niet genoeg bewijs leveren dat een lage of hoge folaat status leukocyt DNA
methylering kan beïnvloeden in individuen met een verschillend onderliggend risico op dikke
darmkanker, is er geen reden om de huidige aanbevelingen om het risico op kanker te ver-
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lagen aan te passen. Omdat DNA methylering patronen niet statisch zijn, en veranderen
tijdens het leven o.a. als reactie op verschillende omgevingsfactoren kan het informatief zijn
om personen te volgen vanaf hun vroege levensjaren en om de tien jaar een epigenomisch-
brede associatie studie uit te voeren. Tevens hebben wiskundige modellen en in vivo studies
aangetoond dat DNA methylering concurreert met DNA synthese. Een lange termijn geran-
domiseerde gecontroleerde studie met foliumzuur suppletie in gezonde jonge mensen zou
onze kennis vergroten over de impact van folium zuur op DNA synthese en methylering
vanaf een jonge leeftijd.
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Abstract
Background and objective: In najaar 2007, a world-renowned scientist and all around bril-
liant lady, by the name of Professor Dr. Ellen Kampman, placed an advertisement for a
PhD student in the looking-for-a-PhD section on a popular academic work-related website.
A visitor to the site, I, Audrey Jung, was successful in securing the PhD position after seri-
ous vetting procedures that may or may not have included anthropometric measurements,
colonoscopies, biomarker analyses, and completion of multiple dietary and lifestyle ques-
tionnaires. The objective for the following years would be for me to complete my thesis
(under the daily coaching of Ellen Kampman) with the least number of casualties and collat-
eral damage.
Subjects and methods: We developed a novel and unique study design that can never be
replicated nor reproduced. Our population consisted of a daily supervisor (n=1 (EK)),
co-supervisors (n=2 (FN&HB)), and a PhD student (n=1 (AJ)) with a number of collab-
orators/coauthors/lab technicians/research assistants (n=lots) and group members (n=lots
too).
Essential to our project were participants from four studies – the Nijmegen Biomedical Study,
the FACIT study, the POLIEP-follow up study, and the GEOLynch study. Without their
enthusiastic participation, this thesis would not have been possible. Thank you so very
much.
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combine all the different aspects of your life. Thank you for the talks, for all your care, all
the dinners, for everything. It has been a privilege working with you.
Fokko Nagengast and Henk Blom, your mentorship was invaluable. Thank you for being a
part of this project and for always helping answer my numerous questions.
The Department for Health Evidence was the main setting for work done on this thesis, and
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the kindness of all the people at this department helped to ensure its completion. Thank you
very much for all your immense support.
I also spent quite some time at the Division of Human Nutrition at Wageningen Univer-
sity, especially with the Nutrigenomics group. Thank you to all at the Division for your
hospitality.
A shout out to Bart Kiemeney, who was not only always able to come up with clever sugges-
tions for issues pertaining specifically to this thesis but was also genuinely concerned about
my well-being and personal situation. Thank you, Bart, for your care, openness, and your
friendliness.
Astrid van Alst and Simone van Wezel at the Department for Health Evidence made sure
that I did not end up homeless and worked tirelessly on sorting out administration matters.
Thank you!
At the Department of Pathology, Patricia van Beuningen and Els Schut taught me how to use
the PALGA database and spent countless days and months helping me collect tissues from
the different hospitals. Elisa Vink-Börger showed me how to cut paraffin-embedded tissues,
do IGF staining, and extract DNA from tissues. She also assessed the histopathology of the
many tissues. Thank you all!
Thank you to the other (former and current) members of Ellen’s team with whom I have had
very fun times working: Akke Botma, Dieuwertje Kok, Renate Heine-Bröring, Fränzel van
Duijnhoven, and Renate Winkels. Akke, it was such super duper fun times with my partner
in crime. I’m so glad you were the “postdoc” on the project :) ! Dieuwertje, thank you for
your very helpful comments on my introduction. Renate H, thank you for all the nice chats!
Fränzel, the Lynch paper was a blast! I learned so much from you! Renate W, our meetings
were always so enjoyable, and you hosted such a tasty dinner at your place.
Thank you so much to Jan Harryvan for your expertise in the lab, in particular with DNA
isolation and genotyping. Thank you Sandra Heil for your instruction on the ins and outs
of DNA isolation and subsequent DNA methylation using the LUMA method.
Much thanks to Karin Borgonjen and Saskia Meijboom at Dietetics for spending so much
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Wu Ming, thank you for all the helpful talks. You have great wisdom. Serendipity made
me your Master’s student, and from there, a friendship was forged. Thank you always for
making time for your former student. 乾杯！
Without Ursula Oldenhof, data collection and organisation for these studies would have
been unachievable. Thank you so much Ursula for your help with sending, entering and
organising FFQs, all the blood collection, and accompanying me to the scary tissue archives
of certain hospitals to obtain samples.
Wim Lemmens, you are a superstar data manager! And a SAS whiz. It has been an hon-
our. To everyone else with whom I worked closely on the NBS: Martin den Heijer, Tessel
Galesloot, Sita Vermeulen, your valuable contributions are gratefully appreciated. Much
thanks also to Ton de Haan, for letting me bug you with incessant questions about statistics.
Maria van Vugt, you are Speedy Gonzales with helping to find information from patients.
Thank you!
Thank you to the members of the reading committee Nicoline Hoogerbrugge, Iris Nagtegaal,
and Cornelia Ulrich for your time. Neli, thank you so much as well for taking the time out
of your busy schedule to supervise me at the Hutch. I learned so much from you, and it was
wonderful to be part of such an incredible team.
My gratitude and appreciation go to Iris van Rooij and Carolien Lute for agreeing to be my
paranymphs. Dear Iris, you will always be fondly known to me as my first officemate. Thank
you for fielding all those initial questions of mine and for all your help. Thank you too for
extending a hand as my “Dutch buddy” and for sharing such nice dinners with me! Good
times were had with Carolien Lute (who moonlights as a personal chauffeur) pipetting and
pyrosequencing in the labs all the livelong days!
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instrumental in making the book chapter happen.
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You guys are awesome too.
Deˇkuji Ti, Jane Mrkosi, byl jsi pro mne obrovskou oporou prˇi dokoncˇování diplomové
práce. Jsi trˇída. Bu˚h ti žehnej.
給我致美的家人: 媽媽，爸爸，祖父，祖母，外祖父，已離開了的外祖母，及所有愛我
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Results: This thesis! The thesis is complete with only few casualties and collateral damage,
nothing that cannot be fixed with tea and stroopwafels. We observed that the relationship
between me carrying out a PhD project and successful completion of the thesis depended
heavily on the patience, involvement, and helpfulness of Ellen Kampman, Fokko Nagengast,
and Henk Blom. And also on numerous other factors such as beautiful friends, family,
colleagues, and collaborators.
Conclusions: A journey of this magnitude is never taken alone. Thank you to everyone
who in your own beautiful way joined in for the ride. To those whom I may have forgotten
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